Document:

EX-10.3

 Exhibit 10.3 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. 
 Confidential 

COLLABORATION AND DISTRIBUTION AGREEMENT 

THIS COLLABORATION AND DISTRIBUTION AGREEMENT (the
“Agreement”) is entered into as of March 1st, 2021 (the “Effective Date”), by and between ARS PHARMACEUTICALS,
INC., a Delaware corporation (“ARS”), having an address of 3525 Del Mar Heights Rd., #855, San Diego, CA 92130, U.S., and Pediatrix Therapeutics, a Cayman corporation
(“Pediatrix”), having a registered office at Aequitas International Management Ltd., Grand Pavilion Commercial Center, Suite 24, 802 West Bay Road, P.O. Box 10281, Grand Cayman
KY1-1003, Cayman Island. ARS and Pediatrix may be referred to herein individually as a “Party” or collectively as the “Parties”. 

RECITALS 

WHEREAS, ARS is developing its proprietary Composition referred to as ARS-1, and
owns or Controls certain ARS Technology (as each of these capitalized terms is defined below) relating to such Composition; 

WHEREAS, Pediatrix is engaged in the research, development and commercialization of pharmaceutical products; and 

WHEREAS, ARS and Pediatrix desire that Pediatrix exclusively collaborate and distribute products containing ARS-1 in the Pediatrix Territory (as defined below), all subject to the terms and conditions of this Agreement. 

AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, and
for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ARS and Pediatrix hereby agree as follows: 
  

	1.	 DEFINITIONS 

  

	1.1	 “Aegis Agreement” means the License Agreement dated
as of June 18, 2018 between ARS and Aegis Therapeutics, LLC (“Aegis”) and the Supply Agreement dated as of June 18, 2018 between ARS and Aegis. 

 

	1.2	 “Affiliate” means, with respect to a Party, any entity that, directly or
indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Party, but for only so long as such control exists. As used in this Section 1.2,
“control” means (a) to possess, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate
governance; or (b) direct or indirect beneficial ownership of more than fifty percent (50%) of the voting share capital or other equity interest in such entity. 

 

	1.3	 “Aggregate Annual Net Sales” means, the aggregate
Net Sales of all Products by Pediatrix and its Affiliates and Sublicensee in the Pediatrix Territory in a given Calendar Year. 

  

	1.4	 “Aggregate Annual Net
Sales Milestone Events” has the meaning set forth in Section 8.2(b)(i). 

 

	1.5	 “Alliance Manager” has the meaning set forth in
Section 3.5. 

  

	1.6	 “Applicable Laws” means the applicable provisions of
any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including NDAs) of or from any
court, arbitrator, Regulatory Authority or governmental agency or authority having jurisdiction over or related to the subject item, including, without limitations, (a) relevant implementing laws in the Pediatrix Territory, (b) U.S. Export
Control Laws, (c) FCPA and all applicable anti-corruption laws and trade control laws, (d) applicable regulations and guidelines of the NMPA and other Regulatory Authorities and the ICH guidelines, (e) applicable Good Clinical
Practices (GCP), Good Laboratory Practices (GLP) and current Good Manufacturing Practices (cGMP) promulgated by NMPA and other Regulatory Authorities or the ICH; (f) all applicable industry and trade standards, including applicable standards of
the ISO with, at a minimum, the ISO 9001/9002 quality standards. 

  
 1 

	1.7	 “ARS Collaborator” means any Third Party licensee of
ARS with respect to the Development and Commercialization of Compositions and Products in any country outside the Pediatrix Territory. 

  

	1.8	 “ARS Indemnitee” has the meaning set forth in
Section 12.2. 

  

	1.9	 “ARS
Know-How” means all Know-How that is Controlled by ARS or its Affiliates as of the Effective Date or during the Term (including Know-How constituting New IP), that is (i) necessary for the development, manufacture, sale, offering for sale, importation, or otherwise commercialization of the Product in the Field in the Pediatrix
Territory; or (ii) arising out of activities related to the development, manufacture, sale, offering for sale, importation, or otherwise commercialization of the Product in the Field in and outside the Pediatrix Territory; provided
that, if a Third Party becomes an Affiliate of ARS after the Effective Date as a result of a Change of Control of ARS, then ARS Know-How shall exclude the Know-How
owned or controlled by such Third Party before the closing of such Change of Control transaction, unless such Know-How is already Controlled by ARS or its Affiliates before the closing of such Change of
Control transaction. For clarity, the ARS Know-How includes the Know-How of ARS’s CMO to the extent that these are necessary or reasonably useful for the
Manufacture of any Composition or Product; provided such Know-How is in ARS’s possession and ARS has the legal right to transfer such Know-How.

  

	1.10	 “ARS Patents” means all Patents in the Pediatrix Territory that are Controlled
by ARS or its Affiliates as of the Effective Date or during the Term (including any Patents constituting New IP) that are (i) necessary for the development, manufacture, sale, offering for sale, importation, or otherwise commercialization of
the Product in the Field in the Pediatrix Territory; or (ii) arising out of activities related to the development, manufacture, sale, offering for sale, importation, or otherwise commercialization of the Product in the Field in and outside the
Pediatrix Territory; and that would be infringed, absent a license or other right to practice granted to Pediatrix under such Patents, by the research, Development, manufacture, use, or importation of any Composition, or research, Development,
Manufacture, use, importation, offer for sale or sale of any Product, in the Field in the Pediatrix Territory (considering patent applications to be issued with the then-pending claims); provided that, if a Third Party becomes an Affiliate of
ARS after the Effective Date as a result of a Change of Control of ARS, then ARS Patents shall exclude the Patents owned or controlled by such Third Party before the closing of such Change of Control transaction, unless such Patent is already
Controlled by ARS or its Affiliates before the closing of such Change of Control transaction. The ARS Patents existing as of the Effective Date are set forth in Exhibit 1 hereof. 

 

	1.11	 “ARS Product Marks” has
the meaning set forth in Section 10.7. 

  

	1.12	 “ARS Technology” means the ARS Know-How and the ARS Patents. 

  

	1.13	 “Business Day” means a day other than a Saturday, Sunday or any day on which
banks located in California, United States, Cayman Islands or Beijing, China are authorized or obligated to close. Whenever the agreement refers to number of days, such number shall refer to calendar days unless Business Days are specified.

  

	1.14	 “Calendar Quarter” means each respective period of three (3) consecutive
months ending on March 31, June 30, September 30, or December 31. 

  

	1.15	 “Calendar Year” means each respective period of twelve (12) consecutive
months ending on December 31. 

  
 2 

	1.16	 “cGMP” means all applicable current Good Manufacturing Practices including, as
applicable, (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Parts 4, 210, 211, 601, 610 and 820, (b) European Directive 2003/94/EC and Eudralex 4, and (c) the principles detailed in the ICH Q7
guidelines, each as may be amended from time to time 

  

	1.17	 “Change of Control” means, with respect to a Party, (a) a merger,
reorganization, consolidation or other transaction involving such Party and any entity that is not an Affiliate of such Party as of the Effective Date, which results in the voting securities of such Party outstanding immediately prior thereto, or
any securities into which such voting securities have been converted or exchanged, ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization, consolidation or
other transaction, (b) any entity that is not an Affiliate of such Party as of the Effective Date becoming the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party or otherwise
acquiring the power (whether through ownership interest, contractual right or otherwise) to direct or cause the direction of the management or policies of such Party. 

 

	1.18	 “Claim” has the meaning set forth in Section 12.3.

  

	1.19	 “CMC” means chemistry, manufacturing, and control. 

 

	1.20	 “CMO” means a Third-Party company who has contracted with either Party to
Manufacture, or engage in Manufacturing activities, of Composition or the Product. 

  

	1.21	 “Commercial Supply
Agreement” has the meaning set forth in Section 7.2(a). 

  

	1.22	 “Commercialization” means the conduct of all activities undertaken before and
after Regulatory Approval relating to the promotion, marketing, sale and distribution (including importing, exporting, transporting, customs clearance, warehousing, invoicing, handling and delivering Products to customers) of Products in the Field
in or outside of the Pediatrix Territory, including: (i) sales force efforts, detailing, advertising, medical education, planning, marketing, sales force training, and sales and distribution; (ii) scientific and medical affairs; and
(iii) post- approval clinical trials. “Commercialize” and “Commercializing” have correlative meanings. 

  

	1.23	 “Commercialization Plan” has the meaning set forth
in Section 6.2. 

  

	1.24	 “Commercially Reasonable Efforts” (a) with respect to a Party’s obligations
or activities under this Agreement [***]. 

  
 3 

	1.25	 “Competitive Product” shall mean any pharmaceutical product (other
than the Product) in the Field to which all of the following conditions apply: (i) contains epinephrine and (ii) delivered via a nasal spray. 

  

	1.26	 “Composition” means (a) the combination of epinephrine and [***]
(“ARS-1”), or (b) any other composition or derivative or improvement of ARS-1 that (i) is claimed in a Patent Controlled by ARS or its
Affiliates existing on the Effective Date or during the Term or (ii) is otherwise Controlled by ARS or its Affiliates. 

  

	1.27	 “Confidential Disclosure Agreement” means that certain Confidential Disclosure
Agreement between ARS and Pediatrix dated as of September 3, 2020. 

  

	1.28	 “Confidential Information” means all
Know-How and other proprietary scientific, marketing, financial or commercial information or data that is not publicly available, and that is generated by or on behalf of a Party or its Affiliates or which one
Party or any of its Affiliates has supplied or otherwise made available to the other Party or its Affiliates, whether made available orally, in writing, or in electronic or visual form, including information comprising or relating to concepts,
discoveries, inventions, data, designs or formulae in relation to this Agreement. All ARS Technology shall be ARS’s Confidential Information. 

  

	1.29	 “Control” or “Controlled” means, with respect to any Know-How, Patents or other intellectual property rights, the legal authority or right (whether by ownership, license or otherwise but without taking into account any rights granted by one Party to the other Party
pursuant to this Agreement) of a Party to grant access, a license or a sublicense of or under such Know-How, Patents or other intellectual property rights to the other Party, or to otherwise disclose
proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party. 

 

	1.30	 “Cost of Goods” means, with respect to any Product supplied by ARS or its
Affiliate to Pediatrix under Article 7 (or the Development Supply Agreement and the Commercial Supply Agreement): (i) in the case of products and services acquired from Third Parties relating directly to the manufacture of such
Product, [***] the amount [***] by ARS or its Affiliate for such Product manufacture; and (ii) in the case of manufacturing services performed by a ARS or its Affiliate, [***] (i), the Actual Unit Costs of such manufacture. “Actual Unit
Costs” shall mean with respect to a Product, Direct Material Costs, Direct Labor Costs, and Manufacturing Overhead [***] in accordance with GAAP. “Direct Material Costs” shall mean [***]. “Direct Labor Costs” shall mean
[***]. “Manufacturing Overhead” attributable to such Product [***] shall mean [***] and [***]. 

  
 4 

	1.31	 “Data” means any and all scientific, technical, test, marketing or sales data
pertaining to any Composition or Product that is generated by or on behalf of Pediatrix or its Affiliates or Sublicensees, or by or on behalf of ARS or its Affiliates or, to the extent Controlled by ARS with a right to disclose to Pediatrix, ARS
Collaborators, including research data, clinical pharmacology data, CMC data (including analytical, manufacturing and quality control data and stability data), pre-clinical data, clinical data or submissions
made in association with an IND or NDA with respect to any Product. 

  

	1.32	 “Develop” means to develop (including clinical,
non-clinical and CMC development), analyze, test and conduct preclinical, clinical and all other regulatory trials for the Composition or Product, as well as all related regulatory activities and any and all
activities pertaining to new indications, pharmacokinetic studies and all related activities including work on new formulations, new methods of treatment and CMC activities including new manufacturing methods. “Developing”
and “Development” have correlative meanings. 

  

	1.33	 “Development Plan” is described in
Section 4.2. 

  

	1.34	 “Development Supply
Agreement” has the meaning set forth in Section 7.1(a). 

  

	1.35	 “Debarred” has the meaning set forth in
Section 11.2(a). 

  

	1.36	 “Discontinued ARS
Patent” has the meaning set forth in Section 10.2(a). 

  

	1.37	 “Discontinued Pediatrix
Patent” has the meaning set forth in Section 10.2(b). 

  

	1.38	 “Drug Product” has the meaning set forth in
Section 7.1(a). 

  

	1.39	 “EMA” means the European Medicines Agency or any successor agency with
comparable responsibilities. 

  

	1.40	 “Excluded Claim” has the meaning set forth in
Section 15.3(f). 

  

	1.41	 “Executive Officers” has the meaning set forth in
Section 3.3. 

  

	1.42	 “Export Control Laws” means all applicable U.S. laws and regulations relating to
(a) sanctions and embargoes imposed by the Office of Foreign Assets Control of the U.S. Department of Treasury or (b) the export or re-export of commodities, technologies, or services, including the
Export Administration Act of 1979, 24 U.S.C. §§ 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. §§ 1701-1706, the Trading with the Enemy Act, 50U.S.C. §§ 1 et. seq., the Arms Export Control Act, 22
U.S.C. §§ 2778 and 2779, and the International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986 (as amended). 

  

	1.43	 “FCPA” means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et. seq.), as amended; and all applicable local anti-bribery laws and regulations. 

  

	1.44	 “FDA” means the U.S. Food and Drug Administration or any successor agencies with
comparable responsibilities. 

  

	1.45	 “FDCA” has the meaning set forth in Section 11.2(a).

  

	1.46	 “Field” means all human uses including the diagnosis, treatment, palliation, or
prevention of all indications, diseases and disorders. 

  

	1.47	 “First Commercial Sale”
means, on a Product-by-Product and region-by-region basis, the first sale by Pediatrix or
any of its Affiliates or Sublicensees to a Third Party for end use or consumption of a Product in a region in the Pediatrix Territory after Regulatory Approval has been granted with respect to such Product in such region. [***].

  
 5 

	1.48	 “First Region” has the meaning set forth in
Section 8.3(b)(ii). 

  

	1.49	 “FTE” means the equivalent of the work of a full-time individual for a twelve
(12) month period. 

  

	1.50	 “GAAP” means the generally accepted accounting principles of the applicable
country or jurisdiction, consistently applied, and means the international financial reporting standards (“IFRS”) at such time as IFRS becomes the generally accepted accounting standard and Applicable Laws require that a
Party use IFRS. 

  

	1.51	 “Generic Product” means, with respect to the Product in a country or regulatory
jurisdiction, any pharmaceutical product that (a) contains the same composition of active ingredient as such Product in the same pharmaceutical form as such Product; (b) has obtained regulatory approval in such country or regulatory
jurisdiction (for an indication for which such Product obtained Regulatory Approval from the applicable Regulatory Authority in such country or regulatory jurisdiction) on an expedited or abbreviated basis in a manner that relied on or incorporated
data submitted by ARS, Pediatrix, their Affiliates, licensees or sublicensees under the provisions of Section 505(j) of the U.S. Federal Food, Drug, and Cosmetic Act, Articles 10.1, 10.2, 10.3 or 10a of EU Pharma Directive 2001/83, or similar
laws in the applicable country or regulatory jurisdiction; (c) is bioequivalent to the Product, as determined by the applicable Regulatory Authority in such country or regulatory jurisdiction; and (d) is sold in such jurisdiction by a
Third Party that is not a sublicensee of Pediatrix or its Affiliates and did not purchase such product in a chain of distribution that included any of Pediatrix or its Affiliates or sublicensees. 

 

	1.52	 “Global Trial” means a clinical trial designed to obtain data to be used to
support filing for and obtaining Regulatory Approval of a Product in the Field in both (a) mainland China or other regions in the Pediatrix Territory and (b) the United States 

 

	1.53	 “GLP” means all applicable Good Laboratory Practice standards, including, as
applicable, as set forth in the then current good laboratory practice standards promulgated or endorsed by the U.S. Food and Drug Administration as defined in 21 C.F.R. Part 58, or the equivalent laws and regulations in the Pediatrix Territory, each
as may be amended from time to time. 

  

	1.54	 “Good Clinical
Practice” or “GCP” means all applicable Good Clinical Practice standards for the design, conduct,
performance, monitoring, auditing, recording, analyses and reporting of Clinical Trials, including, as applicable (a) as set forth in the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals
for Human Use Harmonized Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practice for trials on medicinal products in the Pediatrix Territory, (b) the Declaration of Helsinki
(2004) as last amended at the 52nd World Medical Association in October 2000 and any further amendments or clarifications thereto, (c) U.S. Code of Federal Regulations Title 21, Parts 50 (Protection of Human Subjects), 56 (Institutional
Review Boards) and 312 (Investigational New Drug Application), and (d) the equivalent laws and regulations in the Pediatrix Territory, each as maybe amended from time to time. 

 

	1.55	 “Governmental Authority” means any national, international, federal, state,
provincial or local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing
authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body). 

  
 6 

	1.56	 “ICC” has the meaning set forth in Section 15.3(a).

  

	1.57	 “ICC Rules” has the meaning set forth in
Section 15.3(a). 

  

	1.58	 “ICH” means the International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use. 

  

	1.59	 “IND” means an investigational new drug application or equivalent application
filed with the applicable Regulatory Authority, which application is required to commence human clinical trials in the applicable country. 

  

	1.60	 “Indemnitee” has the meaning set forth in
Section 12.3. 

  

	1.61	 “Indemnitor” has the meaning set forth in
Section 12.3. 

  

	1.62	 “Infringement Claim” has the meaning set forth in
Section 10.5. 

  

	1.63	 “Inventions” means all inventions, whether or not patentable, discovered, made
or conceived as a result of performance of activities contemplated by this Agreement. 

  

	1.64	 “Intellectual Property” shall mean, collectively, all
intellectual property rights and similar proprietary rights, including Trademarks, copyrights, Know-How and Patents, whether registered or unregistered, and all applications and registrations to register, and
renewals and extensions of, any of the foregoing. 

  

	1.65	 “JSC” and “Joint Steering
Committee” has the meaning set forth in Section 3.1. 

  

	1.66	 “Know-How” means all technical
information, know-how and data, including inventions, discoveries, trade secrets, specifications, instructions, processes, formulae, compositions of matter, cells, cell lines, assays, animal models and other
physical, biological, or chemical materials, expertise and other technology applicable to formulations, compositions or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or
processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety,
quality control, manufacturing, nonclinical and clinical data, regulatory documents, data and filings, instructions, processes, formulae, expertise and information, relevant to the research, development, manufacture, use, importation, offering for
sale or sale of, or which may be useful in studying, testing, developing, producing or formulating, products, or intermediates for the synthesis thereof. Know-How excludes Patents. 

 

	1.67	 “License” has the meaning set forth in Section 2.1.

  

	1.68	 “Losses” has the meaning set forth in Section 12.1.

  

	1.69	 “Manufacture” or “Manufacturing” shall mean the
activities required to manufacture Compositions or Products by a Party, itself or through its Affiliate or CMO, including test method development and stability testing, formulation development, process development, manufacturing scale up, process
validation, the manufacturing of the starting material, fill and finish activities and quality assurance/quality control. 

  

	1.70	 “Manufacturing License
Condition” means any event identified in Section 2.1(b). 

  

	1.71	 “Materials” has the meaning set forth in
Section 4.7. 

  
 7 

	1.72	 “Medical Affairs Activities” means the activities related to the dissemination
of scientific information, coordination of medical information requests and field based medical scientific liaisons with respect to a product, including: (a) any associated activities of medical scientific liaisons and the provision of medical
information services with respect thereto; (b) advisory boards; (c) conduct of scientific meetings; (d) publications and (e) any health and economics and research studies. For clarity, “Medical Affairs Activities”
excludes Development and Commercialization. 

  

	1.73	 “Milestone Event” means any event identified in
Section 8.2. 

  

	1.74	 “Milestone Payment” means any payment identified in
Section 8.2 to be made by Pediatrix to ARS on the occurrence of a Milestone Event. 

  

	1.75	 “NDA” means a New Drug Application, as defined by the FDA, a Marketing
Authorization Application (MAA), as defined by the EMA, or equivalent application, and all amendments and supplements thereto, filed with the applicable Regulatory Authority in any country or jurisdiction for approval to market a pharmaceutical
product (but not including application for Pricing and Reimbursement Approval). 

  

	1.76	 “Net Sales” means, with respect to any Product, the gross amount invoiced by
Pediatrix or its Affiliates or Sublicensees for sale or other transfer or disposition for value to Third Parties, less the following deductions, with respect to the sale or other transfer or disposition of such Product: 

[***]. 
 Such
deduction amounts shall be determined in accordance with GAAP, consistently applied. 
 Upon any sale or other transfer or disposition of any
Product that should be included within Net Sales for any consideration other than [***]. For clarity, in the event the Product is sold [***]. 

  
 8 

 The transfer of a Product to an Affiliate, Sublicensee, or other Third Party (w) [***], (x)
[***], or (z) [***]. 
 In no event shall any particular amount identified above be deducted more than once in calculating Net Sales. [***].

 Pediatrix and its Affiliates and Sublicensees shall not sell any Product in combination with or as part of a bundle with other products,
or offer packaged arrangements to customers that include a Product, in such a manner as to disproportionately discount the selling price of the Product as compared with the weighted-average discount applied to the other products, as a percent of the
respective list prices (or if not available, a good faith estimate thereof) of such products and the Product prior to applying the discount. 
  

	1.77	 “New IP” has the meaning set forth in
Section 10.1. 

  

	1.78	 “NMPA” means the National Medical Products
Administration of the People’s Republic of China, and local counterparts thereto, and any successor agency(ies) or authority having substantially the same function. 

 

	1.79	 “Patents” means (a) all national, regional and international patents,
certificates of invention, applications for certificates of invention, priority patent filings and patent applications, and (b) any renewals, divisions, continuations (in whole but not in part), or requests for continued examination of any of
such patents, certificates of invention and patent applications, and any all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, divisions, renewals, substitutions, confirmations,
registrations, revalidations, revisions, and additions of or to any of the foregoing. 

  

	1.80	 “Pediatrix Indemnitee” has the meaning set forth in
Section 12.1. 

  

	1.81	 “Pediatrix Product
Marks” has the meaning set forth in Section 10.7. 

  

	1.82	 “Pediatrix Technology”
means all (i) all Know-How that Pediatrix or its Affiliates Control as of the Effective Date or during the Term that is necessary or reasonably useful for the research, Development, manufacture,
testing, use, importation, offer for sale or sale of any Composition or Product (“Pediatrix Know-How”), and (ii) all Patents that Pediatrix or its
Affiliates Control as of the Effective Date or during the Term that would be infringed, absent a license or other right to practice granted under such Patents, by the research, Development, manufacture, use, importation, offer for sale or sale of
any Product (considering, for this purpose, pending patent applications to be issued with the then-pending claims) (“Pediatrix Patents”); provided that, if a Third Party becomes an
Affiliate of Pediatrix after the Effective Date as a result of a Change of Control of Pediatrix, then Pediatrix Technology shall exclude the Know-How or Patents owned or controlled by such Third Party before
the closing of such Change of Control transaction, unless such Know-How or Patent is already Controlled by Pediatrix or its Affiliates before the closing of such Change of Control transaction. For clarity,
Pediatrix Technology shall exclude New IP (which shall be owned solely by ARS as set forth in Section 10.1). 

  

	1.83	 “Pediatrix Territory” means the People’s Republic of China, including
mainland China, Hong Kong, Macau and Taiwan, each shall be deemed a region for the purpose of this Agreement. 

  
 9 

	1.84	 “Person” means any natural person, corporation, general partnership, limited
partnership, joint venture, proprietorship or other business organization or a Governmental Authority. 

  

	1.85	 “Pricing and Reimbursement Approval” means, with respect to a Product, the
approval, agreement, determination or decision of any Regulatory Authority establishing the price or level of reimbursement for such Product, as required in a given country or jurisdiction prior to sale of such Product in such jurisdiction.

  

	1.86	 “Product” means any pharmaceutical product containing a Composition as the sole
active ingredient and delivered through nasal spray. 

  

	1.87	 “Regulatory Approval” means any and all approvals,
licenses, registrations, permits, notifications and authorizations (or waivers) of any Regulatory Authority that are necessary for the manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale or other
commercialization of a Product in any country or jurisdiction. 

  

	1.88	 “Regulatory Authority” means any Governmental
Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of pharmaceutical
products in a given jurisdiction, including the National Medical Products Administration (NMPA). For countries where governmental approval is required for pricing or reimbursement for a pharmaceutical product to be reimbursed by national health
insurance (or its local equivalent), Regulatory Authority shall also include any Governmental Authority whose review or approval of pricing or reimbursement of such product is required. 

 

	1.89	 “Regulatory Data” means all regulatory information, materials, data and results
relating to a Product which are necessary for Regulatory Approvals and Pricing and Reimbursement Approvals for such Product, including, but not limited to the e-CTD dossiers submitted to and approved by
applicable Regulatory Authorities, in-vitro Product testing data and study data, data queries, data tables reports and case report forms generated during any
pre-clinical or clinical study or registry study, for such Product. 

  

	1.90	 “Regulatory Exclusivity” means any exclusive marketing rights or data
exclusivity rights conferred by any Regulatory Authority in accordance with Applicable Laws with respect to a Product other than Patents, including, as applicable, rights conferred in the U.S. under the Hatch-Waxman Act or the FDA Modernization Act
of 1997, in the EU under national implementations of Article 10 of Directive 2001/83/EC, in mainland China under Section 66 of Provisions for Drug Registration (2007 as updated) (SFDA Order No 28), or rights similar thereto.

  

	1.91	 “Regulatory Filing” means all applications, filings,
submissions, approvals, licenses, registrations, permits, notifications and authorizations (or waivers) with respect to the testing, Development, manufacture or Commercialization of any Product made to or received from any Regulatory Authority in a
given country, including any INDs and NDAs. 

  

	1.92	 “Safety Data” means Data related solely to any adverse drug experiences and
serious adverse drug experience as such information is reportable to Regulatory Authorities in or outside the Pediatrix Territory. Safety Data also includes “adverse events”, “adverse drug reactions”
and “unexpected adverse drug reactions” as defined in the ICH Harmonised Tripartite Guideline for Clinical Safety Data Management: Definitions and Standards for
Expedited Reporting. 

  

	1.93	 “SEC” means the U.S. Securities and Exchange Commission, or any successor
entity. 

  

	1.94	 “Second Region” has the meaning set forth in
Section 8.3(b)(ii). 

  
 10 

	1.95	 “Sublicensee” means a Third Party to whom Pediatrix grants a sublicense to
research, Develop, make, have made, use, import, promote, distribute, offer for sale or sell any Product in the Field in the Pediatrix Territory (either independently from or in cooperation with Pediatrix), beyond the mere right to purchase Products
from Pediatrix and its Affiliates. In no event shall ARS or any of its Affiliates be deemed a Sublicensee. 

  

	1.96	 “Supply Agreement” means the Development Supply Agreement or the Commercial
Supply Agreement, as applicable. 

  

	1.97	 “Tax Withholding Documents” means documents prepared by ARS in order for ARS to
obtain benefits under any applicable tax treaty, including the reduction or exemption from any withholding tax and the procurement of any available tax refunds, as described in Section 9.2(b). 

 

	1.98	 “Term” has the meaning set forth in Section 14.1.

  

	1.99	 “Third Party” means any entity other than ARS or Pediatrix or an Affiliate of
ARS or Pediatrix, respectively. 

  

	1.100	 “Trademark” means any trademark, trade name, service mark, service name, brand,
domain name, trade dress, logo, slogan, or other indicia of origin or ownership including the goodwill and activities associated with each of the foregoing. 

  

	1.101	 “Upstream Licenses” means any and all
agreements between ARS, or any of its Affiliates, on the one hand, and any Third Party (the “Upstream Licensors”), on the other hand, pursuant to which ARS has
(a) in-licensed any Patent or Know-How Controlled by such Third Party that are included as part of the ARS Patents or ARS
Know-How or (b) agreed to provisions that would require Pediatrix to make any payments (including royalties) to any Third Party or to undertake or observe any restrictions or obligations with respect to
the Development, Manufacture or Commercialization of the Products in the Field. Exhibit 2 sets forth a list of all Upstream Licenses as of the Effective Date. 

 

	1.102	 “Upstream Licensors” has the
meaning set forth in Section 1.101. 

  

	1.103	 “U.S.” means the United States of America, including its territories and
possessions and the District of Columbia. 

  

	1.104	 “Valid Claim” means (a) a claim of an issued and unexpired patent that has
not been revoked or held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction that is not appealable or has not been appealed within the time allowed for appeal, and that has not been
abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise, or (b) a claim of a pending patent application that was filed in good
faith, has not been pending for more than [***] from its priority date, and has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken. 

 

	2.	 GRANT OF LICENSES 

 

	2.1	 Licenses Granted to Pediatrix. Subject to the terms and conditions of this Agreement, ARS hereby
grants to Pediatrix, as for ARS Patents until expiration of the last-to-expire Valid Claim in such ARS Patents, and as for ARS
Know-How, during the Term, the following license (the “License”): 

  
 11 

	 	(a)	 an exclusive (even as to ARS, except as expressly set forth herein), nontransferable (except in accordance with
Section 16.5), royalty-bearing license, with the right to grant sublicenses as provided in Section 2.2, under the ARS Technology to Develop, use, register, and import Compositions and Products in
the Field and in the Pediatrix Territory and to promote, offer for sale and sell Products in the Field and in the Pediatrix Territory, which license includes the rights (i) to incorporate Regulatory Data within the ARS Technology in Regulatory
Filings with Regulatory Authorities in the Pediatrix Territory or in Commercialization materials and (ii) to cross-reference Regulatory Filings Controlled by ARS outside the Pediatrix Territory, in each case (i) and (ii) solely for the
purposes of (A) obtaining and holding Regulatory Approval for Products in the Field in the Pediatrix Territory or (B) supporting Commercialization activities for Products in the Field in the Pediatrix Territory. 

 

	 	(b)	 an exclusive (even as to ARS), nontransferable (except in accordance with
Section 16.5), royalty-bearing license, with the right to grant sublicenses as provided in Section 2.2, under the ARS Technology to Manufacture Composition and Products in the Pediatrix Territory
solely for the purpose of exercising the license granted in Section 2.1(a); provided that the license in this Section 2.1(b) shall be subject to and effective only upon after demonstration by Pediatrix to ARS that
Pediatrix or its Affiliate or CMO is able to manufacture Compositions and Products in a manner and at a level of quality that is no less than the manner and quality of manufacture of Compositions and Products by ARS or its Affiliates or CMOs (that
Pediatrix or its Affiliate or CMO possesses such ability, the “Manufacturing License Condition”). In the event that within [***] after Pediatrix’s demonstration described in the preceding sentence the Parties cannot agree on
whether Pediatrix, its Affiliate, or CMO meets the Manufacturing License Condition, then the Parties shall expeditiously and in good faith refer such matter for expedited resolution to an Third Party expert mutually agreed upon by the Parties who
has at least ten (10) years of experience in the manufacture of pharmaceutical products (or who has such other similar credentials as mutually agreed by the Parties), and such expert’s decision on the matter shall be binding upon the
Parties (and, for clarity, such matter shall not be subject to the dispute resolution procedures set forth in Article 15 (Dispute Resolution)). 

 

	2.2	 Sublicenses. Pediatrix shall have the right to grant sublicenses under the licenses granted in
Section 2.1 to (a) any Affiliate (with the right to further sublicense to other Affiliates of Pediatrix) with the prior written notice to ARS; provided that such sublicense shall automatically terminate
if the sublicensee ceases to be an Affiliate of Pediatrix, (b) Third Party subcontractor engaged by Pediatrix with the prior written notice to ARS, solely to the extent necessary for the subcontractor to perform certain obligations of Pediatrix
under this Agreement and provided that Pediatrix retains the economic interest in the Products, and (c) any Third Party in the Pediatrix Territory with the prior written consent of ARS which consent shall not be unreasonably
withheld, delayed or conditioned (for clarity, any further sublicense by such Third Party sublicensees shall also require ARS’s consent). All sublicenses granted under the licenses granted in Section 2.1 shall
be in writing and shall be subject to, and consistent with, the terms and conditions of this Agreement. Pediatrix shall ensure that each agreement with a Sublicensee grants ARS all rights with respect to Data, Inventions, Intellectual Property, and
Regulatory Filings made or generated by such Sublicensee as if such Data, Inventions, Intellectual Property, and Regulatory Filings were made or generated by Pediatrix. Pediatrix shall be responsible for the compliance of its Sublicensees with the
terms and conditions of this Agreement. When Pediatrix requests ARS’s consent to any sublicense, Pediatrix shall provide ARS with a full and complete copy of such sublicense agreement [***]. Within [***] after entering into any such sublicense,
Pediatrix shall deliver a fully executed and redacted (to the extent necessary) copy of the agreement to ARS. Pediatrix shall remain directly responsible for all of its obligations under this Agreement that have been delegated, subcontracted or
sublicensed to any Affiliates or Sublicensees or subcontractors. 

  

	2.3	 Licenses Granted to ARS. Subject to the terms and
conditions of this Agreement, Pediatrix hereby grants to ARS: 

  
 12 

	 	(a)	 an exclusive (even as to Pediatrix and its Sublicensees, except as expressly set forth herein), royalty-free,
fully-paid, irrevocable, perpetual license, with the right to sublicense through multiple tiers, under the Pediatrix Technology to research, Develop, make, have made, use, register, import, promote, sell and offer for sale Compositions and Products
outside the Pediatrix Territory, which license includes the rights (i) to incorporate Regulatory Data within the Pediatrix Technology in Regulatory Filings with Regulatory Authorities outside the Pediatrix Territory and (ii) to
cross-reference Regulatory Filings Controlled by Pediatrix in the Pediatrix Territory, in each case solely for the purpose of (A) obtaining Regulatory Approval for Products outside the Pediatrix Territory or (B) supporting
commercialization activities for Products outside the Pediatrix Territory; and 

  

	 	(b)	 a non-exclusive, royalty-free, fully-paid license, with the right to
sublicense through multiple tiers, under the Pediatrix Technology to exercise the reserved rights in Section 2.4(b). 

  

	2.4	 Reserved Rights. ARS hereby expressly reserves: 

 

	 	(a)	 all rights to practice, and to grant licenses under, the ARS Technology outside of the scope of the licenses
granted in Section 2.1, for any and all purposes, and 

  

	 	(b)	 the right to use the ARS Technology in the Field in the Pediatrix Territory in order to perform its obligations
under this Agreement. 

 Subject only to the rights expressly granted under Section 2.3,
Pediatrix hereby expressly reserves all rights to practice, and to grant licenses under, the Pediatrix Technology for any and all purposes. 
  

	2.5	 No Implied Licenses; Negative Covenant. Except as set forth in this Agreement, neither Party
shall acquire any license or other intellectual property interest, by implication or otherwise, under or to any Patents, Know-How or other Intellectual Property owned or controlled by the other Party. Neither
Party shall, nor shall it permit any of its Affiliates or sublicensees to, practice any Patents or Know-How licensed to it by the other Party outside the scope of the licenses granted to it under this
Agreement. 

  

	2.6	 Technology Transfer and Assistance. 

 

	 	(a)	 Promptly after the Effective Date and in any event within [***] following the Effective Date, ARS shall, at its
costs and expenses, disclose and make available to Pediatrix in reasonable form all ARS Know-How, Regulatory Data, and Regulatory Filings in ARS or its Affiliate’s Control as of the Effective Date.

  

	 	(b)	 Thereafter, throughout the Term, ARS shall without additional compensation, disclose and make available to
Pediatrix, in whatever form Pediatrix may reasonably request (including by providing copies thereof), all ARS Know-How, Regulatory Data, and Regulatory Filings not previously provided to Pediatrix, promptly
after the earlier of the creation, development, making, conception or reduction to practice of such ARS Know-How, Regulatory Data, and Regulatory Filings. 

 

	 	(c)	 From the Effective Date to December 31, 2022, ARS shall, at Pediatrix’s request, provide Pediatrix with
reasonable access to ARS personnel involved in the Development of Compositions and Product, either in-person at ARS’s facility or by teleconference for up to [***], at [***] costs of Pediatrix. In the
event Pediatrix reasonably requests assistance from ARS that would require ARS to provide assistance (i) in the Calendar Year 2021 in [***] in excess of the amounts described in the preceding sentence or (ii) any time after December 31,
2022, ARS [***] provide such assistance to Pediatrix and Pediatrix shall reimburse ARS for such technical assistance and up to a number of [***] as agreed by the Parties in writing at [***] based on written invoices provided by ARS from time to time
and within [***] of the receipt of an invoice from ARS. 

  
 13 

	 	(d)	 Pediatrix shall and shall cause its Affiliates to, without additional compensation, disclose and make available
to ARS, in whatever form ARS may reasonably request (including by providing copies thereof), any Pediatrix Know-How not previously provided to ARS, promptly after the earlier of the development, making,
conception or reduction to practice of such Pediatrix Know-How. 

  

	2.7	 Exclusivity. Pediatrix hereby covenants that, during the Term, neither it nor its Affiliates
shall, directly or indirectly (including via a license to a Third Party), develop, manufacture, market, promote, sell, or otherwise commercialize any Competitive Product anywhere in the world. ARS hereby covenants that, during the Term, neither it
nor its Affiliates shall, directly or indirectly (including via a license to a Third Party), develop, manufacture, market, promote, sell, or otherwise commercialize any Product (except as expressly contemplated under this Agreement) or Competitive
Product in the Pediatrix Territory. If a Third Party becomes an Affiliate of a Party after the Effective Date as a result of a Change of Control of a Party, and such new Affiliate is engaged in any activities of a Competitive Product that, if
conducted by such Party, would breach its exclusivity obligations set forth in this Section 2.7, then such new Affiliate shall have [***] from the closing of such Change of Control transaction to wind down or divest such
Competitive Product, and the continuation of such activities for the Competitive Product during such [***] period shall not constitute a breach of this Section 2.7, so long as such new Affiliate conducts such activities
independently of the activities of this Agreement. 

  

	2.8	 No Diversion. Each Party hereby covenants and agrees that it shall not, shall ensure, that its
Affiliates, and sublicensees shall not, either directly or indirectly, promote, market, distribute, import, sell or have sold any Product, including via Internet or mail order, to any Third Party or to any address or Internet Protocol address or the
like in the other Party’s territory or to any Third Party that such Party knows (or reasonably should know after due injury) has previously exported or is likely to export the Product to the other Party’s territory. Neither Party shall
engage, nor permit its Affiliates and sublicensees to engage, in any advertising or promotional activities relating to any Product for use directed primarily to customers or other buyers or users of the Product located in any country or jurisdiction
in the other Party’s territory, or solicit orders from any prospective purchaser located in any country or jurisdiction in the other Party’s territory. If a Party or its Affiliates or its sublicensees receives any order for the Product
from a prospective purchaser located in a country or jurisdiction in the other Party’s territory, such Party shall immediately refer that order to such order Party and shall not accept any such orders. Neither Party shall, nor permit its
Affiliates and sublicensees to, deliver or tender(or cause to be delivered or tendered) any Product to any Third Party for use in or distribution into the other Party’s territory, except as permitted under this Agreement under
Section 2.4. 

  

	2.9	 Compliance with Law. Each Party shall conduct, and shall use
Commercially Reasonable Efforts to cause its sublicensees, contractors, and consultants to conduct, all of its activities contemplated under this Agreement in accordance with all Applicable Laws. 

 

	3.	 GOVERNANCE 

  

	3.1	 Joint Steering Committee. Promptly after the Effective Date (within
[***] in any event), the Parties shall establish a joint steering committee (the “Joint Steering Committee” or the “JSC”), composed of [***] Party ([***]) to oversee and guide the strategic direction
of the collaboration of the Parties under this Agreement. The JSC shall in particular: 

  
 14 

	 	(a)	 coordinate the Development, regulatory, Commercialization, and other activities of the Parties under this
Agreement, and provide a forum for and facilitate communications between the two Parties under this Agreement; 

  

	 	(b)	 discuss and determine a strategy for the Development, Manufacture and Commercialization of the Product in the
Pediatrix Territory, and approve any (i) Development Plans, and (ii) amendments to the Development Plan; 

  

	 	(c)	 review and coordinate strategy for Regulatory Filings for the Product in the Pediatrix Territory;

  

	 	(d)	 discuss and review Medical Affairs Activities for the Product in the Pediatrix Territory;

  

	 	(e)	 review and discuss the Commercialization Plan for Commercialization of the Product in the Pediatrix Territory;

  

	 	(f)	 facilitate exchange of Regulatory Data; and 

 

	 	(g)	 perform such other functions as appropriate to further the purpose of this Agreement, as expressly set forth in
the Agreement or allocated to it by the Parties’ written agreement. 

  

	3.2	 Membership and Meetings. 

 

	 	(a)	 Members. The JSC representative shall have appropriate knowledge and expertise to make recommendations
and decisions arising within the scope of the JSC’s responsibilities. Each Party may replace its JSC representatives on written notice to the other Party, but each Party shall strive to maintain continuity in the representation of its JSC
members. Each Party shall appoint one (1) of its representatives to act as a co- chairperson of the JSC. The co-chairpersons shall jointly prepare and circulate
agendas to JSC members at least [***] before each regularly scheduled JSC meeting and shall direct the preparation of reasonably detailed minutes for each JSC meeting, which shall be approved by the
co-chairpersons and circulated to JSC members within [***] of such meeting. 

  

	 	(b)	 Meetings. The JSC shall hold meetings at such times as it elects to do so, but in no event shall such
meetings be held less frequently than [***] every [***], unless otherwise agreed by the Parties in writing. Upon reasonable written request by any Party to hold ad-hoc meetings, both Parties agree to schedule
such ad-hoc meetings within a reasonable time frame. Meetings of the JSC may be held in person, or by audio or video teleconference, and all in-person meetings shall be
held at locations alternately selected by the Parties. Each Party shall be responsible for all of its own expenses of participating in [***] meetings. No action taken at any JSC meeting shall be effective [***]. 

 

	 	(c)	 Non-Member Attendance. Each Party may from time to
time invite a [***] of participants, in addition to its representatives, to attend the JSC meetings in a non-voting capacity; provided that if either Party intends to have any Third Party (including any
consultant) attend such a meeting, such Party shall provide at least [***] prior written notice to the other Party and obtain the other Party’s approval for such Third Party to attend such meeting, which approval shall not be unreasonably
withheld or delayed. Such Party shall ensure that such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement. 

  
 15 

	3.3	 Decision-Making. All decisions of the JSC shall be made by [***], with each Party’s
representatives collectively having [***]. If after reasonable discussion and good faith consideration of each Party’s view on a particular matter before the JSC, the representatives of the Parties cannot reach an agreement as to such matter
within [***] after such matter was brought to the JSC for resolution or after such matter has been referred to the JSC, such disagreement shall be referred to the Chief Executive Officer of ARS and the Chief Executive Officer of Pediatrix or its
designee (collectively, the “Executive Officers”) for resolution. If the Executive Officers are not able to resolve such matter within [***] after such matter has been referred to them, the following should apply: if such
matter relates primarily to [***], then the Executive Officer of [***] shall be entitled to make the final decision regarding such matter; provided, that, if [***] reasonably believes that such decision [***] would be reasonably expected to
cause (a) a [***], (b) a [***], or (c) [***], the Executive Officer of [***] shall be entitled to make the final decision regarding such matter. 

  

	3.4	 Limitations on Authority. The JSC shall have only such powers as are expressly assigned to it in
this Agreement, and such powers shall be subject to the terms and conditions of this Agreement. Without limiting the generality of the foregoing, the JSC shall not have the power to amend this Agreement, and no decision of the JSC may be in
contravention of any terms and conditions of this Agreement. 

  

	3.5	 Alliance Managers. Promptly after the Effective Date, each Party shall appoint an
individual to act as the alliance manager for such Party (the “Alliance Manager”). Each Alliance Manager shall be responsible for alliance management between the Parties on a day-to-day basis throughout the Term. Each Alliance Manager shall be permitted to attend JSC meetings as appropriate as non- voting participants. The Alliance Managers
shall be the primary contact for the Parties regarding the day-to-day activities contemplated by this Agreement and shall facilitate all such activities hereunder. Each
Party may replace its Alliance Manager with an alternative representative at any time with prior written notice to the other Party. Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager. Each
Alliance Manager shall be charged with creating and maintaining a collaborative work environment within the JSC. 

  

	4.	 DEVELOPMENT 

  

	4.1	 Development and Medical Affairs Responsibilities. 

 

	 	(a)	 Development in the Pediatrix Territory. Subject to the terms and conditions of this Agreement, Pediatrix
shall be responsible, at its sole cost and expense, for all Development that is necessary for or otherwise supports Regulatory Approval in the Pediatrix Territory for Products, including all clinical trials, and activities related to post- approval
commitments and commercialization tests in the Pediatrix Territory. Pediatrix may reasonably request that ARS conduct, or assist Pediatrix with, certain Development activities for the Products in the Pediatrix Territory on Pediatrix’s behalf,
at Pediatrix’s expense. If ARS agrees to conduct or assist with any such activities, the Parties shall amend the Development Plan accordingly, on terms to be negotiated in good faith, including at minimum that Pediatrix shall reimburse all
reasonable internal (at a fully- burdened rate) and external costs incurred by ARS to conduct or assist with such activities in accordance with the Development Plan; [***]. 

 

	 	(b)	 Medical Affairs Activities in the
Pediatrix Territory. Pediatrix shall be responsible for all Medical Affairs Activities to be conducted with respect to each Product in the Field solely in the Pediatrix Territory at its own cost and expense, and shall keep
ARS reasonably informed on the Medical Affairs Activities planned and/or performed by Pediatrix, its Affiliates and sublicensees for the Product in the Field in the Pediatrix Territory. For clarity, Pediatrix shall not conduct any Medical Affairs
Activities for the Product outside the Pediatrix Territory. 

  
 16 

	 	(c)	 Development Outside the Pediatrix Territory. Subject to Section 4.3, ARS
(itself and with ARS Collaborators, as applicable) shall be responsible, at its sole cost and expense, for all Development of Compositions and Products that support obtaining and maintaining Regulatory Approval outside the Pediatrix Territory. ARS,
itself or through ARS Collaborators, may conduct all such activities in its sole discretion. 

  

	4.2	 Development Plan. Subject to Section 4.1(a), Pediatrix shall be
obligated to conduct Development activities that are necessary for or otherwise support Regulatory Approval in the Pediatrix Territory for Products, and Pediatrix shall conduct all such Development activities in a manner materially consistent with a
written Development plan which shall contain: (a) an outline and synopsis of the clinical trials to be conducted by Pediatrix in the Pediatrix Territory, and (b) the material activities to be performed by the Parties to obtain the
Regulatory Approvals for the Products in the Pediatrix Territory (the “Development Plan”). Pediatrix shall share the Development Plan with the JSC for review, discussion and approval as soon as practicable after the Effective
Date. From time to time, but at least [***], Pediatrix shall propose updates or amendments to the Development Plan and submit such proposed updated or amended plan to the JSC for review, discussion, and approval. Once approved by the JSC, the
updated or amended Development Plan shall become effective. 

  

	4.3	 Global Trials. If the Parties agree to conduct a Global Trial, then the Parties
and, if applicable, the relevant ARS Collaborators, shall discuss in good faith and determine the terms under which the Parties will conduct such Global Trial, including the allocation between the Parties of costs and expenses, decision-making
process and authority for trial design and protocols, management of budget overages, allocation of Development activities and responsibilities and data sharing procedures. Pediatrix shall determine, in its sole discretion, whether and to what extent
it participates in any cost-sharing or other activities related to Global Trials. ARS shall also determine, in its sole discretion, whether and to what extent it participates, and any of its ARS Collaborators participate, in any cost-sharing or
other activities related to Global Trials. Upon agreement to conduct a Global Trial, the Parties shall enter into a written agreement setting forth all such agreed terms. 

 

	4.4	 Conduct of Development Activities. Pediatrix shall
perform its obligations under this Agreement in compliance with all Applicable Laws, including the FCPA and good scientific and clinical practices under the Applicable Laws of the country or jurisdiction in which such activities are conducted.

  

	4.5	 Records and Updates. Pediatrix shall maintain records, in sufficient detail and in good
scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved by or on behalf of Pediatrix in the performance of Development activities pursuant to this Agreement.
Pediatrix shall keep the JSC regularly informed of the status of material Development activities with respect to Compositions and Products in the Field in the Pediatrix Territory conducted by it or on its behalf pursuant to this Agreement. Without
limiting the foregoing, at least every [***], Pediatrix shall provide the JSC with summaries in reasonable detail of all data and results generated or obtained in the course of Pediatrix’s performance of activities with respect to Compositions
and Products in the Field in the Pediatrix Territory. Pediatrix shall document all non-clinical and clinical trial data in formal written study reports according to Applicable Laws and applicable national and
international guidelines (e.g., ICH, GCP, GLP and cGMP). 

  

	4.6	 Development Diligence. Pediatrix shall use Commercially Reasonable Efforts to
Develop Product in the Field throughout the Pediatrix Territory in a manner materially consistent with the Development Plan. 

  
 17 

	4.7	 Materials Transfer. Subject to Section 2.6 and except as
contemplated in Sections 14.5 and 14.6, in order to facilitate the Development activities contemplated by this Agreement, either Party may provide to the other Party certain materials, including but not limited to, the
drug substance and its related compounds including impurities, metabolites and other tangible substance Controlled by the supplying Party (collectively, “Materials”) at [***] for use by the other Party solely for the purpose
of performing its Development activities. For avoidance of doubt, the supply Drug Product for Development use are not subject to this Section 4.7 and shall be governed by Section 7.1
hereof. Except as otherwise provided for under this Agreement, all such Materials delivered to the other Party shall remain the sole property of the supplying Party, shall be used only in furtherance of the other Party’s Development
activities conducted in accordance with this Agreement, shall not be used or delivered to or for the benefit of any Third Party, without the prior written consent of the supplying Party, and shall be used in compliance with all Applicable Laws. The
Materials supplied under this Agreement must be used by the recipient Party with prudence and appropriate caution in any experimental work because not all of their characteristics may be known. If applicable, the receiving Party may require
supplying Party to provide to the recipient Party the certificate of analysis for the Materials supplied by the supplying Party and represent and warrant that the qualities and standards of such Materials meet the specifications specified in the
certificate of analysis. Except as expressly set forth in the preceding sentence, THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING
WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY.

  

	5.	 REGULATORY ACTIVITIES AND PRICING APPROVALS 

 

	5.1	 Conduct of Regulatory Activities. Pediatrix shall be solely responsible, at its own cost and
expense, for formulating regulatory strategy and for preparing, filing, obtaining and maintaining Regulatory Approvals for Products in the Field in the Pediatrix Territory. Pediatrix shall be the holder of all Regulatory Approvals for Products in
the Field in the Pediatrix Territory, except if ARS is required by Applicable Laws to hold an Import Drug License or equivalent for any Product in the Pediatrix Territory, in which case ARS shall (a) hold such Regulatory Approval for
Pediatrix’s benefit, (b) appoint Pediatrix (or an Affiliate or Sublicensee of Pediatrix) as its authorized exclusive legal agent of record to interact with NMPA and serve as its exclusive distributor for the Product in the Pediatrix
Territory, and Pediatrix shall reimburse ARS for all cost and expense incurred in connection therewith, (c) shall provide access to and copies of such Regulatory Filings, Regulatory Approvals and any Pricing and Reimbursement approvals to
Pediatrix promptly upon Pediatrix’s request, and (d) shall promptly transfer such Regulatory Approval to Pediatrix or its designee when allowed by Applicable Laws. Pediatrix shall use Commercially Reasonable Efforts to file NDAs and, as
applicable, seek Pricing and Reimbursement Approval for and seek and maintain Regulatory Approval for Products in the Field in all regions throughout the Pediatrix Territory. Pediatrix shall keep ARS regularly informed of, the preparation,
Regulatory Authority review and approval of substantive submissions and material communications with Regulatory Authorities with respect to Products in the Field in the Pediatrix Territory. ARS shall use Commercially Reasonable Efforts to assist
with Pediatrix with interactions with Regulatory Authorities with respect to Products in the Field in the Pediatrix Territory, and Pediatrix shall reimburse ARS for any third party costs incurred to provide such assistance that are agreed upon
writing by both Parties. Parties shall conduct all such activities in accordance with Applicable Laws. 

  

	 	(a)	 Regulatory Costs. Except as agreed otherwise by the Parties under
Section 4.3, Pediatrix shall bear all expenses to conduct all regulatory activities in the Pediatrix Territory under this Agreement including regulatory filing or equivalent fees, and any costs to translate, analyze or re-analyze any data for regulatory authorities in the Pediatrix Territory. 

  

	 	(b)	 Regulatory Filings. Pediatrix shall be responsible for all regulatory activities
leading up to and including the obtaining of the Regulatory Approval for a Product from the Regulatory Authority on a region-by-region basis in the Pediatrix Territory,
subject to the following coordination: 

  
 18 

	 	(i)	 Each Party shall fully disclose all such Regulatory Data included or incorporated into its Regulatory Filings
that are derived from the other Party’s respective territory; 

  

	 	(ii)	 Each Party shall promptly notify the other Party of any regulatory materials (other than routine
correspondence, administrative documents and excluding documents related to Pricing and Reimbursement Approval) relating to any Composition or Product submitted by or on behalf of each Party to or received from any Regulatory Authority in the
Pediatrix Territory. If any such materials are not in the English language, Pediatrix shall provide ARS with an English summary at the time of provision, and at ARS’s request [***], a true, complete, accurate and certified English translation
thereof as soon as practicable. 

  

	 	(iii)	 Each Party shall promptly provide the other Party with copies of any material documents, information and
correspondence received from a Regulatory Authority in the Pediatrix Territory relating to any Composition or Product, and Pediatrix shall provide ARS with an English summary at the time of provision, and at ARS’s request [***], an English
translation thereof. 

  

	 	(iv)	 Pediatrix shall provide ARS for review and comment copies of all material Regulatory Filings to be submitted to
a Regulatory Authority in the Pediatrix Territory (other than routine correspondence, administrative documents and excluding documents related to Pricing and Reimbursement Approval) with an English summary (and at ARS’s request [***], an
English translation thereof) prior to the relevant submission to allow sufficient time for review, and whenever possible, at least [***] in advance of their intended date of submission. 

 

	 	(v)	 ARS shall provide any comments in due course in order to not delay regulatory activities in the Pediatrix
Territory. Pediatrix shall in good faith take into account ARS’ comments. 

  

	 	(vi)	 Within [***] after a Regulatory Filing is submitted to any Regulatory Authority in the Pediatrix Territory,
each Party shall, and shall require its Affiliates and Sublicensees to, provide the other Party an electronic copy thereof. For avoidance of doubt, Regulatory Filings also include discussions with respect to labeling for a Product in the Pediatrix
Territory. 

  

	 	(vii)	 For the avoidance of doubt, ARS shall not file any Regulatory Filings in the Pediatrix Territory without first
obtaining prior consent from Pediatrix, and Pediatrix shall not file any Regulatory Filings outside the Pediatrix Territory without first obtaining prior consent from ARS. 

 

	 	(c)	 Regulatory Meetings. Pediatrix and its Affiliates shall be responsible for conducting interactions with
Regulatory Authorities in connection with the Product in the Field in the Pediatrix Territory. Pediatrix shall provide ARS with reasonable advance notice of all meetings, conferences and discussions (whether in person or by telephone or video
conference) scheduled with any Regulatory Authority in the Pediatrix Territory concerning the Products. Pediatrix shall lead any such meeting or discussion and ARS shall have the right, but not the obligation, to attend and participate in any such
meeting or discussion unless prohibited or restricted by Applicable Laws or Regulatory Authority at ARS’s sole cost and expense. At Pediatrix’s request, ARS shall reasonably cooperate with Pediatrix in preparing such meeting or discussion.
If ARS elects not to participate in such meetings, conferences or discussions, Pediatrix shall provide written summaries of such meetings, conferences or discussions in English as soon as reasonably practicable after the conclusion thereof.

  
 19 

	 	(d)	 Diligence. Pediatrix shall use Commercially Reasonable Efforts to prepare, obtain, maintain, and renew
all necessary Regulatory Approvals for the Products in the Field in the Pediatrix Territory, including using Commercially Reasonable Efforts to prepare, obtain, maintain, and renew all necessary Regulatory Approvals for Products. In connection
therewith, Pediatrix shall use Regulatory Data and/or the Regulatory materials provided by ARS to Pediatrix, which use shall be in compliance with all Applicable Laws, including all laws governing protection of personal data in the Pediatrix
Territory. If additional quality, pre-clinical or clinical data is required by Applicable Law to obtain Regulatory Approvals in the Pediatrix Territory for such Product, Pediatrix, at its sole cost and
expense, shall be responsible for conducting such necessary additional quality, pre-clinical or clinical Development; provided, however, that the foregoing shall not limit Pediatrix’s
diligence or other obligations under this Agreement. 

  

	 	(e)	 Pricing. Pediatrix shall use Commercially Reasonable Efforts to prepare, obtain, and maintain all
necessary Pricing and Reimbursement Approvals for each Product for which NDA approval has been obtained in the Pediatrix Territory. In connection therewith, Pediatrix shall use Regulatory Data and/or the Regulatory materials provided by ARS to
Pediatrix, which use shall be in compliance with all Applicable Laws, including laws governing protection of personal data in the Pediatrix Territory. [***] shall have final decision-making authority to determine and establish the price and terms of
sale (including any rebates or discounts) for each Product in the Field for each region in the Pediatrix Territory in conformance with Applicable Law. 

  

	5.2	 Regulatory Activities outside the
Pediatrix Territory. ARS agrees to keep Pediatrix informed of the preparation, Regulatory Authority review and approval of submissions and communications with Regulatory Authorities with respect to Products in the Field
outside the Pediatrix Territory. In addition, ARS shall, upon reasonable request by Pediatrix, [***] provide Pediatrix with copies of any material documents, information and correspondence received from a Regulatory Authority outside the Pediatrix
Territory, to the extent the requested items are in ARS’s possession and for which ARS has the legal right to disclose and transfer. In the event that Regulatory Data of ARS shall be incorporated in the Regulatory Filing to obtain Regulatory
Approvals in any region in the Pediatrix Territory, and ARS has been informed in writing of such Regulatory Data that have been so incorporated, ARS shall, to the extent the requested items are in ARS’s possession and for which ARS has the
legal right to disclose and transfer, [***] provide Pediatrix copies of any modification, correction and revision of such Regulatory Data to fulfill Pediatrix’s obligation in Development and Regulatory Approval in the Pediatrix Territory.
Pediatrix shall fully disclose to ARS all such Regulatory Data that has been incorporated into the Regulatory Filing. Upon Pediatrix’s reasonable request and expense, ARS shall assist Pediatrix to fulfill the requirements of any Regulatory
Authority in the Pediatrix Territory related to Regulatory Data provided by ARS and incorporated in the Regulatory Filing in the Pediatrix Territory, and Pediatrix shall reimburse all reasonable external costs agreed upon in writing by both Parties
that are incurred by ARS to conduct such activities. 

  

	5.3	 Inspections and Audits. 

 

	 	(a)	 By Regulatory Authorities. In the event Pediatrix receives any correspondence, inquiry or request for an
inspection or audit from a Regulatory Authority which relates to Regulatory Data or Product, Pediatrix shall promptly notify ARS in writing of such correspondence, inquiry or request of any inspection or audit. ARS shall cooperate with Pediatrix, at
Pediatrix’s expense, in responding to such correspondence, inquiry or any inspection or audit concerning such Regulatory Data, and Pediatrix shall reimburse all reasonable internal (at a fully-burdened rate) and external costs incurred by ARS
to conduct such activities; [***]. 

  
 20 

	 	(b)	 By Pediatrix. In the event that Regulatory Data provided by ARS shall be incorporated in
the Regulatory Filing to obtain Regulatory Approvals in Pediatrix Territory, ARS shall permit Pediatrix or its authorized representatives, which are subject to ARS’ reasonable prior approval, to conduct a reasonable examination or quality
inspection of such Regulatory Data (but no more than once per Calendar Year). 

  

	5.4	 Adverse Event Reporting; Pharmacovigilance Agreement. As between the Parties: (a) [***] shall be
responsible for the timely reporting of all quality issues, complaints and Safety Data relating to Products to the appropriate Regulatory Authorities outside the Pediatrix Territory and shall timely report to [***] the content of the report made to
the Regulatory Authorities; and (b) except as otherwise agreed in writing by the Parties, [***] shall be responsible for the timely reporting of all quality issues, complaints and Safety Data relating to Products to the relevant Regulatory
Authorities in the Pediatrix Territory, in each case in accordance with Applicable Laws of the relevant countries or jurisdictions and Regulatory Authorities. In addition, [***] shall be responsible for responding to technical and medical questions
from all sources in the Pediatrix Territory relating to the use and functioning of the Products, and shall also serve as the batch release, product defect and recall contact in the Pediatrix Territory, for which [***] shall provide reasonably
necessary assistance. The Parties shall cooperate with each other with respect to their respective pharmacovigilance responsibilities, and each Party shall be solely responsible for its costs relating to its respective pharmacovigilance
responsibilities. The Parties shall negotiate in good faith and enter into, in timely manner, a mutually acceptable pharmacovigilance agreement with respect to the Products, pursuant to which ARS shall hold and control the global safety database for
the Products. Until such pharmacovigilance agreement is established, [***] shall report quality issues, complaints and Safety Data relating to clinical trials in the Pediatrix Territory up until the submission of the application to regulatory
authorities in the Pediatrix Territory. Unless otherwise mutually agreed, such pharmacovigilance agreement shall cover the exchange of safety information and appropriate management of pharmacovigilance activities to fulfill all legal and regulatory
requirements both inside and outside of the Pediatrix Territory. 

  

	6.	 COMMERCIALIZATION 

 

	6.1	 Commercialization. Pediatrix shall be responsible for Commercializing Products in the Field in
the Pediatrix Territory during the Term, subject to the terms and conditions of this Agreement. Pediatrix shall perform all Product Commercialization activities, and [***], all at [***] cost. [***]: (a) [***]; (b) [***]; (c) [***]; (d) [***]; and
(e) [***]. 

  

	6.2	 Commercialization Plan. No later than [***] after the submission of the first NDA
for Product approval to Regulatory Authorities in any region of the Pediatrix Territory, Pediatrix shall prepare a preliminary, non-binding and reasonably detailed plan for the Commercialization of Products in
the Field in the Pediatrix Territory during the first [***] after First Commercial Sale in the Pediatrix Territory (the “Commercialization Plan”). Pediatrix shall update the Commercialization Plan [***] and shall promptly
provide each such update and any material amendments to each Commercialization Plan to the JSC for review and discussion before adopting such update and amendment. Pediatrix shall conduct Commercialization activities for the Product in the Pediatrix
Territory in a manner materially consistent with the Commercialization Plan. 

  
 21 

	6.3	 Commercialization Reports. Pediatrix shall update ARS at each regularly scheduled
JSC meeting regarding the significant Commercialization activities with respect to the Product in the Field in the Pediatrix Territory. Each such update shall include a reasonably detailed summary of Pediatrix’s, its Affiliates’ and
Sublicensees’ significant Commercialization activities with respect to the Product in the Field in the Pediatrix Territory, covering subject matter at a level of detail reasonably required by ARS and sufficient to enable ARS to determine
Pediatrix’s compliance with its diligence obligations pursuant to Section 6.4. 

  

	6.4	 Diligence. During the Term, Pediatrix shall use Commercially Reasonable Efforts to market,
promote and otherwise Commercialize Products in the Field throughout the Pediatrix Territory in any region in which Regulatory Approval is obtained, unless agreed otherwise in writing with ARS. Without limiting the foregoing, Pediatrix shall use
Commercially Reasonable Efforts to achieve First Commercial Sale of a Product in a given region in the Pediatrix Territory within a reasonable time, and generally targeting within [***] after the date on which Pediatrix is notified that the Product
has received Regulatory Approval in such region in the Pediatrix Territory. 

  

	7.	 MANUFACTURE AND SUPPLY 

 

	7.1	 Development Supply. 

 

	 	(a)	 Obligations. Subject to the terms and conditions of the Development Supply Agreement, ARS, itself or
through any Affiliate or CMO, shall Manufacture and supply to Pediatrix, and Pediatrix shall purchase from ARS, all Products, in the form of drug product, which is the vial containing the active substance and the sprayer delivery device
(“Drug Product”) for all Development of Compositions and Products in the Field in the Pediatrix Territory to be conducted by Pediatrix or its Affiliate in accordance with this Agreement. The
Parties shall negotiate in good faith and enter into a separate Drug Product supply agreement (the “Development Supply Agreement”), along with a quality agreement, reasonably in advance of anticipated first Development supply
of Drug Product to Pediatrix in the Pediatrix Territory. Unless agreed otherwise by the Parties in writing, all Drug Product supplied by ARS under this Section 7.1 or the Development Supply Agreement shall be used
solely to conduct Development in the Field in the Pediatrix Territory in accordance with the terms of this Agreement. 

  

	 	(b)	 Price. All Drug Product supplied by ARS for Development use shall be supplied at a price of [***]
percent ([***]%) of [***]. ARS shall invoice Pediatrix within thirty (30) days after delivery of Drug Product pursuant to this Section 7.1, and Pediatrix shall pay each such invoice within [***] after receipt of the
respective corresponding air waybill. The [***] of such Drug Product may be changed due to [***]. In such case, ARS shall [***] notify Pediatrix of the proposed changed price and reason for such change. For avoidance of doubt, Pediatrix shall be
solely responsible to bear and pay for any customs or other taxes (including but not limited to VAT) or duties that become payable as a result of Pediatrix’s purchase of such Drug Product from ARS. 

 

	7.2	 Commercial Supply. 

 

	 	(a)	 Commercial Supply Agreement. Unless and until Pediatrix notifies ARS in
writing that it does not need the commercial supply of the Products from ARS after the manufacturing technology transfer described in Section 7.2(c), ARS (either itself or through its Affiliate or CMO) shall
Manufacture and supply, and Pediatrix shall purchase from ARS, all of Pediatrix’s and its Affiliates’ and Sublicensees’ requirements for Drug Product for commercial use in the Field in the Pediatrix Territory, pursuant to a separate
commercial supply agreement to be negotiated in good faith and entered into between the Parties (the “Commercial Supply Agreement”), along with a quality agreement,
reasonably in 

  
 22 

	 	advance of anticipated First Commercial Sale of Product in the Pediatrix Territory. In accordance with the terms of the Commercial Supply Agreement, ARS shall supply unpackaged and unlabeled Drug Product for commercial
use in the Field in the Pediatrix Territory at a price of [***] percent ([***]%) of [***]. ARS shall invoice Pediatrix within [***] after each delivery of Drug Product to Pediatrix pursuant to the Commercial Supply Agreement, and the payment terms
for such invoice shall be determined in the Commercial Supply Agreement. In addition, Pediatrix shall be solely responsible to bear and pay for any customs, or other taxes (including but not limited to VAT) or duties that become payable as a result
of Pediatrix’s purchase of such Products from ARS for sale in a region in the Pediatrix Territory where such taxes or duties would be due and payable. 

  

	 	(b)	 Pediatrix Responsibilities. Notwithstanding any other provision of this Agreement, Pediatrix, at its
sole cost and expense, shall be responsible for labeling, packaging (other than primary packaging), releasing and distributing the Products in the Field in the Pediatrix Territory in compliance with all Applicable Laws related thereto, including all
quality related obligations and any incremental Manufacturing validations required by local Governmental Authorities in the Pediatrix Territory. 

  

	 	(c)	 Pediatrix’s Manufacture and Transition. Upon written
notice to ARS and satisfaction of the of the Manufacturing License Condition in accordance with Section 2.1(b), Pediatrix may elect to assume responsibility for manufacturing and supplying all of the Drug Product
requirements for Pediatrix’s and its Affiliates’ and Sublicensees’ Commercial use in the Pediatrix Territory. ARS shall, within [***] following ARS’s receipt of such written notice, provide access to and transfer to Pediatrix, or
an Affiliate or a CMO all Know-How Controlled by ARS or its Affiliates that is necessary or used by ARS or a CMO of ARS, for Pediatrix to Manufacture the Compositions and Product in the Pediatrix Territory.
Upon reasonable request from Pediatrix and at Pediatrix’s cost, ARS shall provide to Pediatrix all necessary assistance and services to enable Pediatrix to Manufacture the Compositions and Product in substantially the same manner as ARS, its
Affiliate or a CMO on behalf of ARS Manufactures the Compositions and Product for Pediatrix or its Affiliates. 

 For
clarity, in case Pediatrix assumes full responsibility for the manufacturing and supplying of Drug Product as described in the foregoing subsection (c), ARS shall not unreasonably refuse Pediatrix the right to use the CMO (including the CMO for the
manufacturing of the starting material) that is the same as the one ARS uses to manufacture Drug Product or is otherwise reputable and recognized in the Pediatrix Territory. The Parties agree to discuss in good faith a joint purchasing arrangement,
to the extent permitted by Applicable Law. 
  

	7.3	 Information on Manufacture. To the extent ARS, itself or through any Affiliate or
CMO, supplies Drug Product to Pediatrix for Development or Commercialization under this Agreement, ARS shall, at ARS’s cost, make available to Pediatrix all information, in its possession and that ARS has the legal right to transfer, that is
relevant and necessary to maintain or obtain Regulatory Approval for the Product, to enable Pediatrix to maintain or obtain the Regulatory Approval in the Pediatrix Territory. ARS shall, [***], use Commercially Reasonable Efforts to require that its
CMO provide Pediatrix access to and the right to use ARS’ Drug Master File, to the extent that such information is reasonably useful for Development or Commercialization of Products in the Field for the Pediatrix Territory, including
preparation and filing of NDAs for a Product with the applicable Regulatory Authorities in the Pediatrix Territory, in accordance with this Agreement. 

  

	8.	 FEES AND PAYMENTS 

 

	8.1	 Definitive Agreement Upfront Payment. Pediatrix shall make a
one-time, non-refundable, non-creditable payment to ARS of three million US dollars ($3,000,000) within [***] after the Effective
Date. 

  
 23 

	8.2	 Milestone Payments. 

 

	 	(a)	 Regulatory and Commercial Milestone Payments. 

 

	 	(i)	 Pediatrix shall notify ARS immediately (within [***] in any event) upon achievement of the Milestone Event set
below. Within [***] after the first achievement of the Milestone Event below (whether by Pediatrix or any of its Affiliates or Sublicensees) and Pediatrix’s receipt of a corresponding invoice from ARS, Pediatrix shall pay to ARS the [***]
Milestone Payment corresponding to the Milestone Event as shown below. 

  

			
	Regulatory and Commercialization Milestone Events	  	Milestone Payments
	[***]	  	$[***]

  

	 	(ii)	 For clarity, the Milestone Payments set forth in this Section 8.2(a) shall be
payable only once, upon the first achievement of the Milestone Event for the first Product in the Field in the Pediatrix Territory to achieve the Milestone Event. Therefore, the maximum total amount payable under this
Section 8.2(a) is $4,000,000. Notwithstanding the foregoing, Pediatrix’s failure to notify ARS in accordance with this Section 8.2(a) shall not relieve it of its obligation to
make payments set above. 

  

	 	(b)	 Aggregate Annual Net Sales Milestone Events and Milestone Payments. 

 

	 	(i)	 As part of the royalty report in Section 8.3(g), Pediatrix shall notify ARS if any of the Aggregate Annual
Net Sales Milestone Event is achieved in the time period to which the royalty report pertains. After the end of each Calendar Quarter in which Aggregate Annual Net Sales of all Products first exceed any threshold indicated in the
“Aggregate Annual Net Sales Milestone Events” column listed below and Pediatrix’s receipt of a corresponding invoice from ARS, Pediatrix shall pay to ARS the corresponding
non-refundable, non-creditable Milestone Payment set forth below in accordance with Section 8.3(g): 

 

			
	Aggregate Annual Net Sales Milestone Events	  	Milestone Payments
	[***]	  	$[***]
	[***]	  	$[***]
	[***]	  	$[***]
	[***]	  	$[***]
	[***]	  	$[***]
	[***]	  	$[***]

  
 24 

	 	(ii)	 For clarity, the Milestone Payments corresponding to each Aggregate Annual Net Sales Milestone Event set forth
in this Section 8.2(b) shall be payable only once, upon the first achievement of the applicable Aggregate Annual Net Sales Milestone Event, and shall be additive so that if all [***] Aggregate Annual Net Sales
Milestone Events set forth in Section 8.2(b)(i) are achieved in the same Calendar Year, Pediatrix shall pay to ARS all [***] corresponding Milestone Payments. The maximum total amount payable under this
Section 8.2(b) is $80,000,000. Notwithstanding the foregoing, Pediatrix’s failure to notify ARS in accordance with this Section 8.2(b) shall not relieve it of its obligation to
make payments set above. 

  

	8.3	 Additional Drug Product Supply Payments. 

 

	 	(a)	 Royalty Rate. Subject to the terms and conditions of this Agreement, in each Calendar Quarter, Pediatrix
shall pay ARS the royalties at the rate set forth below on aggregate annual Net Sales of Products in a given Calendar Year (“Aggregate Annual Net Sales”) in all regions in the Pediatrix Territory combined during the Royalty
Term, as such royalty amounts are calculated by multiplying the applicable royalty rate set forth below by the corresponding amount of the portion of Aggregate Annual Net Sales within each royalty rate tier in such Calendar Year.

  

			
	Aggregate Annual Net Sales in the Pediatrix Territory (Tier)	  	Royalty Rate
	 For the portion of Aggregate Annual Net Sales of all Products less than or equal to
$[***]
	  	[***]%
	 For the portion of Aggregate Annual Net Sales of all Products in excess of $[***], but less than
or equal to $[***]
	  	[***]%
	 For the portion of Aggregate Annual Net Sales of all Products in excess of $[***], but less than
or equal to $[***]
	  	[***]%
	 For the portion of Aggregate Annual Net Sales of all Products in excess of $[***]
	  	[***]%

  

	 	(b)	 Royalty Term. 

  

	 	(i)	 Pediatrix’s obligations to pay royalties under this Section 8.3 shall
continue, on a Product-by-Product and region-by-region basis in the Pediatrix Territory,
until the latest of (i) expiration of the last-to-expire Valid Claim of the ARS Patents set forth in Exhibit 1 covering such Product in such region;
(ii) the expiration of all Regulatory Exclusivities that covering such Product in such region; or (iii) ten (10) years after the First Commercial Sale of such Product in such region (the “Royalty Term”). All Net
Sales of all Products in all regions in the Pediatrix Territory shall be added together to determine the Aggregate Annual Net Sales and applicable royalty tier described in Section 8.3(a). 

  
 25 

	 	(ii)	 For clarity, if a Product is first sold in a region in which the Royalty Term for such Product has expired or
any royalty reduction applies (the, “First Region”), and such Product is subsequently exported from such region and imported into a region in which the Royalty Term for such Product has not expired or the royalty
reduction does not apply (the, “Second Region”), [***]. 

  

	 	(c)	 No Valid Claim. On a
Product-by-Product and region-by-region basis in the Pediatrix Territory, If a Product is
sold in a region during the applicable Royalty Term at a time when there is no Valid Claim in the ARS Patents set forth in Exhibit 1 that covers such Product in such region, then the royalty rate applicable to the Net Sales of such
Product in such region during such time shall be reduced by [***] percent ([***]%) of the rate set forth in Section 8.3(a). 

  

	 	(d)	 Generic Competition. On a
Product-by-Product and region-by-region basis in the Pediatrix Territory, if a Generic
Product is sold in such region in any, then the royalty payment payable to ARS with respect to such Product in such region during such [***] shall be reduced by [***] percent ([***]%) of the rate set forth in
Section 8.3(a), Where, if the unit volume of Generic Product(s) sold in such region in a Calendar Quarter is at least [***] percent ([***]%) of the total unit volume of Generic Product(s) plus unit volume of Product sold by
Pediatrix, its Affiliates and Sublicensees in such region in such [***], then the royalty payment payable to ARS with respect to such Product in such region during such [***] shall be reduced by [***] percent ([***]%). Unless otherwise agreed by the
Parties, the unit volumes of Generic Product(s) sold during a [***] shall be as reported by [***] or any successor to [***] or any other independent sales auditing firm reasonably agreed upon by the Parties. 

 

	 	(e)	 Third Party IP. 

 

	 	(i)	 Notwithstanding anything to the contrary hereunder, ARS shall be solely responsible for any and all payments
ARS owes to the Upstream Licensors under the applicable Upstream Licenses and in no event shall Pediatrix, its Affiliates, Sublicensees or contractors be liable for any of such payments. Without limiting the foregoing, ARS shall be solely
responsible for any royalty payments to Aegis under the Aegis Agreement (which may be amended) under which ARS obtained rights to certain ARS Patents or ARS Know-How. 

 

	 	(ii)	 If Pediatrix obtains a license from a Third Party under any Patent owned or controlled by such Third Party that
would be infringed, absent such a license, by the practice of the ARS Technology in the Development, Manufacture or Commercialization of a Product in the Field in a region in the Pediatrix Territory, then Pediatrix shall have the right to deduct,
from the royalty payment that would otherwise have been due pursuant to this Section 8.3 with respect to Net Sales of such Product in such region in a [***], an amount equal to [***] percent ([***]%) of the royalties
paid by Pediatrix to such Third Party pursuant such license on account of the sale of such Product in such region during such [***]. For clarity, the royalty reduction under this Section 8.3(e)(ii) shall apply only
to Third Party Patent that is necessary for the freedom to operate of the ARS Technology, and shall not apply to any other intellectual property that Pediatrix may elect to use or incorporate into the Product. 

 

	 	(f)	 Royalty Floor. Notwithstanding the foregoing, the operation of Sections 8.3(c),
8.3(d), and 8.3(e)(ii) individually or in combination shall not reduce the royalties that would otherwise have been due under Section 8.3(a) with respect to Net Sales of any Product in any
region during any [***] by more than [***] percent ([***]%). 

  
 26 

	 	(g)	 Royalty and Net Sales Milestone Payment. Within [***] days after the end of each [***],
commencing with the [***] during which the First Commercial Sale of a Product is made anywhere in the Pediatrix Territory, Pediatrix shall provide to ARS a report setting forth a calculation of the royalties due to ARS for such [***] and whether any
sales milestone has been achieved during such time period. Promptly following the receipt of the applicable quarterly report, ARS shall invoice Pediatrix for the royalties due to ARS with respect to Net Sales by Pediatrix, its Affiliates and their
respective Sublicensees for such [***] and, if any sales milestone is achieved, the corresponding sales milestone payment. Pediatrix pay such amounts to ARS within [***] following Pediatrix’s receipt of such invoice; [***].

  

	9.	 PAYMENT; RECORDS; AUDITS 

 

	9.1	 Exchange Rate; Manner and Place of Payment. All references to dollars and
“$” herein shall refer to U.S. dollars. All payments hereunder shall be payable in U.S. dollars unless otherwise expressly stated. When conversion of payments from any currency other than U.S. dollars is required, the Parties
shall use the average rate of exchange for U.S. dollars prevailing on the last day of each of [***] hereunder as published in The Wall Street Journal under the heading “Foreign Exchange,” unless otherwise agreed upon in writing by the
Parties. All payments owed under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by ARS, unless otherwise specified in writing by ARS. 

 

	9.2	 Taxes. 

  

	 	(a)	 Cooperation and Coordination. The Parties acknowledge and agree that it is
their mutual objective and intent to minimize, to the extent feasible and in compliance with Applicable Laws, taxes payable with respect to their collaborative efforts under this Agreement and that they shall use Commercially Reasonable Efforts to
cooperate and coordinate with each other to achieve such objective and intent. Pediatrix shall not change the country or jurisdiction from which all of its payments to ARS originate (which, for the avoidance of doubt, the Parties agree is the Cayman
Islands) without the prior written consent of ARS. The Parties shall cooperate to help each other obtain benefits under any applicable tax treaty, including the reduction or exemption from any withholding tax and the procurement of any available tax
refunds. 

  

	 	(b)	 Payment of Tax. Each Party shall be responsible for all taxes, fees, duties,
levies or similar amounts imposed on its own income, assets, capital, employment, personnel, and right or license to do business. If Applicable Laws requires Pediatrix to withhold any taxes from payments made to ARS under this Agreement, then such
taxes shall be deducted by Pediatrix as required by and shall be paid by Pediatrix to the proper tax authorities; provided that Pediatrix shall cooperate and work with ARS to complete necessary steps and procedures, or ARS shall provide the
Tax Withholding Documents to Pediatrix prior to such payment to ARS for avoiding or minimizing withholding taxes. Pediatrix shall use Commercially Reasonable Efforts to provide ARS with [***] advance written notice before making any such tax
deduction or withholding of the intention to make such deduction or withholding, and shall use Commercially Reasonable Efforts to cooperate with any reasonable request from ARS to obtain reduction of or relief from such deduction or withholding. In
case the Tax Withholding Documents are not available to Pediatrix at the due date of such payments to ARS or the Tax Withholding Documents provided by ARS to 

  
 27 

	 	Pediatrix do not call for a complete exemption on withholding taxes, Pediatrix shall (i) deduct applicable withholding taxes from the payment made to ARS, (ii) timely pay such taxes to the proper taxing
authority, and (iii) send proof of such withholding tax payment to ARS and certify its receipt by the taxing authority within [***] following such payment. Pediatrix shall assist ARS in filing for the refund, if any, of any withholding taxes
paid within [***] following the receipt of the Tax Withholding Documents from ARS. Any such refund filing shall request that the amount of the refund be wired directly to an ARS authorized bank account. 

 

	 	(c)	 Source of Payment. To the extent (i) any payment under this Agreement
is triggered due to activities of an Affiliate or sublicensee of Pediatrix incorporated or established in the Pediatrix Territory, whose Applicable Laws require the withholding of taxes in relation to such payment if it were to be made from such
Affiliate or sublicensee of Pediatrix to ARS, and (ii) Pediatrix receives a payment from its such Affiliate or sublicensee in relation to such activity, and such payment is reduced due to withholding taxes required by Applicable Laws to be
withheld on such payment, then Pediatrix shall have the right to deduct an amount that equals to [***] percent ([***]%) of the deducted amount for withholding taxes from the payments due to ARS under this Agreement. Pediatrix shall promptly provide
to ARS applicable receipts evidencing payment of such withholding taxes and other documentation reasonably requested by ARS. Upon ARS’s request, Pediatrix shall provide reasonable assistance to ARS for ARS to recover or obtain a credit in
relation to any such withholding taxes. For the avoidance of doubt, this Section 9.2(c) only applies to withholding for income taxes and does not apply to any other taxes including but not limited to VAT or other
surcharges or surtaxes. In addition, for the avoidance of doubt, ARS shall not be responsible for bearing any withholding tax levied on any amount which is larger than the amount of the actual payment due to ARS from Pediatrix.

  

	9.3	 Records; Audit. Pediatrix shall keep, and shall cause its Sublicensees to keep, complete and
accurate records pertaining to the sale or other transfer or disposition for value of Products in sufficient detail to permit ARS to confirm the accuracy of all payments due hereunder. Such records shall be kept for such period of time required by
Applicable Laws, but no less than [***] following the end of the Calendar Year to which they pertain. ARS shall have the right to cause an independent, international, certified public accounting firm [***] to Pediatrix to audit such records to
confirm payments for a period covering not more than [***] following the Calendar Year [***] to which they pertain. Such audits may be exercised during normal business hours upon [***] prior written notice to Pediatrix, and except for good cause,
shall not be more than [***]. Prompt adjustments shall be made by the Parties to reflect the results of such audit. ARS shall bear the full cost of such audit unless such audit discloses an underpayment by Pediatrix of more than [***] percent
([***]%) of the total amount owed under this Agreement for the period then being audited, in which case, Pediatrix shall bear the cost of such audit and shall promptly remit to ARS the amount of any underpayment plus such audit costs plus interest
(as set forth in Section 9.4 below) from the original due date. Any overpayment by Pediatrix revealed by an audit shall be credited against future payments owed by Pediatrix to ARS (and if no further payments are
due, shall be refunded by ARS to Pediatrix within [***]). 

  

	9.4	 Late Payments. In the event that any payment due under this Agreement is not paid when due
in accordance with the applicable provisions of this Agreement, the payment shall accrue interest from the date due at a per annum rate of [***] percent ([***]%) [***]; provided, however, that in no event shall such rate exceed the
maximum legal annual interest rate. The payment of such interest shall not limit the Party entitled to receive payment from exercising any other rights and/or remedies it may have as a consequence of the lateness of any payment.

  
 28 

	10.	 INTELLECTUAL PROPERTY 

 

	10.1	 Ownership. 

  

	 	(a)	 The Parties acknowledge and agree that, as between the Parties, all right, title and interest in and to any ARS
Technology shall be owned solely by ARS, and all right, title and interest in and to any Pediatrix Technology shall be owned solely by Pediatrix. 

  

	 	(b)	 All right, title, and interest in and to any inventions made, developed, conceived or reduced to practice by or
on behalf of Pediatrix, its Affiliates or Sublicensees (whether solely or jointly with ARS) in the course of performance of this Agreement that are related to the Composition or Product, including Data, and any Patents and Know-How relating thereto (collectively, the “New IP”) shall be owned solely by ARS. In connection with the foregoing: (i) Pediatrix shall promptly disclose in writing to ARS all New
IP, (ii) Pediatrix hereby does, and shall cause its Affiliates and Sublicensees and its and their employees and representatives to, assign and transfer to ARS all right, title, and interest in and to such New IP and agrees to take all further
acts reasonably required to evidence such assignment and transfer to ARS; and (iii) such New IP shall constitute ARS Know-How or ARS Patents, as applicable, for purposes of this Agreement. Notwithstanding
the foregoing, ARS Patents primarily derived from New IP shall not be considered ARS Patents for purposes of determining Royalty Term or royalty reductions. 

  

	 	(c)	 Other than New IP, ownership of inventions and intellectual property rights generated by or on behalf of each
Party or jointly by Parties shall follow inventorship in accordance with the patent law of the United States. Inventions made solely by either Party shall be exclusively owned by such Party. Inventions jointly made by both Parties shall be owned
jointly. 

  

	 	(d)	 All Intellectual Property owned by a Party as of the Effective Date shall continue to be owned by such Party,
and except as expressly set forth in this Agreement, neither Party shall have any rights to any Intellectual Property of the other Party. 

  

	10.2	 Patent Prosecution and Maintenance. 

 

	 	(a)	 Subject to this Section 10.2(a), ARS shall have the sole right, as between ARS and
Pediatrix, but not obligation, to control the preparation, filing, prosecution (including any interferences, reissue proceedings and re-examinations) and maintenance of all ARS Patents, at its sole cost and
expense and by counsel of its own choice. Pediatrix shall, upon request of ARS, provide ARS with all reasonable assistance and cooperation in connection therewith. ARS shall keep Pediatrix reasonably informed of progress with regard to the
preparation, filing, prosecution and maintenance of ARS Patents, including content, timing and jurisdiction of the filing of such ARS Patents in the Pediatrix Territory. In the event that ARS desires to abandon or cease prosecution or maintenance of
any ARS Patent in any region in the Pediatrix Territory (“Discontinued ARS Patent”), ARS shall provide reasonable prior written notice to Pediatrix of such intention to abandon (which notice shall, to the extent possible, be
given no later than [***] prior to the next deadline for any action that must be taken with respect to any such ARS Patent in the relevant patent office) and such Discontinued ARS Patent in such region shall not be taken into account in determining
the Royalty Term or royalty reductions. Pediatrix shall, upon written notice to ARS provided no later than [***] after such notice from ARS, have the right, but not the obligation, at its cost and expense, to file, prosecute and/or maintain such
Discontinued ARS Patent in the applicable region or regions in the Pediatrix Territory, at Pediatrix’s sole cost and expense, in the name of and on behalf of ARS. In such case, Pediatrix shall keep ARS regularly and reasonably informed of
progress with regard to the preparation, filing, prosecution and maintenance of each of such Discontinued ARS Patents, including content, timing and jurisdiction of the filing of such

  
 29 

	 	
Discontinued ARS Patents, and shall consult with, and consider in good faith the requests and suggestions of, ARS with respect to strategies for filing and prosecuting such Discontinued ARS
Patents (particularly to avoid prosecution inconsistencies with ARS Patents in the Pediatrix Territory that ARS has not abandoned and corresponding Patents of ARS outside the Pediatrix Territory). If Pediatrix does not provide such election within
such [***] after such notice from ARS, ARS may, in its sole discretion, continue prosecution and maintenance of such ARS Patent or discontinue prosecution and maintenance of such ARS Patent. ARS shall have the sole right, as between ARS and
Pediatrix, but not obligation, to control the preparation, filing, prosecution (including any interferences, reissue proceedings and re-examinations) and maintenance of all Patents Controlled by ARS outside of
the Pediatrix Territory that relate to any Composition or Product (including any Patents within the New IP), at its sole cost and expense and by counsel of its own choice. 

 

	 	(b)	 Subject to this Section 10.2(b), Pediatrix shall have the sole right, as between ARS
and Pediatrix, but not obligation, to control the preparation, filing, prosecution (including any interferences, reissue proceedings and re-examinations) and maintenance of all Pediatrix Patents worldwide, at
its sole cost and expense and by counsel of its own choice. In the event that Pediatrix desires to abandon or cease prosecution or maintenance of any Pediatrix Patent in any country outside the Pediatrix Territory (“Discontinued Pediatrix
Patent”), Pediatrix shall provide reasonable prior written notice to ARS of such intention to abandon (which notice shall, to the extent possible, be given no later than [***] prior to the next deadline for any action that must be taken
with respect to any such Pediatrix Patent in the relevant patent office). In such case, upon ARS’s written election provided to Pediatrix no later than [***] after such notice from Pediatrix, ARS shall have the right to assume prosecution and
maintenance of such Discontinued Pediatrix Patent at ARS’s sole cost and expense, in the name of and on behalf of Pediatrix. In such case, ARS shall keep Pediatrix regularly and reasonably informed of progress with regard to the preparation,
filing, prosecution and maintenance of each of such Discontinued Pediatrix Patents, including content, timing and jurisdiction of the filing of such Discontinued Pediatrix Patents, and shall consult with, and consider in good faith the requests and
suggestions of, Pediatrix with respect to strategies for filing and prosecuting such Discontinued Pediatrix Patents (particularly to avoid prosecution inconsistencies with Pediatrix Patents that Pediatrix has not abandoned). If ARS does not provide
such election within such [***] after such notice from Pediatrix, Pediatrix may, in its sole discretion, continue prosecution and maintenance of such Pediatrix Patent or discontinue prosecution and maintenance of such Pediatrix Patent. Pediatrix
shall have the sole right, as between ARS and Pediatrix, but not obligation, to control the preparation, filing, prosecution (including any interferences, reissue proceedings and re-examinations) and
maintenance of all Patents Controlled by Pediatrix in the Pediatrix Territory at its sole cost and expense and by counsel of its own choice. 

  

	10.3	 Cooperation of the Parties. Each Party agrees to cooperate fully in the preparation, filing,
prosecution and maintenance of Patents under Section 10.2 and in the obtaining and maintenance of any extensions, supplementary protection certificates and their equivalent with respect thereto respectively, at its
own cost (except as expressly set forth otherwise in this Article 10). Such cooperation includes: (a) executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments,
reasonably requested by the other Party so as enable the other Party to apply for and to prosecute patent applications in any country as permitted by Section 10.2; and (b) promptly informing the other Party of any
matters coming to such Party’s attention that may affect the preparation, filing, prosecution or maintenance of any such patent applications. 

  
 30 

	10.4	 Infringement by Third Parties. 

 

	 	(a)	 Notice. In the event that either ARS or Pediatrix becomes aware of any infringement or threatened
infringement by a Third Party of any ARS Patent, or any declaratory judgment or equivalent action challenging any ARS Patent in connection with any such infringement, it shall promptly notify the other Party in writing to that effect. Any such
notice shall include evidence to support an allegation of infringement or threatened infringement, or declaratory judgment or equivalent action, filed by such Third Party. 

 

	 	(b)	 Response. Subject to this Section 10.4(b), [***] shall have the first right,
as between ARS and Pediatrix, but not the obligation, to bring and control any action or proceeding with respect to infringement or challenge of any ARS Patent by a Third Party that is developing or commercializing a Product or Competitive Product
in the Field in the Pediatrix Territory (a “Product Infringement”), [***]. In such case, [***] counsel shall reasonably cooperate with [***] and its counsel in strategizing, preparing and prosecuting any such action or proceeding in
the Pediatrix Territory. When [***] becomes a party to such action in the Pediatrix Territory, [***] shall have the right, at its own expense, to be represented in any such action, by counsel of [***] own choice, and [***] and its counsel shall
reasonably cooperate with [***] and its counsel in strategizing, preparing and prosecuting any such action or proceeding in the Pediatrix Territory. If [***] fails to bring an action or proceeding with respect to a Product Infringement of any ARS
Patent in the Pediatrix Territory within (i) [***] following receipt or delivery (as applicable) of the notice of alleged infringement or (ii) [***] before the time limit, if any, set forth in the appropriate laws and regulations for the filing of
such actions, whichever comes first, then following a discussion with [***] regarding the reasons why [***] did not bring such action or proceeding, which reasons [***] shall consider in good faith, [***] shall have the right, but not the
obligation, to bring and control such action or proceeding to enforce or defend the ARS Patent against the Product Infringement in the Pediatrix Territory at its own expense and by counsel of its own choice, and [***] shall have the right, at its
own expense, to be represented in any such action or proceeding by counsel of its own choice. [***] and its counsel shall reasonably cooperate with [***] and its counsel in strategizing, preparing and prosecuting any such action or proceeding in the
Pediatrix Territory. 

  

	 	(c)	 Recovery. Except as otherwise agreed by the Parties in writing as part of a cost-sharing arrangement,
any recovery or damages realized as a result of such action or proceeding with respect to ARS Patents against Product Infringement shall be used first to [***], and any remaining compensatory, punitive, or other damages that were awarded in respect
of Products (including awards made in respect of lost sales or lost profits with respect to Products) shall be [***]. 

  

	 	(d)	 Cooperation. In the event a Party brings an action in accordance with this
Section 10.4, the other Party shall cooperate fully, including, if required to bring such action, the furnishing of a power of attorney or being named as a party to such action. 

 

	 	(e)	 ARS shall have the sole right, but not the obligation, to bring and control any action or proceeding to enforce
or defend the ARS Patent against any infringement or challenge that is not a Product Infringement, [***], and shall be entitled to retain all recoveries. 

  

	10.5	 Infringement of Third Party Rights. Each Party shall
promptly notify the other Party in writing of any allegation by a Third Party that the Manufacture, Development, use or Commercialization of any Composition or Product in the Field in the Pediatrix Territory infringes or may infringe the
intellectual property rights of a Third Party (each an “Infringement Claim”). The notice shall set 

  
 31 

	 	forth the facts of the Infringement Claim in reasonable detail, to the extent such notifying Party has the right to disclose them. [***] shall have the first right to control any defense of any such Infringement Claim
at its own expense and by counsel of its own choice, and [***] shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If [***] fails to defend against such Infringement Claim action, or notifies
[***] that it does not intend to defend against such Infringement Claim action, within (A) ninety (90) days following the notice of alleged infringement or (B) [***] or as promptly as reasonably practical before the time limit, if any, set
forth in the appropriate laws and regulations for the response to such action, whichever comes first, [***] shall have the right, but not the obligation, to defend any such Infringement Claim action at its own expense and by counsel of its own
choice, and [***] shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

  

	10.6	 Consent for Settlement. Neither Party shall unilaterally enter into any settlement or compromise
of any action or proceeding in the Pediatrix Territory under this Article 10 that would in any manner alter, diminish, or be in derogation of the other Party’s rights under this Agreement without the prior written
consent of such other Party, which shall not be unreasonably withheld, conditioned or delayed. 

  

	10.7	 Trademarks. Pediatrix may use (pursuant to this Section 10.7) the
Trademarks Controlled by ARS in the Pediatrix Territory as ARS may provide to Pediatrix in writing from time to time (the “ARS Product Marks”) and may use the English mark thereof with Chinese phonetic translation below. ARS
hereby grants to Pediatrix, during the Term and subject to the terms and conditions of this Agreement, a royalty-free, exclusive license under ARS’s rights to use such ARS Product Marks in connection with the Commercialization of the Products
in the Field in the Pediatrix Territory in compliance with Applicable Laws and this Agreement. Pediatrix shall comply with ARS’s brand usage guidelines provided to Pediatrix in its use of the ARS Product Marks. Pediatrix may also brand the
Products in the Pediatrix Territory using other Trademarks, including Trademarks specific for the Products that differ from the ARS Product Marks and do not contain the name of ARS (the “Pediatrix
Product Marks”). Subject to consultation with ARS through the JSC, Pediatrix shall be responsible for selecting, registering, prosecuting, defending, and maintaining all Pediatrix Product Marks
at Pediatrix’s sole discretion, cost and expense. Pediatrix shall own all rights in the Pediatrix Product Marks in the Pediatrix Territory and shall register and maintain the Pediatrix Product Marks in the Pediatrix Territory that it determines
reasonably necessary. 

  

	10.8	 ARS Controlled Patents Outside the Pediatrix Territory. For clarity, ARS reserves all rights to
prepare, file, prosecute (including any interferences, reissue proceedings and re-examinations), maintain, defend and enforce all Patents owned or controlled by ARS related to Compositions and Products outside
the Pediatrix Territory. In the event that ARS becomes aware of any infringement or threatened infringement by a Third Party of any such Patent outside the Pediatrix Territory, or any declaratory judgment or equivalent action challenging any such
Patent in connection with any such infringement outside the Pediatrix Territory, ARS shall notify Pediatrix in writing to that effect. 

  

	10.9	 Patents Licensed From Upstream Licensors. Each Party’s rights under this Article
10 with respect to the prosecution and enforcement of any ARS Patent that is in-licensed by ARS from Upstream Licensors under Upstream Licenses shall be subject to the rights retained by
Upstream Licensors to prosecute and enforce such Patent. 

  

	11.	 REPRESENTATIONS AND WARRANTIES 

 

	11.1	 Mutual Representations and Warranties. Each Party
represents and warrants to the other Party that, as of the Effective Date: (a) it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to
enter into this Agreement and to carry out the provisions hereof, (b) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has
been duly authorized to do so by all requisite corporate 

  
 32 

	 	or partnership action, (c) this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is
a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it, and (d) except for any Regulatory Approvals, Regulatory Filings, or
similar approvals necessary for the Development, Manufacture or Commercialization of Products, all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required to be obtained by it in connection with
the execution, delivery and performance of this Agreement have been obtained, and it has the right to grant the licenses granted by it under this Agreement. 

  

	11.2	 Mutual Covenants. Each Party hereby covenants to the other Party as follows:

  

	 	(a)	 Neither Party shall use in any capacity, in connection with the Development, manufacture or Commercialization
of any Product, any individual or entity who has been Debarred. Each Party shall inform the other Party in writing immediately upon becoming aware that any individual or entity who is performing hereunder is Debarred, or if any claim is pending or,
to the best of such Party’s knowledge, is threatened, relating to the Debarment of such Party or any individual or entity used in any capacity by such Party in connection with the Development, manufacture or Commercialization of any Product.
“Debarred” means, with respect to an individual or entity, that such an individual or entity (a) is debarred by the FDA pursuant to Section 306 of the United States Federal Food, Drug, and Cosmetic Act
(“FDCA”), or is the subject of a conviction described in such section (or subject to a similar sanction of any other applicable Regulatory Authority), (b) is the subject of an FDA debarment investigation or proceeding (or similar
proceeding of any other applicable Regulatory Authority), or (c) has been charged with or convicted under U.S. Law for conduct relating to the development or approval, or otherwise relating to the regulation, of any product under the Generic
Drug Enforcement Act of 1992. 

  

	11.3	 Additional ARS Representations and Warranties. ARS represents and warrants to Pediatrix that, as
of the Effective Date: 

  

	 	(a)	 all ARS Patents as of the Effective Date are listed in Exhibit 1. Except as otherwise
noted in Exhibit 1, ARS is the sole and exclusive owner of the ARS Patents, all of which are free and clear of any claims, liens, charges or encumbrances that would conflict or interfere with any rights or licenses granted by
ARS to Pediatrix under this Agreement. With respect to ARS Patents not solely owned by ARS, ARS licenses such ARS Patents in a manner that permits exclusive sublicenses as provided in this Agreement. All ARS Patents owned by ARS and, to ARS’s
knowledge, all other ARS Patents, are (i) subsisting and in good standing and (ii) being diligently prosecuted in the respective patent offices in accordance with Applicable Laws, and have been filed and maintained properly. To ARS’s
knowledge, as if the Effective Date, all issued ARS Patents are valid and enforceable; 

  

	 	(b)	 (i) ARS has obtained from all individuals and entities that participated with ARS in the invention of any ARS
Patents (except for any ARS Patents in-licensed by ARS under the Upstream Licenses) effective assignments of all ownership rights of such individuals and entities in such ARS Patents either pursuant to written
agreements or by operation of law; (ii) to its knowledge, all such assignments are valid and enforceable, and (iii) to its knowledge, the inventorship of the ARS Patents that are solely owned by ARS or its Affiliates is properly identified on
each issued patent or patent application in such ARS Patents; 

  

	 	(c)	 all application, registration, maintenance and renewal fees in respect of the ARS Patents have been paid and to
ARS’s knowledge, all necessary documents and certificates have been filed with the relevant agencies for the purpose of maintaining such ARS Patents; 

  
 33 

	 	(d)	 ARS has not received any written notice or does not otherwise have knowledge prior to Effective Date that its
activities with the Product has infringed or would infringe any Third Party Patents; 

  

	 	(e)	 ARS has not, of the Effective Date, granted any Third Party rights under the ARS Technology or to Develop,
Manufacture, register, use or Commercialize the Product in the Field in the Pediatrix Territory that would conflict with Pediatrix’s rights hereunder; 

  

	 	(f)	 there are no pending or, to ARS’s knowledge, no threatened in writing, adverse actions, suits or
proceedings against ARS involving the ARS Technology or Product; 

  

	 	(g)	 ARS has not initiated or been involved in any proceedings or claims in which it alleges that any Third Party is
or was infringing or misappropriating any ARS Patents or ARS Know- How; 

  

	 	(h)	 the ARS Technology includes (i) all Know-How Controlled by ARS or
its Affiliates that is necessary to Develop, Manufacture and Commercialize the Compositions and Products in the Field in the Pediatrix Territory as such Development, Manufacture, and Commercialization is currently being conducted by ARS or
contemplated to be conducted by the Parties hereunder, and (ii) all Patents in the Pediatrix Territory that are Controlled by ARS or its Affiliates that are necessary to Develop, Manufacture and Commercialize a Product in the Field in the
Pediatrix Territory as such Development, Manufacture, and Commercialization is currently being conducted by ARS or contemplated to be conducted by the Parties hereunder; 

 

	 	(i)	 ARS has complied in all material respects with all material Applicable Laws applicable to its Development and
Manufacture of Products in the Field; 

  

	 	(j)	 ARS has taken all reasonable precautions to preserve the confidentiality of the ARS Know- How that is existing
and documented as of the Effective Date; 

  

	 	(k)	 all Upstream Licenses as of the Effective Date are listed in Exhibit 2. ARS and its
Affiliates 

  

	 	(i)	 have been in compliance (1) with all payment terms and (2) in all material respects with all other
terms and conditions with the Upstream Licenses as of the Effective Date and all Upstream Licenses as of the Effective Date are in full force and effect; (ii) have not received any written notice that alleges breach or default by ARS of,
requests a material amendment of, termination of any Upstream License; (iii) are not aware of any material breach, potential breach, default, or potential default of any Upstream License; (iv) are not aware of any other facts that would
result in a material amendment or termination of any Upstream License; and (v) have full rights and authority to grant Pediatrix the right and license to Manufacture the Compositions and Product by Pediatrix, its Affiliates, or Pediatrix’s
CMO in the Pediatrix Territory as contemplated under this Agreement (subject to Intravail or dodecyl maltoside being supplied by Aegis to ARS, its Affiliates and its sublicensees including Pediatrix per the Aegis Agreement). 

 

	11.4	 Covenants of ARS. ARS covenants to Pediatrix that during the Term:

  

	 	(a)	 It shall not grant any license or other right under the ARS Technology that is inconsistent with the License;

  

	 	(b)	 ARS and its Affiliates (i) [***] (1) [***] and (2) [***]; (ii) [***] [***]; (iii) [***]; (iv) [***].

  
 34 

	11.5	 Disclaimer. Except as expressly set forth in this Agreement, THE TECHNOLOGY AND INTELLECTUAL
PROPERTY RIGHTS PROVIDED BY EACH PARTY HEREUNDER ARE PROVIDED “AS IS” AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN,
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO. Without limiting the
foregoing, (a) neither Party represents or warrants that any true and accurate data obtained in compliance with the laws and regulations of a particular country or jurisdiction from conducting clinical trials in that country or jurisdiction
will comply with the laws and regulations of any other country or jurisdiction, and (b) neither Party represents or warrants the success of any study or test conducted by pursuant to this Agreement or the safety or usefulness for any purpose of
the technology it provides hereunder. 

  

	12.	 INDEMNIFICATION 

 

	12.1	 Indemnification by ARS. ARS hereby agrees to defend, indemnify and hold harmless Pediatrix, its
Sublicensees and their respective directors, officers, employees and agents (each, an “Pediatrix Indemnitee”) from and against any and all liabilities, expenses and losses, including reasonable legal expenses
and attorneys’ fees (collectively, “Losses”), to which any Pediatrix Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise out of:
(a) the Development, use, handling, storage, Manufacture sale or other Commercialization of any Composition or Product by ARS or its Affiliates or ARS Collaborators (excluding any activities by or on behalf of Pediatrix or its Affiliates or
Sublicensees, or any activities under any Supply Agreement, which are separately addressed in such Supply Agreement), (b) the negligence or willful misconduct of any ARS Indemnitee, or (c) the breach by ARS of any warranty, representation, or
covenant made by ARS in this Agreement; except, in each case (a)-(c), to the extent Pediatrix is obligated to indemnify ARS Indemnitees under Section 12.2. 

 

	12.2	 Indemnification by Pediatrix. Pediatrix hereby agrees to defend, indemnify and hold harmless ARS,
its Affiliates and the ARS Collaborators and their respective directors, officers, employees and agents (each, an “ARS Indemnitee”) from and against any and all Losses to which any ARS Indemnitee may become subject as a
result of any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise out of: (a) the Development, use, handling, storage, Manufacturing, sale or other Commercialization of any Composition or Product by
Pediatrix or its Affiliates or Sublicensees (excluding any activities by or on behalf of ARS or its Affiliates or ARS Collaborators), (b) the negligence or willful misconduct of any Pediatrix Indemnitee, or (c) the breach by Pediatrix of any
warranty, representation or covenant made by Pediatrix in this Agreement; except, in each case (a)-(c), to the extent ARS is obligated to indemnify Pediatrix Indemnitees under Section 12.1. 

 

	12.3	 Procedure. A Party that intends to claim indemnification under this Article
12 (the “Indemnitee”) shall promptly notify the indemnifying Party (the “Indemnitor”) in writing of any Third Party claim, demand, action or other proceeding (each, a
“Claim”) in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense or settlement thereof. The Indemnitee may participate at its expense in the
Indemnitor’s defense of and settlement negotiations for any Claim with counsel of the Indemnitee’s own selection. The 

  
 35 

	 	indemnity arrangement in this Article 12 shall not apply to amounts paid in settlement of any action with respect to a Claim, if such settlement is effected without the consent of the Indemnitor,
which consent shall not be withheld, conditioned, or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve
the Indemnitor of its indemnification obligations under this Article 12 if and to the extent the Indemnitor is actually prejudiced thereby. The Indemnitee shall cooperate fully with the Indemnitor and its legal representatives
in the investigation of any action with respect to a Claim covered by this indemnification. 

  

	12.4	 Insurance. Each Party, at its own expense, shall maintain product liability and other appropriate
insurance (or self-insure) in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement during the Term. Each Party shall provide a certificate of insurance (or evidence of self-insurance)
evidencing such coverage to the other Party upon request. 

  

	12.5	 Limitation of Liability. EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE
13 AND UNLESS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE
GRANTED HEREUNDER; PROVIDED, HOWEVER, THAT THIS SECTION 12.5 SHALL NOT BE CONSTRUED TO LIMIT EITHER PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 12. 

 

	13.	 CONFIDENTIALITY 

 

	13.1	 Confidential Information. Except to the extent expressly authorized by this Agreement or
otherwise agreed in writing by the Parties, during the Term and for [***] thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in
this Agreement any Confidential Information of the other (disclosing) Party under this Agreement, and both receiving Parties shall keep confidential and, subject to Sections 13.2, 13.3 and 13.5, shall not publish
or otherwise disclose the terms of this Agreement. Each receiving Party may use the disclosing Party’s Confidential Information only to the extent required to accomplish the purposes of this Agreement, including exercising its rights or
performing its obligations. Each receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, agents,
consultants, contractors and other representatives do not disclose or make any unauthorized use of the disclosing Party’s Confidential Information. Each receiving Party shall promptly notify the disclosing Party upon discovery of any
unauthorized use or disclosure of the disclosing Party’s Confidential Information. New IP shall be considered the Confidential Information of ARS, and ARS shall be considered the disclosing Party and Pediatrix the receiving Party with respect
to all New IP. 

  

	13.2	 Exceptions. The obligations of confidentiality and restriction on use under
Section 13.1 shall not apply to any information that the receiving Party can demonstrate through contemporaneous written records: (a) is now, or hereafter becomes, through no act or failure to act on the part of
the receiving Party or its representatives, generally known or available to the public; (b) is known by the receiving Party at the time of receiving such information, other than by previous disclosure of the disclosing Party, or its Affiliates,
employees, agents, or contractors; (c) is hereafter furnished to the receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right; or (d) is
independently discovered or developed by the receiving Party without the use of Confidential Information belonging to the disclosing Party. 

  
 36 

	13.3	 Authorized Disclosure. Each receiving Party may disclose Confidential Information
belonging to the disclosing Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances: 

 

	 	(a)	 filing, prosecuting, or maintaining Patents as permitted by this Agreement; 

 

	 	(b)	 regulatory filings for Products (for Pediatrix, only in the Pediatrix Territory) that such Party has a license
or right to Develop hereunder in a given country or jurisdiction; 

  

	 	(c)	 prosecuting or defending litigation arising under this Agreement; 

 

	 	(d)	 complying with applicable court orders or governmental regulations; and 

 

	 	(e)	 disclosure to its and its Affiliates’ employees, contractors and agents, to ARS Collaborators (in the case
of ARS) and to Sublicensees (in the case of Pediatrix), in each case on a need- to-know basis in connection with the Development and manufacture of Compositions, and Development, manufacture and
Commercialization of Products in accordance with the terms of this Agreement, in each case under written obligations of confidentiality and non- use at least as stringent as those herein; and

  

	 	(f)	 disclosure to potential and actual investors, acquirers, licensees and other financial or commercial partners
solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition or collaboration in such receiving Party, in each case under written or professional obligations of confidentiality and non-use at least as stringent as those herein. 

 Notwithstanding the foregoing, in the
event a receiving Party is required to make a disclosure of the disclosing Party’s Confidential Information pursuant to Section 13.3(c) or (d), and before making any such disclosure, it shall, except
where impracticable or prohibited, give prompt advance written notice to the disclosing Party of such requirement and its intended disclosure, and shall cooperate with the disclosing Party’s efforts to limit or avoid such disclosure and/or to
seek a protective order, confidential treatment of such Confidential Information or other available remedy. In any event, the Parties agree to take all reasonable action to avoid disclosure of a disclosing Party’s Confidential Information
hereunder. Any information disclosed pursuant to Section 13.3(c) or (d) shall remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing
provisions of this Article 13. 
  

	13.4	 Publications. ARS shall have the right to review and comment on any material proposed for public
disclosure or publication by Pediatrix regarding results of and other information regarding the other Pediatrix’s Development or Commercialization activities with respect to Products, whether by oral presentation, manuscript or abstract, or
other means of public disclosure, and including disclosures to the investment community, if such proposed public disclosure or publication might negatively affect Development and/or Commercialization of Products outside the Pediatrix Territory. For
the sake of clarity, any press release by Pediatrix shall follow the process set forth in Section 13.5 below, and not the process contained in this Section 13.4. Before any such material
described in this Section 13.4 is submitted for publication or presentation of any such material is made, Pediatrix shall deliver a complete copy in the English language to ARS prior to submitting the material to a
publisher or initiating any other public disclosure. ARS shall review any such material and give its comments to Pediatrix as soon as practicable. With respect to oral presentation materials and abstracts, ARS shall make reasonable efforts to
expedite review of such oral presentation materials and abstracts, and shall return its comments if any, on such items as soon as practicable to Pediatrix. Pediatrix shall comply with ARS’ request to delete references to ARS’ Confidential
Information in any such material and shall delay any submission for publication or other public disclosure for a period of up to an additional [***] for the purpose of preparing and filing appropriate patent applications. 

  
 37 

	13.5	 Publicity; Public Disclosures. The Parties may issue an initial press release following the
Effective Date. It is understood that each Party may desire or be required to issue subsequent press releases relating to this Agreement or activities hereunder. The Parties shall consult with each other reasonably and in good faith with respect to
the text and timing of all press releases prior to the issuance thereof, to the extent practicable, provided that a Party may not unreasonably withhold, condition or delay consent to such press releases, and that either Party may issue such
press releases or make such disclosures to the SEC or other applicable stock exchange or similar agencies as it determines, based on advice of counsel, are reasonably necessary to comply with rules of the stock exchange or Applicable Law. Each Party
shall provide the other Party with advance notice of legally required disclosures to the extent practicable. The Parties shall consult with each other on the provisions of this Agreement to be redacted in any filings made by a Party with the SEC or
other stock exchange or as otherwise required by Applicable Laws; provided that each Party shall have the right to make any such filing as it reasonably determines necessary under the rules of the stock exchange or Applicable Laws. In
addition, following the initial press release announcing this Agreement, either Party shall be free to disclose, without the other Party’s prior written consent, the existence of this Agreement, the identity of the other Party and those terms
of the Agreement which have already been publicly disclosed in accordance herewith. 

  

	13.6	 Prior Confidentiality Agreement. As of the Effective Date, the terms of this Article
13 shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) relating to the subject of this Agreement, including the
Confidentiality Agreement. Any information disclosed pursuant to any such prior agreement shall be deemed Confidential Information for purposes of this Agreement. 

 

	13.7	 Equitable Relief. Given the nature of the Confidential Information and the
competitive damage that a Party would suffer upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages would not be a sufficient remedy for any breach of this Article
13. In addition to all other remedies, a Party shall be entitled to specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 13. 

 

	14.	 TERM AND TERMINATION 

 

	14.1	 Term. This Agreement shall commence on the Effective Date and, unless terminated earlier as
provided in this Article 14 or by mutual written agreement of the Parties, shall continue, on a Product-by-Product and region-by-region basis, until the expiration of the applicable Royalty Term in the Pediatrix Territory (the “Term”). Upon expiration (but not
termination) of this Agreement for a Product in a region in the Pediatrix Territory, Pediatrix’s licenses under Section 2.1 shall become perpetual, irrevocable, exclusive, fully
paid-up and royalty free with respect to such Product in such region. 

  

	14.2	 Termination for Cause. 

 

	 	(a)	 Material Breach. Each Party shall have the right to terminate this Agreement in its
entirety upon written notice of termination delivered to the other Party, if such other Party materially breaches this Agreement and has not cured such breach within sixty (60) days (thirty (30) days with respect to any payment breach)
after receipt of written notice from the non- breaching Party describing such breach and demanding its cure; provided that if such breach is not reasonably capable of cure within the above cure period,
but is capable of cure within 120 days from such notice, then, provided the breaching Party submits a reasonable cure plan to remedy such breach, the above cure period shall be automatically extended for so long as the breaching Party
continues to use Commercially Reasonable Efforts to cure such breach in accordance with the cure plan, but for no more than 60 additional days. If the allegedly breaching Party in good faith disputes such material breach and provides written notice
of that dispute to the other Party within the applicable period set forth above, the matter shall be addressed under the dispute resolution provisions in Article 15, and the termination shall not become effective unless and until it
has been determined under Article 15 that the allegedly breaching Party is in material breach of this Agreement and has failed to cure such breach within the time periods provided in this
Section 14.2(a). It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their
respective obligations hereunder. 

  
 38 

	 	(b)	 Bankruptcy. Each Party shall have the right to terminate this Agreement in its entirety upon written
notice to the other Party if such other Party makes a general assignment for the benefit of creditors, files a voluntary insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee or similar officer to
liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its dissolution, liquidation or any other similar proceeding for the release of financially distressed
debtors or becomes a party to any proceeding or action of the type described above and such proceeding is not dismissed within [***] after the commencement thereof. 

 

	14.3	 Termination for Patent Challenge. ARS shall have the right to terminate this Agreement in its
entirety upon written notice to Pediatrix if Pediatrix or any of its Affiliates or Sublicensees directly, or indirectly through any Third Party, (a) commences any interference or opposition proceeding with respect to, or opposes any extension
of or the grant of a supplementary protection certificate with respect to, any ARS Patent, or (b) institutes, actively participates as an adverse party in, or otherwise provides material support to, any action, suit or other proceeding to
invalidate any ARS Patent or to obtain a ruling that any claim within any ARS Patent is unenforceable or not patentable; provided, however, that ARS shall not have the right to terminate this Agreement under this
Section 14.3, if (i) such challenge was brought by a Sublicensee and Pediatrix has terminated such sublicense within thirty (30) days of ARS’s notice to Pediatrix under this
Section 14.3, (ii) such challenge is based solely on the scope of an ARS Patent or whether a claim therein qualifies as a Valid Claim and made in defense of a breach claim first brought by ARS against Pediatrix pursuant to
this Agreement, or (iii) such challenge is dismissed within thirty (30) days of ARS’s notice to Pediatrix under this Section 14.3 and not thereafter continued. 

 

	14.4	 Termination by Pediatrix. 

 

	 	(a)	 Termination without Cause. Pediatrix shall have the right to
terminate this Agreement at any time for any reason or for no reason upon ninety (90) days written notice to ARS. 

  

	14.5	 Effects of Termination in Certain Situations. Upon any termination of this Agreement by ARS
pursuant to Section 14.2, 14.3 or the termination of this Agreement by Pediatrix pursuant to 14.4, the following shall apply: 

 

	 	(a)	 Termination of Licenses and Other Rights. All licenses granted to Pediatrix shall automatically
terminate, all other rights and obligations of the Parties under this Agreement shall terminate except as provided in to Section 14.8, and all sublicenses under the ARS Technology granted from Pediatrix to any Sublicensee
shall automatically terminate (provided that, upon the request of a Sublicensee that is not in breach of the sublicense agreement, ARS shall consider in good faith to enter into direct agreement with such Sublicensee), in each case on the
effective date of termination. 

  

	 	(b)	 Pediatrix Technology. The license granted to ARS pursuant to
Section 2.3 shall continue and shall become worldwide. 

  

	 	(c)	 Assignments. ARS shall notify Pediatrix within [***] after the effective date of termination whether it
wishes to obtain the assignments set forth in this Sections 14.5(c). Except as otherwise specified below, all such assignments under Sections 14.5(c) shall be without cost to ARS. 

  
 39 

	 	(i)	 Regulatory Filings. As promptly as practicable (and in any event within [***]) after such
notice, Pediatrix shall: (A) to the extent not previously provided to ARS, deliver to ARS true, correct and complete copies of all Regulatory Filings (including Regulatory Approvals) for Products in the Field in the Pediatrix Territory, and
provide to ARS all Pediatrix Know-How not previously disclosed to ARS; (B) to the extent permissible under Applicable Laws, transfer and assign, or cause to be transferred or assigned, to ARS or its
designee (or to the extent not so assignable, take all reasonable actions to make available to ARS or its designee all of the benefits of) all Regulatory Filings (including Regulatory Approvals) for Products in the Field in the Pediatrix Territory,
whether held in the name of Pediatrix or its Affiliate or Sublicensee; and (C) take such other actions and execute such other instruments, assignments and documents as may be necessary to effect, evidence, register and record the transfer,
assignment or other conveyance of rights under this Section 14.5(c)(i) to ARS. If the assignment of the Regulatory Filings to ARS is not permitted by Applicable Law or otherwise upon ARS’s request, [***],
Pediatrix shall continue to hold any such Regulatory Filings for the sole benefit of ARS or its designee (in which case, Pediatrix shall appoint ARS or its designee as the exclusive distributor (with the right to subcontract and appoint
subdistributors) under such Regulatory Filings for the Product in the Pediatrix Territory, and also as its agent to interact with the applicable Regulatory Authority in the Pediatrix Territory with respect to such Regulatory Filings), until such
time ARS or its designee files its own Regulatory Filings and obtains its own Regulatory Approvals for the Product in the Pediatrix Territory, at which time Pediatrix shall terminate or withdraw its Regulatory Fillings for the Product in the
Pediatrix Territory. 

  

	 	(ii)	 Trademarks. Pediatrix shall, and hereby does, effective upon such termination, assign to ARS all of
Pediatrix’s and its Affiliates’ right, title and interest in and to any and all Pediatrix Product Trademarks in the Pediatrix Territory, including all goodwill therein, and Pediatrix shall promptly take such actions and execute such
instruments, assignments and documents as may be necessary to effect, evidence, register and record such assignment. 

  

	 	(d)	 Wind-Down. Pediatrix shall, as directed by ARS, either wind-down any ongoing Development activities of
Pediatrix and its Sublicensees with respect to any Compositions or Products in the Field in the Pediatrix Territory in an orderly fashion or promptly transfer such Development activities to ARS or its designee, in compliance with all Applicable
Laws. 

  

	 	(e)	 Transition Assistance. Pediatrix shall, [***], provide reasonable consultation and assistance for a
period of no more than [***] for the purpose of transferring or transitioning to ARS all Pediatrix Know-How not already in ARS’s possession and, at ARS’s request, all then-existing commercial
arrangements relating specifically to Compositions and Products that Pediatrix is able, using Commercially Reasonable Efforts, to transfer or transition to ARS, in each case, to the extent reasonably necessary or useful for ARS to commence
Developing, manufacturing, or Commercializing Products in the Pediatrix Territory. The foregoing shall include transferring, upon request of ARS, any agreements with Third Party suppliers or vendors that specifically cover the supply or sale of
Compositions or Products in the Pediatrix Territory. If any such contract between Pediatrix and a Third Party is not assignable to ARS (whether by such contract’s terms or because such contract does not relate specifically to Compositions or
Products) but is otherwise reasonably necessary or useful for ARS to commence Developing, manufacturing, or Commercializing Products in the Pediatrix Territory, or if Pediatrix manufactures the Product itself (and thus there is no contract to
assign), then at ARS’s cost, Pediatrix shall reasonably cooperate with ARS to negotiate for the continuation of services or supply from such entity, or Pediatrix shall supply such Composition or Product, as applicable, to ARS for a reasonable
period (not to exceed [***]) until ARS establishes an alternate, validated source of such services or supply of finished, packaged, labeled Product for the Pediatrix Territory. Such supply shall be at a price equal to [***]% [***], with such cost
calculated as [***]. 

  
 40 

	 	(f)	 Remaining Inventories. Pediatrix shall have the right, for a period of [***] following termination of
this Agreement, to sell or otherwise dispose of any Products, as applicable, on hand at the time of such termination or in the process of Manufacturing; provided that Pediatrix continue to pay royalty to ARS on the sale of such Products. Thereafter,
at ARS’s election and request, Pediatrix shall transfer to ARS or its designee some or all inventory of Compositions and Products then in the possession or control of Pediatrix, its Affiliates or sublicensees, at a price equal to [***], with
such cost calculated as described [***]. 

  

	14.6	 Effects of Termination by Pediatrix. If Pediatrix terminates this Agreement
pursuant to Section 14.2: 

  

	 	(a)	 Sections 14.5(a), 14.5(c)-14.5(f) shall apply, provided
that, [***] shall reimburse all internal (at a fully-burdened rate) and external costs incurred by [***] to conduct activities under 14.5(c)-14.5(f), notwithstanding anything to the contrary in
14.5(c)-14.5(f). 

  

	 	(b)	 The license granted to ARS pursuant to Section 2.3 shall continue outside the
Pediatrix Territory. Upon ARS’s request, Pediatrix shall negotiate in good faith with ARS the terms and conditions to expand such license to the Pediatrix Territory. 

 

	14.7	 Confidential Information. Upon termination of this Agreement in its entirety,
except to the extent that a receiving Party obtains or retains the right to use the disclosing Party’s Confidential Information, each receiving Party shall promptly return to the disclosing Party, or delete or destroy, all relevant records and
materials in such receiving Party’s possession or control containing Confidential Information of the disclosing Party; provided that such receiving Party may keep one copy of such materials for archival purposes only subject to
continuing confidentiality obligations. All Pediatrix Know-How assigned to ARS after the termination of this Agreement as set forth in Section 14.5 and 14.6(a)
shall be deemed ARS’s Confidential Information and no longer Pediatrix’s Confidential Information. 

  

	14.8	 Survival. Expiration or termination of this Agreement shall not relieve the Parties of any
obligation or right accruing prior to such expiration or termination. Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or
termination of this Agreement: Article 1(Definitions), Article 8 (Fees and Payments) (solely to the extent payments have accrued prior to the effective date of termination), Article 9
(Payments; Records; Audits) (solely to the extent payments have accrued prior to the effective date of termination), Article 12 (Indemnification)(excluding Section 12.4 (Insurance)),
Article 13 (Confidentiality), Article 15 (Dispute Resolution), Article 16 (General Provisions), Section 10.1 (Ownership),
Section 11.5 (Disclaimer), Section 14.1 (Term) (which shall survive only with respect to licenses that have become perpetual and irrevocable prior to the expiration or early
termination of this Agreement), and Section 14.5 (Effects of Termination in Certain Situations) through Section 14.11 (Rights in Bankruptcy) (as applicable). 

 

	14.9	 Exercise of Right to Terminate. The use
by either Party hereto of a termination right provided for under this Agreement shall not give rise to the payment of damages or any other form of compensation or relief to the other Party with respect thereto; provided, however, that
termination of this Agreement shall not preclude either Party from claiming any other damages, compensation or relief that it may be entitled to upon such termination. 

 

	14.10	 Damages; Relief. Subject to Section 14.8, termination of
this Agreement shall not preclude either Party from claiming any other damages, compensation or relief that it may be entitled to upon such termination. 

  
 41 

	14.11	 Rights in Bankruptcy. All rights and licenses granted under or
pursuant to this Agreement by one Party to the other Party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, licenses of
right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws. A Party that is a licensee of such rights under this
Agreement shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws. In the event of the commencement of a bankruptcy proceeding by or
against a Party to this Agreement under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, the other Party shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such
intellectual property and all embodiments of such intellectual property that are necessary for use and exploitation of such other Party’s licenses and rights hereunder, and same, if not already in its possession, shall be promptly delivered to
it (a) upon any such commencement of a bankruptcy or insolvency proceeding upon its written request therefor, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered
under (a) above, following the rejection of this Agreement by or on behalf of the bankrupt Party upon written request therefor by the other Party. In the event where any Third Party other than the bankrupt Party (including but not limited to
CMO) owns or possesses a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property that are necessary for use and exploitation of such other Party’s licenses
and rights hereunder, and same, the bankrupt Party shall procure such Third Party to deliver such complete duplicate to the other Party, upon such other Party’s written request. 

 

	15.	 DISPUTE RESOLUTION 

 

	15.1	 Objective. The Parties recognize that disputes as to matters (i) arising under, or relating
to, this Agreement or (ii) either Party’s rights and obligations hereunder may arise from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of such disputes in an expedient manner by
mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 15 to resolve any such dispute if and when it arises.

  

	15.2	 Resolution by Executive Officers. Except as otherwise provided in Article 3, if an
unresolved dispute as to matters arising under or relating to this Agreement or either Party’s rights and obligations hereunder arises, either Party may refer such dispute to the Executive Officers, who shall meet in person or by telephone
within [***] after such referral to attempt in good faith to resolve such dispute. If such matter cannot be resolved by discussion of such Executive Officers within such [***] period (as may be extended by mutual written agreement), such dispute
shall be resolved in accordance with Section 15.3. 

  

	15.3	 Arbitration. 

 

	 	(a)	 If the Parties do not resolve a dispute as provided in Section 15.2, and a Party
wishes to pursue the matter, each such dispute that is not an Excluded Claim (defined below) shall be resolved by binding arbitration in accordance with the Rules of Arbitration of the International Chamber of Commerce
(“ICC”) as then in effect (the “ICC Rules”), which ICC Rules are deemed to be incorporated by reference into this clause, using the laws of the State of New York. The
arbitration award rendered in any such arbitration shall be final and not appealable and may be executed by any court of competent jurisdiction. If either Party intends to commence binding arbitration of such dispute, such Party shall provide
written notice to the other Party informing the other Party of such intention and the issues to be resolved. Within [***] after the receipt of such notice, the other Party may, by written notice to the Party initiating binding arbitration, add
additional issues to be resolved. 

  

	 	(b)	 The arbitration shall be conducted by a panel of [***] appointed in accordance with the ICC Rules, none of whom
shall be a current or former employee or director, or a then-current stockholder, of either Party, their respective Affiliates or any Sublicensee. The place of arbitration shall be New York City, NY, and all proceedings and communications shall be
in English. 

  
 42 

	 	(c)	 It is the intention of the Parties that discovery, although permitted as described herein, shall be limited
except in exceptional circumstances. The arbitrators shall permit such limited discovery necessary for an understanding of any legitimate issue raised in the arbitration, including the production of documents. No later than [***] after selection of
the arbitrators, the Parties and their representatives shall hold a preliminary meeting with the arbitrators, to mutually agree upon and thereafter follow procedures seeking to assure that the arbitration shall be concluded within [***] from such
meeting. Failing any such mutual agreement, the arbitrators shall design and the Parties shall follow procedures to such effect. 

  

	 	(d)	 Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered
or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party
pending the arbitration award. The arbitrators shall have no authority to award punitive or any other non- compensatory damages. The award shall be in writing and shall describe the basis for the award and the
arbitrators’ decision(s). The arbitrators shall have the power to order that all or part of the legal or other costs incurred by a Party in connection with the arbitration be paid by the other Party. Each Party shall bear an equal share of the
arbitrators’ and any administrative fees of arbitration. 

  

	 	(e)	 Except to the extent necessary to confirm or enforce an award or as may be required by Applicable Law, neither
a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable
proceeding based on the dispute, controversy or claim would be barred by the applicable statute of limitations. 

  

	 	(f)	 As used in this Section, the term “Excluded Claim” means a
dispute, controversy or claim that concerns (i) the validity, enforceability or infringement of a patent, trademark or copyright or (ii) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory.

  

	16.	 GENERAL PROVISIONS 

 

	16.1	 Governing Law. This Agreement, and all questions regarding the existence, validity,
interpretation, breach or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles. The application of
the U.N. Convention on Contracts for the International Sale of Goods (1980) is excluded. 

  

	16.2	 Entire Agreement; Modification. This Agreement is both a final expression of the Parties’
agreement and a complete and exclusive statement with respect to all of its terms. This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written or otherwise, concerning any and all matters contained
herein. This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement. 

  

	16.3	 Relationship Between the Parties. The Parties’ relationship, as established by this
Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between the Parties. Neither Party is a legal representative of the other Party, and neither Party
can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. 

  
 43 

	16.4	 Non-Waiver. The failure of a Party to insist upon strict
performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any
other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party. 

 

	16.5	 Assignment. Except as expressly provided hereunder, neither this Agreement nor any rights or
obligations of a Party hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld, conditioned or delayed); provided,
however, that either Party may, upon the prior notice to the other Party, assign or otherwise transfer this Agreement in its entirety without the other Party’s consent: 

 

	 	(a)	 in connection with the transfer or sale to a Third Party of all or substantially all of the business or assets
of such Party relating to Products, whether by merger, consolidation, divesture, restructure, sale of stock, sale of assets or otherwise, provided that in the event of any such transaction (whether this Agreement is actually assigned
or is assumed by the acquiring Party by operation of law (e.g., in the context of a reverse triangular merger)), intellectual property rights of the acquiring party to such transaction (if other than one of the Parties to this Agreement)
prior to the closing of such transaction or developed or acquired by the acquiring party thereafter independent of this Agreement shall not be included in the technology licensed hereunder; or 

 

	 	(b)	 to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non-assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate. 

The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the
Parties specified above, and the name of a Party appearing herein shall be deemed to include the name of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this section. Any assignment not in
accordance with this Section 16.5 shall be null and void. 
  

	16.6	 Performance by Affiliates. Each Party may discharge any obligations and exercise any right
hereunder through any of its Affiliates and each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, without sublicense or assignment, and shall cause its Affiliates to comply with the
provisions of this Agreement in connection with such performance. Any breach by such Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such
Party (or such Affiliate) without any obligation to first proceed against such Party’s Affiliate (or such Party). 

  

	16.7	 Severability. If, for any reason, any part of this Agreement is adjudicated invalid,
unenforceable or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement. All
remaining portions shall remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part. 

 

	16.8	 Notices. Any notice to be given under this Agreement must be in writing and delivered either in
person, or by (a) air mail (postage prepaid) requiring return receipt, (b) overnight courier, or (c) facsimile or electronic mail (with written confirmation of the recipient) thereafter by any of the foregoing, to the Party to be
notified at its address(es) given below, or at any address such Party may designate by prior written notice to the other in accordance with this Section 16.8. Notice shall 

  
 44 

	 	
be deemed sufficiently given for all purposes upon the earliest of: (i) the date of actual receipt; (ii) if air mailed, [***] after the date of postmark; (iii) if delivered by
overnight courier, the next day the overnight courier regularly makes deliveries, (iv) if sent by facsimile, the date of confirmation of receipt if during the recipient Party’s normal business hours, otherwise the next business day, and
(v) if notice is given by electronic mail, a hard copy shall be provided via air mail (postage prepaid) requiring return receipt, or courier service; the receipt of such hard copy by the receiving Party shall constitute notice here under.

 If to Pediatrix, notices must be addressed to: 

Pediatrix Therapeutics 

Attention: Chief Executive Officer 

Fascimile: 
 with a copy to: 

F-Prime Capital, 1 Main St., 13th Flr, Cambridge, MA 02142 

Attention: Ketan Patel and Chong Xu 

Fascimile: 
 If to ARS, notices
must be addressed to: 
 ARS Pharmaceuticals, Inc. 

3525 Del Mar Heights Rd., #855 San Diego, CA 92130, USA 

Attention: Chief Executive Officer 

Facsimile: 
 with a copy to: 

ARS Pharmaceuticals, Inc. 
 3525
Del Mar Heights Rd., #855 San Diego, CA 92130, USA 
 Attention: Chief Business Officer 

Facsimile: 
  

	16.9	 Force Majeure. Each Party shall be excused from liability for the failure or delay
in performance of any obligation under this Agreement (other than failure to make payment when due, except that the force majeure event itself prevents the making of such payment) by reason of any event beyond such Party’s reasonable control
including but not limited to Acts of God, fire, flood, explosion, earthquake, epidemic, pandemic or related government orders, or other natural forces, war, civil unrest, acts of terrorism, accident, destruction or other casualty, or any other event
similar to those enumerated above. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the affected Party has not directly or indirectly
caused such event(s) to occur. Notice of a Party’s failure or delay in performance due to force majeure must be given in writing to the other Party within [***] after its occurrence. All delivery dates under this Agreement that have been
affected by force majeure shall be tolled for the duration of such force majeure, provided the affected Party shall promptly undertake and continue to undertake all reasonable efforts necessary to cure such force majeure or to perform its
obligations despite the ongoing force majeure. In no event shall any Party be required to prevent or settle any labor disturbance or labor dispute. 

  
 45 

	16.10	 Interpretation. The headings of clauses contained in this Agreement preceding the text of the
sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All references in this
Agreement to the singular shall include the plural where applicable. Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections and paragraphs in such Article, references to any Section shall
include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection. The word “including” and similar words means including without limitation. The word
“or” means “and/or” unless the context dictates otherwise because the subject of the conjunction are mutually exclusive. The words “herein,” “hereof” and “hereunder” and other words of similar import
refer to this Agreement as a whole and not to any particular Section or other subdivision. All references to days in this Agreement mean calendar days, unless otherwise specified. Ambiguities and uncertainties in this Agreement, if any, shall not be
interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language and the English language shall control its interpretation. In
addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties regarding this Agreement shall be in the English language. 

 

	16.11	 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments,
and to do all such other acts, as necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

  

	16.12	 Counterparts; Electronic or Facsimile Signatures. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together shall constitute one instrument. This Agreement may be executed and delivered electronically or be executed by facsimile or PDF signature or other electronic signature
means, and upon such delivery such electronic delivery or facsimile, PDF or electronic signature(s) shall be deemed to have the same effect as if the original signature had been delivered to the other Party. 

[SIGNATURE PAGE FOLLOWS] 

  
 46 

 IN WITNESS WHEREOF, the Parties hereto
have caused this Collaboration And Distribution Agreement to be executed and entered into by their duly authorized representatives as of the Effective Date. 
  

									
	ARS PHARMACEUTICALS, INC.	  		  	PEDIATRIX
					
	By:	 	 /s/ Richard Lowenthal
	  		  	By:	 	 /s/ Ketan Patel

	Name:	 	Richard Lowenthal	  	        	  	Name:	 	Ketan Patel
	Title:	 	President & Chief Executive Officer	  		  	Title:	 	Officer
	Date:	 	28 February 2021	  		  	Date:	 	1 March 2021

  

  

SIGNATURE PAGE TO COLLABORATION AND LICENSE
AGREEMENTEX-10.4

 Exhibit 10.4 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT ATERIAL AND
(II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. 
 ARS PHARMACEUTICALS,
INC. 
 and 

RECORDATI IRELAND, LTD 

 
  

 
 LICENSE AND
SUPPLY AGREEMENT 
 for the finished product 

ARS-1 
  

 

 

 TABLE OF CONTENTS 

 

							
	 SECTION I – CERTAIN DEFINITIONS
	  	 	1	 
	 1.
	 	RECITALS AND ANNEXES	  	 	1	 
	 2.
	 	DEFINITIONS AND INTERPRETATION	  	 	2	 
	 SECTION II – SCOPE OF THIS AGREEMENT
	  	 	14	 
	 3.
	 	GRANT OF LICENSE	  	 	14	 
	 4.
	 	LICENSE EXCLUSIVITY PERIOD	  	 	15	 
	 5.
	 	IMPROVEMENTS	  	 	15	 
	 SECTION III – DEVELOPMENT AND REGULATORY MATTERS
	  	 	16	 
	 6.
	 	DEVELOPMENT OF THE PRODUCT IN THE TERRITORY	  	 	16	 
	 7.
	 	REGULATORY ACTIVITIES IN THE TERRITORY	  	 	18	 
	 8.
	 	REGULATORY COSTS	  	 	20	 
	 SECTION IV – MANUFACTURING OF THE PRODUCT
	  	 	21	 
	 9.
	 	MANUFACTURING UNDERTAKINGS	  	 	21	 
	 10.
	 	LABELLING AND PACKAGING	  	 	22	 
	 11.
	 	QUALITY TEST OF THE PRODUCT	  	 	23	 
	 12.
	 	AUDIT OF PRODUCT MANUFACTURING FACILITIES	  	 	24	 
	 13.
	 	TECHNOLOGY TRANSFER	  	 	24	 
	 SECTION V – SUPPLY OF THE PRODUCT
	  	 	25	 
	 14.
	 	SUPPLIER APPOINTMENT	  	 	25	 
	 15.
	 	SUPPLY EXCLUSIVITY PERIOD	  	 	25	 
	 16.
	 	NON-COMPETE	  	 	25	 
	 17.
	 	PRODUCT PRE-LAUNCHING PERIOD	  	 	25	 
	 18.
	 	FORECAST AND ORDERS	  	 	26	 
	 19.
	 	PRODUCT PURCHASE AGREEMENT	  	 	27	 
	 20.
	 	DELIVERY	  	 	27	 
	 21.
	 	QUALITY INSPECTION OF THE PRODUCT AND CLAIMS	  	 	27	 
	 22.
	 	INABILITY TO SUPPLY	  	 	28	 
	 SECTION VI – CONDITION PRECEDENT
	  	 	29	 
	 23.
	 	CONDITION PRECEDENT	  	 	29	 
	 SECTION VII – PAYMENTS
	  	 	29	 
	 24.
	 	UPFRONT PAYMENT	  	 	29	 
	 25.
	 	REGULATORY MILESTONES	  	 	29	 
	 26.
	 	LAUNCH MILESTONE	  	 	29	 
	 27.
	 	SALES MILESTONES	  	 	30	 
	 28.
	 	SUPPLY PRICE AND ROYALTY	  	 	30	 
	 29.
	 	REPORT	  	 	31	 
	 30.
	 	PAYMENT METHOD	  	 	32	 
	 31.
	 	ACCOUNTING AUDIT	  	 	32	 
	 32.
	 	TAXES AND DUTIES	  	 	33	 
	 SECTION VIII – FURTHER OBLIGATION OF THE PARTIES
	  	 	34	 
	 33.
	 	GOVERNANCE AND REPORTING	  	 	34	 
	 34.
	 	PHARMACOVIGILANCE AND RECALL	  	 	35	 
	 SECTION IX – FURTHER OBLIGATIONS OF RECORDATI
	  	 	36	 
	 35.
	 	SELLING PRICE REIMBURSEMENT	  	 	36	 
	 36.
	 	MARKETING OF THE PRODUCT	  	 	36	 
	 37.
	 	PRODUCT STORAGE	  	 	36	 
	 SECTION X – FURTHER OBLIGATIONS OF ARS
	  	 	37	 
	 38.
	 	UNDERTAKINGS OF ARS	  	 	37	 
	 SECTION XI – REPRESENTATION AND WARRANTIES
	  	 	37	 
	 39.
	 	REPRESENTATION AND WARRANTIES	  	 	37	 
	 SECTION XII – INDEMNIFICATION – NOTICE OF CLAIM
	  	 	40	 
	 40.
	 	LIMITED LIABILITY	  	 	40	 
	 41.
	 	INDEMNIFICATION	  	 	41	 
	 42.
	 	NOTICE OF CLAIM	  	 	41	 
	 SECTION XIII – SPECIAL PROVISIONS
	  	 	42	 
	 43.
	 	IP OWNERSHIP; IP RIGHTS INFRINGEMENT LAWSUIT	  	 	42	 
	 SECTION XIV – TERM AND TERMINATION OF THIS AGREEMENT
	  	 	44	 
	 44.
	 	TERM	  	 	44	 
	 45.
	 	TERMINATION OF THIS AGREEMENT	  	 	44	 
	 46.
	 	EFFECTS OF TERMINATION	  	 	45	 
	 SECTION XV – GENERAL PROVISIONS
	  	 	46	 
	 47.
	 	CONFIDENTIALITY	  	 	46	 
	 48.
	 	FORCE MAJEURE	  	 	47	 
	 49.
	 	INSURANCE	  	 	48	 

							
	 SECTION XVI – MISCELLANEOUS
	  	 	48	 
	 50.
	 	ENTIRE AGREEMENT	  	 	48	 
	 51.
	 	AMENDMENTS	  	 	48	 
	 52.
	 	PARTIAL INVALIDITY	  	 	48	 
	 53.
	 	NOTICES	  	 	48	 
	 54.
	 	NO ASSIGNMENT	  	 	49	 
	 55.
	 	WAIVER	  	 	49	 
	 56.
	 	INDEPENDENT CONTRACTORS	  	 	49	 
	 57.
	 	COSTS AND EXPENSES	  	 	49	 
	 58.
	 	COUNTERPARTS	  	 	49	 
	 59.
	 	ANNOUNCEMENT	  	 	49	 
	 SECTION XVII – GOVERNING LAW AND JURISDICTION
	  	 	50	 
	 60.
	 	GOVERNING LAW	  	 	50	 
	 61.
	 	DISPUTE RESOLUTION	  	 	50	 
	 SECTION XVIII – ANNEXES
	  	 	51	 
	 62.
	 	ANNEXES	  	 	51	 

 This LICENSE AND SUPPLY AGREEMENT (the Agreement) is made and entered into effective as
of the last date of execution by the parties hereto (the Effective Date) by and between: 
 ARS PHARMACEUTICALS,
INC., a company incorporated and existing under the laws of Delaware (hereinafter, ARS), having its registered office at 3525 Del Mar Heights Rd., #855, San Diego, CA 92130, U.S., represented by Richard
Lowenthal, in his capacity as President & Chief Executive Officer of the company, duly authorized; 
 - on the one side - 

and 
 RECORDATI
IRELAND, LTD, a company incorporated and existing under the laws of Ireland (Recordati), having its registered office at Raheens East, Ringaskiddy, Co Cork, P43 KD30, Republic of
Ireland, represented by Cédric Ripert, in his capacity as Managing Director of the company, duly authorized,  
 - on the
other side - 
 (ARS and Recordati are referred to collectively as the Parties, and each of them a Party). 

WHEREAS: 
  

	(A)	 ARS is a company engaged, inter alia, in the field of developing, registering manufacturing,
purchasing, selling and distributing of certain pharmaceutical products; 

  

	(B)	 ARS is engaged in the development of the Product; 

 

	(C)	 Recordati is a pharmaceutical company, with a size and a position on the market adequate to, directly or
through its Affiliates or Sublicensees, Commercialize specialty care pharmaceuticals throughout the Territory; 

  

	(D)	 Recordati has completed a satisfactory due diligence on the Product and on ARS’ capability and ARS
has completed a satisfactory due diligence on Recordati’s capability; and 

  

	(E)	 by entering in this Agreement, the Parties intend to confirm the terms and conditions under which ARS
desires to grant to Recordati, and Recordati desires to obtain from ARS, an exclusive license to Commercialize the Product in the Territory. 

Now, in light of the above, it is hereby agreed as follows. 

SECTION I – CERTAIN DEFINITIONS 
  

	1.	 RECITALS AND ANNEXES 

 

	1.01	 The recitals and the annexes attached hereto (the Annexes) constitute an integral part of
this Agreement. 

  
 1 

	2.	 DEFINITIONS AND INTERPRETATION 

 

	2.01	 As used in this Agreement, the following terms, unless the context otherwise requires, shall have the
meanings set out below: 

  

			
	[***]	  	means [***] limited liability company;
		
	[***] License Agreement	  	means the license agreement executed between [***] and ARS on 18 June 2018, as may be amended (subject to Paragraph 38.01(vii)), granting rights with respect to Excipient for use in Products;
		
	[***] Supply Agreement	  	means the supply agreement executed between [***] and ARS on 18 June 2018, as may be amended (subject to Paragraph 38.01(vii)), pursuant to which [***] undertook to supply to ARS the Excipient;
		
	Affiliate	  	means, with regards to a Party, any Person that, directly or indirectly through one or more intermediaries, controls, is under control of, or is under common control with such Party, but for only so long as such control exists save
that, in respect of Recordati, no member of the [***] network shall be considered as an Affiliate of Recordati; where “control” as used in this definition means (i) to possess, directly or indirectly, the power to direct
the management or policies of a Person, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (ii) direct or indirect beneficial ownership of more than 50% of the voting share
capital or other equity interest in such Person;
		
	Aggregate Supply Price	  	means the sum of the results of each of the multiplication of: (i) Supply Price applicable to the relevant Presentation; and (ii) the number of Presentations indicated in the relevant invoice;
		
	Agreement	  	has the meaning given in the Headings;
		
	Annexes	  	has the meaning given in Clause 1;
		
	Annual Cap	  	means, on a Calendar Year basis, the sum of the: (i) First Cap; (ii) Second Cap; and (iii) Third Cap;
		
	Annual Aggregate Supply Price	  	means, on a Calendar Year basis, the sum of the results of each of the multiplication of: (i) [***]; and (ii) [***];
		
	Annual Net Sales	  	means, with respect to any Annual Net Sales Period, the Net Sales earned in such Annual Net Sales Period;
		
	Annual Net Sales Period	  	means (i) the period from the First Launching Date through 31 December of the Calendar Year in which the First Launching Date took place; and (ii) each Calendar Year
thereafter;

  
 2 

			
	Anti-Falsification Regulations	  	means the serialisation, aggregation and other safety and traceability requirements under the EU Falsified Medicines Directive 2011/62/EU (EUFMD) (and delegated legislation including Regulation (EU) 2016/161) and/or the Drug Supply
Chain Security Act and/or any successor legislation or materially equivalent legislation enacted or adopted as of the date hereof in the Territory; 
		
	Applicable Laws	  	means all present and future applicable provisions of all statutes, laws, rules, regulations, administrative codes, ordinances, decrees, orders, decisions, injunctions, awards, judgments, permits and licenses of or issued from any
competent court, governmental, tax or revenue authorities or Regulatory Authority, including those relating to or governing the use or regulation of the fulfilment of each Party’s obligation set out in this Agreement;
		
	[***]	  	means [***], a company engaged in the field of developing, manufacturing and supplying drug delivery solutions (such as the [***]) for pharmaceutical usage; 
		
	ARS	  	has the meaning given in the Headings;
		
	ARS Intellectual Property Rights	  	means all Intellectual Property Rights in relation to the Product (including, without limitation, the Compound and/or the Excipient contained in the Product), in the Territory which are Controlled by ARS as of the Effective Date or
become during the Term Controlled by ARS, including, without limitation, the Dossier(s), the Patents and the ARS Know-How; including, without limitation, all rights granted to ARS under the [***] License
Agreement in respect to the Excipient(s) and/or the Product;
		
	ARS Know-How	  	means any and all Know-How relating to the Product (including, without limitation, the Compound and/or the Excipient contained in the Product), in the Territory which is Controlled by ARS as
of the Effective Date or become during the Term Controlled by ARS;
		
	ARS Representatives	  	has the meaning given in Paragraph 41.02;
		
	Breach Process Dispute	  	has the meaning given in Paragraph 45.01(i);
		
	Calendar Year	  	means (i) for the first Calendar Year of the Term of this Agreement, the period beginning on the Effective Date and ending on 31 December of the Calendar Year in which the Effective Date took place; (ii) for each
Calendar Year thereafter, each successive period beginning on 1 January and ending, 12

  
 3 

			
		  	(twelve) consecutive calendar months later, on 31 December; and (iii) for the last Calendar Year of the Term of this Agreement, the period beginning on 1 January of the Calendar Year in which this Agreement expires or
terminates and ending on the effective date of expiration or termination of this Agreement;
		
	Calendar Quarter	  	means the respective period of 3 (three) consecutive calendar months ending on 31 March, 30 June, 30 September and 31 December; provided however that (i) the first Calendar Quarter of this Agreement shall extend
from the Effective Date to the end of the first complete Calendar Quarter thereafter; and (ii) the last Calendar Quarter shall end upon the expiration of termination of this Agreement;
		
	[***]	  	means [***], a company engaged in the field of supplying active pharmaceuticals ingredients for pharmaceutical usage;
		
	cGDP	  	means the current good distribution practices of medicinal products for human use in accordance with the Directive 2001/83/EC and Commission Delegated Regulation (EU) No 1252/2014 (3) and EudraLex Volume 4, Part II as complemented
by the European Commission Guidelines dated 5 November 2013 (2013/C 343/01);
		
	cGMP	  	means the current good manufacturing practices in accordance with all Applicable Laws, including: (i) International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH);
Guidance for Industry: Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, and (ii) EudraLex Volume 4 of “The rules governing medicinal products in the European Union”; and (iii) the United States of
America Food and Drug Administration Code of Federal Regulations Title 21;
		
	CoA	  	means the certificate of analysis confirming the quality of the Product and demonstrating that the batch conforms to the Specifications in the destination country of the Territory, according to the requirements of the analytical
certification contained in the document “International harmonised requirements for batch certification” (EMA/INS/MRA/387218/2011);

  
 4 

			
	CoC	  	means the certificate of conformity confirming that the manufacturing stages of the batch of the Product have been carried out in full compliance with the cGMP requirements of the countries of the Territory and with the requirements
of the applicable Marketing Authorisations, in full respect of the batch certification requirements contained in the EU cGMP, annex (Appendix II);
		
	Commercially Reasonable Efforts	  	means, with respect to the efforts to be expended by a Party to achieve any objective, [***];
		
	Commercialize	  	means all activities relating to the market access, pre-marketing, marketing, distribution, import, use, sale and offer for sale of a product and Commercializing,
Commercialization and Commercialized shall be construed accordingly;
		
	Common Technical Document	  	is the document assembling all the quality, safety and efficacy information in a common format developed by the EMA, the FDA and the Japanese Ministry of Health, Labour and Welfare or any successor agency, maintained by the
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH);
		
	Competing Product	  	means [***];
		
	Compound	  	means epinephrine [***];
		
	Confidential Information	  	all Know-How and other proprietary scientific, marketing, financial or commercial information or data that is not publicly available, and that is generated by or on behalf of a Party or its
Affiliates or which one Party or any of its Affiliates has supplied or otherwise made available to the other Party or its Affiliates, whether made available orally, in writing, or in electronic or visual form, including information comprising or
relating to concepts, discoveries, inventions, data, designs or formulae in relation to this Agreement;
		
	Concept	  	has the meaning given in Paragraph 5.01;
		
	Concept Development Activity	  	has the meaning given in Paragraph 5.01;
		
	Condition Precedent	  	has the meaning given in Paragraph 23.01;
		
	Control or Controlled	  	means, with respect to any Intellectual Property Right, possession of the right, whether by ownership, licence or otherwise (but without taking into account any rights granted by one Party to the other Party pursuant to this
Agreement), to use, assign, or

  
 5 

			
		  	grant a licence, sub-licence or other right to or under, such Intellectual Property Rights, without violating the terms of any agreement or other arrangement with any Third Party and without
requiring any further consent from a Third Party;
		
	Counter Inspection	  	has the meaning given in Paragraph 21.04;
		
	Cure Period	  	has the meaning given in Paragraph 45.01(i);
		
	Dossier	  	means the Common Technical Document in respect of the Product; 
		
	Effective Date	  	has the meaning given in the Headings;
		
	EMA	  	means the European Medicines Agency and its committees (e.g. PDCO) and any successor agency;
		
	End-Users	  	has the meaning given in Paragraph 14.02 (ii);
		
	EU	  	means the European Union; 
		
	EU Marketing Authorization	  	means the marketing authorization granted in the EU for authorising medicinal products as regulated by Directive (EC) 2001/83 as amended from time to time, and Regulation (EC) No 726/2004 as amended from time to time;
		
	EU Territory	  	means all the countries of the EU and their possessions as better described in Annex 1, and any amendment to such list according to Applicable Laws and agreed in writing by the Parties;
		
	Ex-EU Marketing Authorization	  	means any and all marketing authorizations and other similar forms of licenses and permits that are obtained from the competent Regulatory Authority in the Ex-EU Territories as necessary for
the Commercialization of the Product within the Ex-EU Territories;
		
	Ex-EU Territory	  	means the countries and their possessions described in Annex 2, expressly excluding, for the avoidance of doubt, the UK;
		
	Excipient	  	means [***]’s proprietary chemically synthesizable delivery enhancement agents (including without limitation the Intravail® absorption enhancement agents), licensed by
[***] to ARS, that, among other things, allow non-invasive systemic delivery of potent peptide, protein, and small and large molecule drugs;

  
 6 

			
	FDA	  	means the U.S. Food and Drug Administration and any successor agency;
		
	Feedback	  	has the meaning given in Paragraph 39.03(iii);
		
	Field	  	means the treatment, palliation, diagnosis, or prevention of any human or animal disease, disorder, or condition;
		
	First Cap	  	has the meaning given in Paragraph 28.04(i);
		
	First Launching Date	  	means the day of the 1st (first) sale of the Strength 1 Presentation to an End-User;
		
	Force Majeure	  	means any act, circumstance or event beyond the reasonable control of either of the Parties, including but not limited to earthquakes, hurricanes, fires, storms, tidal waves or other acts of God, riots, strikes, lockouts, picketing,
boycotts, shortage in energy, breakage or accidents to one of the Parties’ plants, machinery, equipment, pipelines and storage which could not have been reasonably foreseen or prevented, insurrections, rebellions, civil disturbances,
epidemic(s), pandemic(s), war and dispositions or orders of governmental authority;
		
	Forecast	  	has the meaning given in Paragraph 18.01;
		
	GAAP	  	means the generally accepted accounting principles of the applicable country or jurisdiction, consistently applied, and means the international financial reporting standards (“IFRS”) at such time as IFRS
becomes the generally accepted accounting standard and Applicable Laws require that a Party use IFRS;
		
	Improvement	  	shall mean and include changes, modifications and amendments, conceived, reduced to practice or otherwise developed, relating to the formulation, the device or use of the Compound and Excipient delivered intranasally in the Field
which: (i) significantly improve the clinical efficacy of the form of Compound and Excipient delivered intranasally; (ii) significantly reduce any side effects, drug interactions or other adverse effects of the form of Compound and
Excipient delivered intranasally; (iii) otherwise represent significant physical enhancements;
		
	Indemnified Party	  	has the meaning given in Paragraph 42.01; 
		
	Indemnifying Party	  	has the meaning given in Paragraph 42.01;
		
	Inspection	  	has the meaning given in Paragraph 21.01;

  
 7 

			
	Intellectual Property Rights	  	means all rights in respect of the following: (i) all inventions, materials, compounds, compositions, substances and other results of whatsoever nature, whether or not patentable, and whether or not applied for registration as
a patent; (ii) Know-How; (iii) all patents, including all reissues, extensions, renewals, patents of addition, substitution, re-registrations, re-examinations, as well as all patent applications, including all provisional applications, continuations, continuations-in-part and
divisionals; (iv) copyrights; (v) trademarks, and similar marks; and (vi) designs;
		
	Joint Steering Committee or JSC	  	means the committee to be established by the Parties with a view to oversee the activities to be performed by each Party pursuant to this Agreement;
		
	JSC Meeting	  	has the meaning given in Paragraph 33.01;
		
	Key-Countries	  	means [***];
		
	Know-How	  	means all technical, secret processes or formulae or other secret information concerning industrial, commercial or scientific experience, whether protected or not by patent, copyright or a related right, including know-how, information, inventions, trade secrets, knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, ideas, technical assistance, designs, drawings,
assembly procedures, specifications, data, results and other intangible materials, including pre-clinical and clinical trial results, manufacturing procedures, test procedures and purification and isolation
techniques and all tangible embodiments of any of the foregoing in written, electronic or any other form (including the oral form) or other tangible materials that are used as research or development tools, such as assays and reference
substances;
		
	License	  	has the meaning given in Clause 3.01;
		
	Losses	  	has the meaning given in Paragraph 41.01;
		
	Manufacture	  	means the manufacturing, processing, compounding, storage, filling, packaging, labelling, leafleting, testing, waste disposal, quality assurance and control, dispatch, sample retention and, to the extent permitted by Applicable Laws
and required under the applicable Technical and Quality Agreement, stability testing and release, preparation of Annual Product Quality Reviews of the Product and Manufactured and Manufacturing shall be construed
accordingly;

  
 8 

			
	Market Exclusivity Period	  	means in respect of a Product in a particular country of the Territory, the shortest period provided for in the relevant Applicable Law of such country after which a Regulatory Authority may grant a marketing authorization to a
Third Party by reference to data filed with or available to such Regulatory Authority by ARS, Recordati or any of their Affiliates or Third Party Local Distributor in respect of that Product pursuant to the Applicable Law;
		
	Marketing Authorizations	  	means collectively the EU Marketing Authorization, the Ex-EU Marketing Authorization and UK Marketing Authorization;
		
	Marketing Authorization Holder	  	means a Person to which a Marketing Authorization is issued by the competent Regulatory Authority in the Territory for the purpose of Commercializing a pharmaceutical product after evaluation for safety, efficacy and
quality;
		
	Material Breach	  	means a breach of a breaching-Party of this Agreement that it is so fundamental that it renders it unacceptable for the non-breaching Party to continue the business relationship with the
breaching-Party;
		
	Medical Device Regulation	  	means the provisions set out under the Directive 93/42/EEC and Regulation (EU) 2017/745; 
		
	MHRA	  	means the Medicines and Healthcare products Regulatory Agency in the UK and any successor agency;
		
	Minutes	  	has the meaning given in Paragraph 39.03(iii);
		
	Net Sales	  	means [***].
		
	New IP	  	has the meaning given in Paragraph 43.01;
		
	New Launching Date	  	means the day of any new 1st (first) sale of any new Strength 3 Presentation to an End-User;
		
	Non-Fit for Use Notice	  	has the meaning given in Paragraph 21.02;
		
	[***]	  	means [***], a company engaged in the field of supplying glass containers for pharmaceutical usage;
		
	Parties	  	has the meaning given in the Headings;

  
 9 

			
	Party	  	has the meaning given in the Headings;
		
	Patent(s)	  	means any and all patent documents pending or granted on the Product (and/or the Compound and/or the Excipient contained in the Product) which are Controlled by ARS as of the Effective Date or become during the Term of this
Agreement Controlled by ARS; the Patents at the Effective Date are listed in Annex 3;
		
	Paediatric Development	  	means all those activities or studies requested by the PDCO and described in the Paediatric Investigational Plan attached as Annex 4;
		
	PDCO	  	means the Paediatric Committee of the EMA or any successor committee fulfilling comparable functions;
		
	Person	  	means any individual, company, firm, partnership, joint venture, corporation, proprietorship, association, trust, governmental body, agency or institution of a government, unincorporated organization, or any other organization or
entity, private or public (including international, supranational, foreign, federal, national, state, provincial, local or otherwise);
		
	PO	  	has the meaning given in Paragraph 18.02;
		
	Presentation	  	means each stock keeping unit of each Strength as described in Annex 6. Presentations may be added or amended or updated from time to time with mutual written consent of the Parties;
		
	Product	  	means any composition or derivative or Improvement (implemented pursuant to Paragraph 5.02,) of the Compound and the Excipient delivered intra-nasally through a device that is claimed in a Patent;
		
	Product Purchase Agreement	  	has the meaning given in Paragraph 14.02(i);
		
	Raw Materials	  	means all raw materials [***], primary packaging materials and components needed for the manufacturing of the Product; 
		
	Recall	  	means with respect to the Product, a “recall”, “correction” or “market” withdrawal, whether mandatory or voluntary, as those terms are defined by Applicable Laws, as the same may be amended from time to
time, and shall include any post-sales warning or mailing of information regarding the Product;
		
	Recordati	  	has the meaning given in the Headings;

  
 10 

			
	Recordati’s Development Activities	  	means all of those clinical or non-clinical activities carried out by or on behalf of Recordati or its Affiliates or Sublicensees on the Product (i) after EU Marketing Authorization
approval and UK Marketing Authorization approval for regulatory or commercial purposes; or (ii) before and after Ex-EU Marketing Authorization approval for regulatory or commercial purposes;

		
	Recordati Livery	  	means the packaging to be used in relation to the Product in the Territory, which includes Recordati’s proprietary Trademarks, logo, get-up and branding, the design and prototypes which
are provided by Recordati to ARS from time to time and including any Trademarks and trade dress belonging or licensed to Recordati;
		
	Recordati Representatives	  	has the meaning given in Paragraph 41.01;
		
	Regulatory Approvals	  	means the grant of an Ex-EU Marketing Authorization or of the EU Marketing Authorization or of the UK Marketing Authorization, and any pricing approval, reimbursement approval, or any other
approval required to Commercialize the Product in any country or other regulatory jurisdiction of the Territory;
		
	Regulatory Authority	  	means any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity in a given country or region in the Territory with authority over the manner in
which a clinical study is conducted or which is responsible for granting and administering any marketing authorization and other governmental approvals necessary or useful to manufacture, distribute, promote, market and sell pharmaceutical products,
or for pharmacovigilance of such products;
		
	Remaining Strength 1 Studies	  	means those studies as described in Annex 5;
		
	Remaining Strength 2 Studies	  	means those studies as described in Paediatric Development;
		
	Remaining Strength 3 Studies	  	means those studies as described in Paediatric Development;
		
	[***]	  	means [***], a company engaged in the field of providing, inter alia, nasal spray and sterile manufacturing production services for pharmaceutical usage;
		
	Royalty Report	  	has the meaning given in Paragraph 29.02;
		
	Sample	  	has the meaning given in Paragraph 38.01(iv);

  
 11 

			
	Second Launching Date	  	means the day of the 1st (first) sale of Strength 2 Presentation to an End-User;
		
	SDEA	  	means the agreement to be executed by the Parties with the scope to detail the responsibilities of each Party regarding safety information exchange and each Party’s pharmacovigilance obligations and tasks for the Product to
ensure compliance with regulatory requirements, which may be modified, amended or supplemented from time to time by written agreement between the Parties;
		
	Second Cap	  	has the meaning given in Paragraph 28.04(ii);
		
	Second Source	  	means the company engaged, inter alia, in the field of manufacturing and selling of medicinal products which can be used by the Parties as an alternative Manufacturing and supplying source of the Product (including also for
the Territory) to be validated pursuant to the terms and conditions of this Agreement;
		
	Specifications	  	means the technical specifications and testing methods for the Product approved by the relevant Regulatory Authority. Specifications may be added or amended or updated, and in any case approved by the relevant Regulatory Authority,
from time to time with mutual written consent of the Parties;
		
	Strength(s)	  	means collectively the Strength 1, Strength 2 and Strength 3;
		
	Strength 1	  	means the Product in [***] form intended for [***];
		
	Strength 2	  	means the Product in [***] form (or any other dosage form) intended for [***];
		
	Strength 3	  	means the Product in any dosage form or delivery system different from Strength 1 and Strength 2 developed by ARS, intended for [***];
		
	Sublicensee	  	means those Third Parties to be appointed by Recordati, if deemed necessary by Recordati, for the Commercialization of the Product within one or more countries in the Territory;
		
	Supply Price	  	means the supply price set out in Annex 6;
		
	Tax Withholding Documents	  	means documents prepared by ARS in order for ARS to obtain benefits under applicable tax treaty or domestic provisions, including the reduction or exemption from any withholding tax and the procurement of any available tax refunds,
as described in Paragraph 32.02;

  
 12 

			
	Technical and Quality Agreement	  	means the agreement to be executed by the Parties which sets out among other things the Parties’ respective responsibilities for each step of the activities involved in the quality control of the Product and the communication
processes between the Parties with respect thereto, which may be modified, amended or supplemented from time to time by written agreement between the Parties;
		
	Technology Transfer Activity	  	means all of the activities necessary for reproducing the Manufacturing activities of the Product as described in the approved Dossier and according to the Specifications;
		
	Term	  	has the meaning given in Paragraph 44.01;
		
	Terminated Party	  	has the meaning given in Paragraph 45.01;
		
	Terminating Party	  	has the meaning given in Paragraph 45.01; 
		
	Territory	  	means collectively the EU Territory, the Ex-EU Territory and the UK;
		
	Tier 1 Royalty	  	has the meaning given in Paragraph 28.02(i);
		
	Tier 2 Royalty	  	has the meaning given in Paragraph 28.02(ii); 
		
	Tier 3 Royalty	  	has the meaning given in Paragraph 28.02(iii);
		
	Third Cap	  	has the meaning given in Paragraph 28.04(iii);
		
	Third Party	  	means a Person other than a Party or an Affiliate of a Party;
		
	Third Party Claim	  	has the meaning given in Paragraph 41.01;
		
	Trademarks	  	means with regard to a certain country of the Territory, all marks, logos, trademarks and brand names designated by a Party to Commercialize the Product within one or more countries of the Territory;
		
	UK	  	means the United Kingdom (including, for the avoidance of doubt, the Channel Islands, the Isle of Man and Gibraltar);
		
	UK Marketing Authorization	  	means any and all marketing authorizations and other similar forms of licenses and permits that are obtained by the competent Regulatory Authority in the UK as necessary for the Commercialization of the Product within the
UK.

  
 13 

	2.02	 In this Agreement: 

 

	 	(i)	 words denoting the singular include the plural and the other way round; 

 

	 	(ii)	 words denoting one gender include each gender and all genders; and 

 

	 	(iii)	 the headings are for convenience only and do not affect the interpretation of this Agreement.

  

	2.03	 In this Agreement, unless otherwise specified or the context otherwise requires, a reference to:

  

	 	(i)	 a document, instrument or agreement (including, without limitation, this Agreement) is a reference to any such
document, instrument or agreement as modified, amended, varied, supplemented or novated from time to time; 

  

	 	(ii)	 a Section, a Clause or a Paragraph or an Annex is a reference to a section, a clause, a paragraph or an annex
of this Agreement and a reference to this Agreement includes the Annexes; and 

  

	 	(iii)	 a provision of any statute or other legislation is to be construed as a reference to such provision as amended
or re-enacted or as its application is modified from time to time (whether before or after the date of this Agreement) and shall include a reference to any provision of which it is a re-enactment (whether with or without modification) and to any orders, regulations, instruments or other subordinate legislation (and relevant codes of practice) made under the relevant statute or other legislation
except to the extent that any amendment or re-enactment coming into force after the date of this Agreement would increase or extend the liability of any Party to any other Person under this Agreement.

 SECTION II – SCOPE OF THIS AGREEMENT 

 

	3.	 GRANT OF LICENSE 

 

	3.01	 On and subject to the terms and conditions set out in this Agreement, ARS hereby grants to Recordati an
exclusive (even as to ARS and to ARS’ Affiliates, except as expressly set forth herein), royalty-bearing, sublicensable (as provided in Clause 3.03) license under the Patents until expiration of the last-to-expire Patent and under the ARS Intellectual Property Rights other than Patents during the Term to (i) perform Recordati’s Development Activities on the Product for Commercialization in the
Territory, (ii) Manufacture (or have Manufactured) the Product for Commercialization in the Territory, (iii) file and hold Regulatory Approvals for the Product in the Territory, and (iv) Commercialize the Product in the Territory (the
License). 

  

	3.02	 Without prejudice to the License granted to Recordati pursuant to Clause 3.01 above, ARS shall have and
retain (a) all rights to practice, and to grant licenses under, the ARS Intellectual Property Rights outside the Territory, for any and all purposes, and (b) the right to develop and Manufacture (or have Manufactured) the Product in the
Territory: 

  

	 	(i)	 in order to exercise its rights and fulfill its obligations set out in this Agreement; and

  

	 	(ii)	 for the purpose of developing, filing for and obtaining regulatory approvals for and Commercializing the
Product outside the Territory. 

  
 14 

	3.03	 Recordati shall have the right to grant sublicenses of the rights granted under the License to
(i) any Affiliate with written notice to ARS; (ii) any Third Party in countries of the Territory outside the Key-Countries with written notice to ARS; and (iii) any Third Party in the Key-Countries with the prior written consent of ARS, [***] subject to, and consistent with, the terms and conditions of this Agreement. Recordati shall ensure that each agreement with a Sublicensee grants ARS all
rights with respect to data, results and Intellectual Property Rights made or generated by such Sublicensee as if such data, results and Intellectual Property Rights were made or generated by Recordati. Recordati shall be responsible for the
compliance of its Sublicensees with the terms and conditions of this Agreement. 

  

	3.04	 Subject to the terms and conditions of this Agreement, Recordati hereby grants to ARS, with the right of
ARS to grant to its licensees with respect to the Products outside the Territory through multiple tiers, the royalty-free, fully-paid, irrevocable, perpetual right to cross-reference Marketing Authorizations and other regulatory filings of Recordati
and its Affiliates and Sublicensees with respect to the Products in the Territory (and data included in such regulatory filings) solely for the purpose of (i) obtaining regulatory approval supporting Commercialization activities for Products
outside the Territory, and/or (ii) fulfilling its obligations set out in this Agreement. 

  

	3.05	 Subject to the terms and conditions of this Agreement, ARS hereby grants to Recordati, with the right of
Recordati to grant to its Affiliates and Sublicensees with respect to the Products within the Territory through multiple tiers, the royalty-free, fully-paid, irrevocable, perpetual right to cross-reference Marketing Authorizations and other
regulatory filings of ARS and its Affiliates and licensees with respect to the Products outside the Territory (and data included in such regulatory filings) solely for the purpose of (i) obtaining regulatory approval supporting
Commercialization activities for Products within the Territory, and/or (ii) fulfilling its obligations set out in this Agreement. 

  

	3.06	 Except as set forth in this Agreement, neither Party shall acquire any license or other intellectual
property interest, by implication or otherwise, under or to any Intellectual Property Rights owned or controlled by the other Party. Neither Party shall, nor shall it permit any of its Affiliates or sublicensees to, practice any Intellectual
Property Rights licensed to it by the other Party outside the scope of the licenses granted to it under this Agreement. 

  

	4.	 LICENSE EXCLUSIVITY PERIOD 

 

	4.01	 On the terms and conditions set out in this Agreement, starting from the Effective Date and up to the
expiration (or the termination) of this Agreement, ARS undertakes: 

  

	 	(i)	 not to grant any further licenses or rights to any Third Party (including, without limitation, its Affiliates)
which are encompassed by the License; and 

  

	 	(ii)	 not to exercise (and cause its Affiliates not to exercise) any of the rights encompassed by License, except as
expressly provided herein. 

  

	5.	 IMPROVEMENTS 

 

	5.01	 In the event that during the Term, ARS conceives an Improvement concept (each a Concept)
ARS will [***] deliver to Recordati a written proposal to commence cooperating on the Concept development activity (the Concept Development Activity) which shall include, inter alia, a complete written disclosure of the Concept.

  

	5.02	 Should Recordati be willing to cooperate with ARS on the Concept Development Activity, the Parties shall
commence good faith negotiation of a separate agreement setting out the Parties’: 

  

	 	(i)	 obligations in respect to the Concept Development Activity; and 

 

	 	(ii)	 rights in respect to the possible Improvement arising out of the Concept Development Activity.

  
 15 

	5.03	 In case Recordati does not indicate willingness to cooperate on the Concept Development Activity within
a [***] period starting from the date on which ARS delivered to Recordati the proposal set out in Paragraph 5.01 above or the Parties are unable to agree on the terms and conditions of the separate agreement described in Paragraph 5.02 above within
a [***] period starting from the date on which the ARS delivered to Recordati the proposal set out in Paragraph 5.01 above, ARS shall have the right (but not the obligation) to carry out the Concept Development Activity at its own costs and risk.

  

	5.04	 In the event that the Improvement arising out of the Concept Development Activity carried out by ARS
pursuant to Paragraph 5.03 above can be reasonably utilized in the Territory, ARS shall deliver to Recordati a written proposal to exploit the rights under such Improvement in the Territory. 

 

	5.05	 Should Recordati be willing to exploit the Improvement described ARS proposal pursuant to Paragraph 5.04
above, the Parties shall negotiate in good faith the terms and conditions according to which ARS will license to Recordati the rights to exploit such Improvement in the Territory. 

 

	5.06	 In case the Parties are unable to agree on the terms and conditions of the license agreement described
in Paragraph 5.05 above within a [***] period starting from the date on which the ARS delivered to Recordati the proposal set out in Paragraph 5.04 above, neither Party shall exploit such Improvement in the Territory. 

 

	5.07	 It is acknowledged by the Parties that any improvement, which either does not have any impact on the
Dossier or the impact on the Dossier is limited to regulatory variations which do not imply any clinical or material development, will not be considered an Improvement and the rights to such any improvement shall be included in the rights granted to
Recordati pursuant to this Agreement without any additional charge. For clarity, the following modifications to the Product cannot be considered as an Improvement: 

 

	 	(i)	 any change in the size or to the shape or to the appearance of the device, also in order to comply with the new
Medical Device Regulation, while keeping the same function as the approved device; 

  

	 	(ii)	 any change in the Manufacturing process or in the Raw Material with the scope to reduce costs or increase
efficiency of the Manufacturing process; 

  

	 	(iii)	 any change in the device with the scope to increase the compliance of the administration.

 SECTION III – DEVELOPMENT AND REGULATORY MATTERS 

 

	6.	 DEVELOPMENT OF THE PRODUCT IN
THE TERRITORY 

  

	6.01	 As of the Effective Date, to ARS’ knowledge based upon feedback ARS has received from EMA, the
studies of Strength 1 that it has completed are the only studies of Strength 1 that would be required by EMA to grant the EU Marketing Authorization for the Strength 1. 

 

	6.02	 ARS undertakes to: 

 

	 	(i)	 perform [***]: 

  

	 	(a)	 the Remaining Strength 1 Studies; 

 

	 	(b)	 the Remaining Strength 2 Studies and 

  
 16 

	 	(c)	 the Remaining Strength 3 Studies (if Strength 3 is required by EMA and provided that ARS and Recordati agree to
make Commercially Reasonable Efforts to renegotiate or modify the Paediatric Development requirements for Strength 3, in good faith, irrespective of the Party who is the Marketing Authorization Holder, with EMA or other Regulatory Authorities in the
Territory after approval of either Strength 1 or Strength 2); 

  

	 	(ii)	 use Commercially Reasonable Efforts to complete: 

 

	 	(a)	 the Remaining Strength 1 Studies by no later than the end of the [***] accordance with the timeline set out in
Annex 5; 

  

	 	(b)	 the Remaining Strength 2 Studies with a view to allowing submission of the post-approval variation to the EU
Marketing Authorization and to the UK Marketing Authorization by [***] and the related stability studies of the Strength 2 by [***] in accordance with the timeline set out in Annex 4; and 

 

	 	(c)	 the Remaining Strength 3 Studies (if Strength 3 is required by EMA) by [***] in accordance with the timeline
set out in Annex 4 or as otherwise required by EMA. 

  

	6.03	 The Parties agree that the following development activities and the related development costs shall be
borne according to the following scheme: 

  

	 	(i)	 any studies requested by the EMA to be performed before the grant of the EU Marketing Authorization for
Strength 1, Strength 2 and Strength 3, and/or by the MHRA before the grant of the UK Marketing Authorization, shall be performed by ARS at its own costs; 

  

	 	(ii)	 any post-approval studies requested by the relevant Regulatory Authority to be performed after the grant of an
EU Marketing Authorization for the Product (Strength 1, Strength 2 and Strength 3), and/or after the grant of the UK Marketing Authorization shall be performed by Recordati at its own costs (in case such studies are required also outside the
Territory, the Parties shall discuss in good faith how to split the costs of such studies); and 

  

	 	(iii)	 any studies requested by Regulatory Authorities other than the EMA and the MHRA to grant the Ex-EU Marketing Authorization or after the grant of the Ex-EU Marketing Authorization for the Product, shall be performed by Recordati at its own costs. 

 

	 	(iv)	 The Parties shall discuss in good faith the way to conduct such requested studies, provided that (a) the
Parties shall cooperate and implement risk minimization activities in order to reduce the potential impact on the business of both Parties, and (b) each Party shall have the final say on the manner to conduct the study that has to be performed
by such Party. 

  

	6.04	 For the avoidance of doubt, the results and all Intellectual Property Rights arising from:

  

	 	(i)	 the activities set out under Paragraph 6.03(i) above shall be the exclusive property of ARS and included in the
License; 

  

	 	(ii)	 the activities set out under Paragraphs 6.03(ii) and 6.03(iii) above shall be New IP subject to Paragraph 43.01
and included in the License but Recordati shall have the royalty-free, fully paid-up right (with the right to sublicense) to use such New IP for the Territory during the Term. 

  
 17 

	7.	 REGULATORY ACTIVITIES IN THE
TERRITORY 

  

	7.01	 As of the Effective Date, based upon the Feedback and the Minutes, ARS plans to submit the application
for the EU Marketing Authorization for the Strength 1 to the EMA on the legal basis of article 8(3) of the EU Directive 2001/83/EC. 

  

	7.02	 Notwithstanding the provision set out in Paragraph 7.01 above, in order to avoid any possible delays
after submission of the EU Marketing Authorization application for the Strength 1 to the EMA pursuant to the provision set out in Paragraph 7.03 and Paragraph 7.04(i) below, ARS, starting from the Effective Date, undertakes to promptly commence
also: 

  

	 	(i)	 the preparation of a Dossier and other documentation required under article 10(a) of the EU Directive
2001/83/EC; 

  

	 	(ii)	 the activities necessary in order to allow the UniDose System as described in the Dossier to be compliant to
the EU Regulation 2017/745 by [***] and promptly provide Recordati with the documentation necessary to evidence such compliance in accordance with the relevant EU guidelines as soon as available, and in any event by no later than [***].

  

	7.03	 Starting from the Effective Date, ARS and Recordati undertake to discuss in good faith the most
appropriate legal basis for the submission of the EU Marketing Authorization application for the Strength 1 to the EMA. ARS shall provide Recordati the comments of Rapporteur and of Co-Rapporteur
on the Minutes and the final minutes and, also based on such comments, Parties shall finally determine the legal basis for the application for the EU Marketing Authorization for the Strength 1 to the EMA, which may include a different type of
submission to be made in accordance with article 10(a) of the EU Directive 2001/83/EC. 

  

	7.04	 ARS undertakes to: 

 

	 	(i)	 submit the application for the EU Marketing Authorization for the Strength 1 to the EMA, using Commercially
Reasonable Efforts to do so on [***] and in any case [***], with a view to obtaining a positive validation of such submission from the EMA; provided that should EMA raises questions during validation, ARS undertakes to take any action needed to
address such questions, including promptly changing the legal basis of the submission (if needed). 

  

	 	(ii)	 submit the application for the UK Marketing Authorization for the Strength 1 to the MHRA, using Commercially
Reasonable Efforts to do so no later than [***], with a view to obtaining a positive validation of such submission from the MHRA; 

  

	 	(iii)	 include in the applications set out in points (i) and (ii) above, 2 (two) Trademarks respectively
indicated and owned by ARS and Recordati; 

  

	 	(iv)	 manage the regulatory process with an aim to obtain EU Marketing Authorization and the UK Marketing
Authorization in a timely manner; 

  

	 	(v)	 promptly – after the grant of the EU Marketing Authorization and of the UK Marketing Authorization of the
Strength 1, even at different times and upon written request by Recordati – transfer to Recordati the ownership of each such Marketing Authorizations in order for Recordati to become the Marketing Authorization Holder; 

 

	 	(vi)	 deliver to Recordati a copy of the Dossier as submitted to EMA and the MHRA pursuant to points (i) and
(ii) above and all the following documentation and/or information and/or correspondence with those Regulatory Authorities even at different times, that is useful or required for regulatory purposes in the Territory; and 

  
 18 

	 	(vii)	 promptly cooperate with Recordati in order to implement the changes, modifications and/or updates to the
Dossier requested by any Regulatory Authority of the Territories concerning the Product. 

  

	7.05	 After the completion of the activity set forth in Paragraph 7.04(v) and 7.04(vi) above, Recordati
undertakes to: 

  

	 	(i)	 use Commercially Reasonable Efforts to submit the application for the post-approval variation to the EU
Marketing Authorization and to the UK Marketing Authorization of the Strength 2 and/or Strength 3, with an aim to obtain such Regulatory Approvals in a timely manner; 

 

	 	(ii)	 use Commercially Reasonable Efforts to submit the application for the
Ex-EU Marketing Authorization for the Product on a country-by-country basis to the Regulatory Authorities in the Ex-EU Territory in the time frame as defined by Recordati taking into account the commercial impact on a country-by-country basis; and

  

	 	(iii)	 comply with all regulatory activities that are required to a Marketing Authorization Holder under Applicable
Laws. 

  

	7.06	 The Parties acknowledge that any regulatory activities pursuant to Paragraph 7.01 and 7.05 above need
the collaboration of both Parties in order to be successfully completed. As such, the Parties agree that: 

  

	 	(i)	 promptly by no later than [***] from the Effective Date, ARS shall deliver to Recordati the latest version of
the Dossier together with any other documentation and/or information in ARS’s possession and Control that is useful or required for the purpose of obtaining Regulatory Approvals in the EU Territory, or complying with all Applicable Laws, with
respect to the Product; 

  

	 	(ii)	 within [***] following receipt of the documentation set out in Paragraph 7.06(i) above, Recordati shall review
such documentation and provide comments to ARS; 

  

	 	(iii)	 promptly after the comments provided by Recordati to ARS, ARS shall review such comments and:

  

	 	(a)	 in case of agreement, ARS shall promptly implement such comments; or 

 

	 	(b)	 in case of disagreement between the Parties, the matter will be promptly addressed to the JSC; and

  

	 	(iv)	 after the submission of the application for the EU Marketing Authorization and the UK Marketing Authorization,
ARS will promptly provide Recordati with all documentation and communications with respect to the Product received from the Regulatory Authorities and with all ARS’ drafts documents with respect to the Product in response to such Regulatory
Authorities, for Recordati’s review. The provisions set out in Paragraphs 7.06(ii) to 7.06(iii) above shall apply mutatis mutandis. 

  
 19 

	8.	 REGULATORY COSTS 

 

	8.01	 [***] will bear: 

 

	 	(i)	 all of the Regulatory Authorities’ fees relating to the applications, filing, obtainment, variations and
transfer of the Marketing Authorizations in the Territory and all the costs for maintenance of such Marketing Authorizations in the Territory; and 

  

	 	(ii)	 Third Parties costs related to regulatory activities conducted by ARS upon Recordati’s written request, to
support Recordati for the applications, filing, obtainment, variations and transfer of the Marketing Authorizations in the Territory; for the avoidance of doubt, ARS acknowledges that any costs relating to Third Party appointed by ARS without the
prior written request of Recordati will be fully borne by ARS. 

  

	8.02	 [***] undertakes: 

 

	 	(i)	 in the event Recordati, Recordati’s Affiliates or a Sublicensee, following Commercialization of the
Product in the EU Territory and UK, receives from EMA and/or MHRA a mandatory requirement to modify the Dossier, [***], will make its Commercially Reasonable Efforts to support [***] to promptly submit such modification to EMA and/or MHRA (as the
case may be) in order to implement such modification, provided however that ARS undertakes to supply the Product under the current Dossier until the aforementioned modifications are implemented and approved by EMA and/or MHRA (as the case may be);

  

	 	(ii)	 in the event Recordati, Recordati’s Affiliates or a Sublicensee, following Commercialization of the
Product in the Ex-EU Territory, receives from any Regulatory Authority in the Ex-EU Territory a mandatory requirement to modify the Dossier, [***], will make its
Commercially Reasonable Efforts to support [***] to promptly submit such modification to the relevant Regulatory Authority in the Ex-EU Territory in order to implement such modification, provided however that
[***] undertakes to supply the Product under the current Dossier until the aforementioned modifications are implemented and approved by the relevant Regulatory Authority in the Ex-EU Territory; and [***] shall
reimburse all external costs incurred by [***] to conduct such modifications, provided such items and costs are discussed and agreed upon in advance between [***] and [***]; 

 

	 	(iii)	 in the event Recordati deems appropriate to implement certain modifications to the Dossier, including changes
in the design, Manufacturing or packaging, [***], at [***], will make its Commercially Reasonable Efforts to support [***], to promptly submit such modification to relevant Regulatory Authority of the Territory in order to implement such
modification; provided however that [***] undertakes to supply the Product under the current Dossier until the aforementioned modifications are implemented and approved by the relevant Regulatory Authority; 

 

	 	(iv)	 in the event ARS deems appropriate to implement certain modifications to the Dossier (including, for the
avoidance of doubt, changes of the Product suppliers listed in Clause 9 below), ARS will: 

  

	 	(a)	 promptly request in writing [***] implement such modifications [***]; 

 

	 	(b)	 [***], promptly submit all the documentation concerning such modification to the Marketing Authorization Holder
in order to allow such Marketing Authorization Holder to file such documentation with the relevant Regulatory Authority; and 

  
 20 

	 	(c)	 [***], 

provided however that ARS undertakes to supply the Product under the current Dossier until the aforementioned modifications are implemented
and approved by the relevant Regulatory Authority. 
  

	8.03	 For the avoidance of doubt, the Parties acknowledge that the changes and modifications arising out of:

  

	 	(i)	 the activities set out under Paragraph 8.01 shall be the exclusive property of Recordati and ARS shall have the
rights set forth in Paragraph 3.04 to such changes and modifications; 

  

	 	(ii)	 the activities set out under Paragraph 8.02 shall be the exclusive property of ARS and included in the License
and Recordati shall have the rights set forth in Paragraph 3.05 to such changes and modifications 

 SECTION IV –
MANUFACTURING OF THE PRODUCT 
  

	9.	 MANUFACTURING UNDERTAKINGS 

 

	9.01	 On the terms and conditions set out in this Agreement, ARS undertakes to [***]: 

 

	 	(i)	 [***] to supply – pursuant to the term of the [***] Supply Agreement – to [***] the Excipient as
described in the Dossier to be supplied in adequate quantities and adequate lead time in order to allow the Manufacture of the Product pursuant to the provisions set out in Paragraph 9.01(v) below; 

 

	 	(ii)	 [***] (or any other supplier following approval in the Dossier) to supply to [***] the glass vial as described
in the Dossier to be supplied in adequate quantities and adequate lead time in order to allow the Manufacture of the Product pursuant to the provisions set out in Paragraph 9.01(v) below and pursuant to the Applicable Laws; 

 

	 	(iii)	 [***] (or any other supplier following approval in the Dossier) to supply to [***] the [***] (or equivalent
system) as described in the Dossier to be supplied in adequate quantities and adequate lead time in order to allow the Manufacture of the Product pursuant to the provisions set out in Paragraph 9.01(v) below and pursuant to the Applicable Laws
(including, for the avoidance of doubt, the Medical Device Regulation); 

  

	 	(iv)	 [***] (or any other supplier following approval in the Dossier) to supply to [***] the Compound as described in
the Dossier to be supplied in adequate quantities and adequate lead time in order to allow the Manufacture of the Product pursuant to the provisions set out in Paragraph 9.01(v) below and pursuant to the Applicable Laws; 

 

	 	(v)	 [***] (or other contract manufacturer engaged by ARS in accordance to this Agreement) to:

  

	 	(a)	 use its Commercially Reasonable Effort to Manufacture – by no later than first Calendar Quarter [***]
– scale-up pilot batches of the Product in compliance with the Applicable Laws (including, but not limited to, all applicable cGMP standards) and prepare and deliver to Recordati the relevant
documentation to be used for the updating of the Dossier; 

  
 21 

	 	(b)	 use its Commercially Reasonable Effort to devote adequate Manufacturing capacity to be capable of Manufacturing
and supplying the Product for the Territory to Recordati in accordance with the terms and conditions of this Agreement; 

  

	 	(c)	 purchase the Raw Materials in sufficient quantities to enable the continued Manufacturing of the Product for
the Territory in accordance with the terms and conditions of this Agreement; 

  

	 	(d)	 Manufacture, supply, store and test the Product for the Territory (including disposing of all waste and other
materials) in compliance with the terms and conditions of: 

  

	 	(1)	 this Agreement; 

  

	 	(2)	 the Dossier and the Specifications; 

 

	 	(3)	 the Technical and Quality Agreement; and 

 

	 	(4)	 the Applicable Laws relating to the Manufacturing and supplying of the Product, including, but not limited to,
all applicable cGMP standards and/or guidelines and cGDP; 

  

	 	(e)	 maintain records to allow performance of a complete batch history via batch tracing of the Product for the
Territory; and 

  

	 	(f)	 keep on file for the relevant Product shelf life such Manufacturing records and analytical results pertaining
to the Manufacture of each lot of the Product for the Territory as are required under the Dossier. 

  

	10.	 LABELLING AND PACKAGING 

 

	10.01	 Starting from the Effective Date and up to the expiration or termination of this Agreement, Recordati
grants to ARS the non-exclusive, paid-up, royalty-free, transferable license to use the Recordati Livery and the Recordati’s Trademarks which ARS is requested to
use in order to perform its obligation set out in this Agreement. 

  

	10.02	 For the avoidance of doubt, ARS acknowledges that ARS will not acquire, in whatsoever manner, any rights
or interests in the Recordati Livery and/or Recordati’s Trademarks. 

  

	10.03	 ARS undertakes: 

 

	 	(i)	 not to use (or have used) the Recordati Livery and/or Recordati’s Trademarks for any purpose other than
the fulfilment of ARS’ obligations set out in this Agreement; 

  

	 	(ii)	 not to make, or cause to be made, changes, modifications and/or updates to the Recordati Livery and/or
Recordati’s Trademarks; 

  

	 	(iii)	 not to use nor register any trademarks which, in any way, might conflict with or imitate the Recordati’s
Trademarks and to refrain from acting in a way which could diminish their value; 

  

	 	(iv)	 to make it explicitly clear to its employees and to [***] (or other contract manufacturer engaged by ARS in
accordance to this Agreement) that the ownership of the Recordati Livery and/or Recordati’s Trademarks vest and belong exclusively to Recordati; and 

  
 22 

	 	(v)	 to promptly notify Recordati in writing, of any infringement, counterfeiting or passing off [***] of the
Recordati’s Trademarks of which ARS becomes aware. 

  

	10.04	 ARS undertakes to [***] (or other contract manufacturer engaged by ARS in accordance to this Agreement)
to: 

  

	 	(i)	 label and package the Product for the Territory using the Recordati Livery; 

 

	 	(ii)	 procure that serialisation and aggregation of the Product or other measures implemented pursuant to
Anti-Falsification Regulations will be carried out in accordance with the Technical and Quality Agreement, the Applicable Laws including, but not limited to, all applicable cGMP standards and/or guidelines and cGDP; and 

 

	 	(iii)	 support at its own costs and in compliance with the Anti-Falsification Regulations and the Applicable Laws, the
implementation of the serialization data exchange with Recordati. 

  

	10.05	 The Parties acknowledge that the Marketing Authorization Holder shall be responsible, at its own costs
for: 

  

	 	(i)	 the creation of the serial codes pursuant to the Anti-Falsification Regulations to be provided to [***] (or
other contract manufacturer engaged by ARS in accordance to this Agreement) during the Term; and 

  

	 	(ii)	 the uploading of master data and such serial codes into the European Hub (EMVS) or into the system foreseen by
the Anti-Falsification Regulations in force on a Territory country-by-country basis. 

 

	10.06	 ARS further undertakes to [***] (or other contract manufacturer engaged by ARS in accordance to this
Agreement): 

  

	 	(i)	 not to use any labels, packages or other materials containing the Recordati Livery for any other products; and

  

	 	(ii)	 to store the Recordati Livery and pack inventory of the same in compliance with the terms and conditions of:

  

	 	(a)	 this Agreement; 

  

	 	(b)	 the Dossier; 

  

	 	(c)	 the Technical and Quality Agreement; and 

 

	 	(d)	 the Applicable Laws relating to the storage of the Product, including, but not limited to, all applicable cGMP
standards and/or guidelines and cGDP. 

  

	11.	 QUALITY TEST OF THE PRODUCT

  

	11.01	 ARS undertakes to [***] (or other contract manufacturer engaged by ARS in accordance to this Agreement)
to: 

  

	 	(i)	 test the Compound, the Raw Material, the [***] (or equivalent system approved in the Dossier) and the Product
for the Territory according to the Dossier and the Specifications; and 

  
 23 

	 	(ii)	 perform in process and final quality controls on the Product for the Territory according to cGMP and to the
Specifications set forth in the Dossier and the Technical and Quality Agreement and shall approve the release of the Product in accordance with EU cGMP prior to shipment of the Product to Recordati by means of issuing of a CoA and a CoC.

  

	12.	 AUDIT OF PRODUCT MANUFACTURING
FACILITIES 

  

	12.01	 Upon reasonable prior notice to ARS and during regular business hours, Recordati or the entity
designated by Recordati and reasonably acceptable to ARS shall have the right [***] to audit the Product’s Manufacturing facility, including the access to the Manufacturing, packaging, warehousing and laboratory areas related to the Manufacture
of the Product for the Territory, to check the compliance with Applicable Laws, cGMP and cGDP with the provisions of this Agreement and the Technical and Quality Agreement (also for the purpose of qualifying such Manufacturing facility). This right
for Recordati and/or the entity designated by Recordati includes access to audit documents and records relating to the performance of the Manufacture of the Product for the Territory. 

 

	12.02	 ARS shall, within [***] of any written notice of any deficiencies discovered during such inspection,
respond to Recordati with a plan to remedy any deficiencies within a reasonable time which may be noted in any such audit. 

  

	12.03	 ARS will maintain all legally required and proper records relating to the Manufacture of the Product for
the Territory in accordance with industry practice and, if required in writing by Recordati, will provide Recordati with copies of such records relating to all stages of the Manufacturing and supplying of the Product for the Territory.

  

	12.04	 In addition to the above, ARS undertakes to promptly notify Recordati in writing, in accordance with the
Technical and Quality Agreement, of any inspection of the Product Manufacturing facility requested or proposed or scheduled with any governmental authority that relates to the Product or to general matters at the Product Manufacturing facility that
might affect the Product for the Territory. 

  

	12.05	 Pursuant to the provisions of Paragraph 12.04 above, ARS undertakes to ensure that any implementation
requested by any governmental authority’s audit report to the Product Manufacturing site will be [***] fulfilled [***]. 

  

	13.	 TECHNOLOGY TRANSFER 

 

	13.01	 ARS acknowledges that it is of the Parties’ best interest that a second Manufacturing and supplying
source of the Product is validated and thus ARS undertakes to use Commercially Reasonable Efforts to qualify a Second Source at its [***] discretion. 

  

	13.02	 Notwithstanding the provisions set out in the above Paragraph 13.01, Recordati may appoint a Second
Source for the Manufacturing of the Product for its Territory. In such a case, ARS undertakes to use its Commercially Reasonable Effort in assisting Recordati and the Second Source appointed by Recordati, in the completion of the Technology Transfer
Activities required to allow such Second Source to Manufacture technology transfer batches of the Product and to prepare the relevant documents for the updating of the Dossier. 

  
 24 

 SECTION V – SUPPLY OF THE PRODUCT 

 

	14.	 SUPPLIER APPOINTMENT 

 

	14.01	 On the terms and conditions set out in this Agreement, Recordati hereby appoints ARS, who accepts, as
its supplier for the Commercialization of the Product within the Territory. 

  

	14.02	 The Parties agree that, as a result of the appointment set out in Paragraph 14.01 above:

  

	 	(i)	 the Parties shall enter into purchase agreements under which ARS shall sell to Recordati and Recordati shall
purchase from ARS, the Product (each a Product Purchase Agreement); and 

  

	 	(ii)	 Recordati or its Affiliates or its Sublicensees shall Commercialize the Product to wholesalers or to or any
other user or consumer of the Product, within the Territory (the End-Users). 

  

	15.	 SUPPLY EXCLUSIVITY PERIOD 

 

	15.01	 On the terms and conditions set out in this Agreement, starting from the Effective Date and up to the
expiration (or the termination) of this Agreement, ARS undertakes to Manufacture (or have Manufactured) and supply the Product for the re-sale into the Territory exclusively to Recordati, and Recordati
undertakes to purchase all of its and its Affiliates’ and Sublicensees’ requirements of Product for the Territory from ARS. 

  

	16.	 NON-COMPETE 

 

	16.01	 Starting from the Effective Date and up to the later of (i) expiration the last Patent in effect or
(ii) expiration of the Market Exclusivity Period, both Parties mutually agree to undertake: 

  

	 	(i)	 not to develop, register, purchase and/or Commercialize in the Territory any pharmaceutical products: (a)
[***]; and (b) [***]; and 

  

	 	(ii)	 to discontinue and not initiate any discussions with any other Third Party regarding the business arrangements
contemplated hereby in the Territory. 

  

	17.	 PRODUCT PRE-LAUNCHING
PERIOD 

  

	17.01	 Without prejudice to the provision set out under Paragraph 18.01 below, the Parties agree to collaborate
with each other in order for Recordati to be able to launch the Product as soon as possible. 

  

	17.02	 No later than [***] prior to the expected First Launching Date, Recordati shall submit to ARS a PO (as
defined below) for a quantity of Product (Strength 1) which Recordati deems appropriate to fulfill Recordati’s expected requirements of the Product (Strength 1) during the launch period as well as the [***] Forecast covering the requirements of
the [***] starting from the First Launching Date in accordance with Paragraph 18.01. 

  

	17.03	 No later than [***] prior to the expected Second Launching Date, Recordati shall submit to ARS a PO for
a quantity of Product (Strength 2) which Recordati deems appropriate to fulfill Recordati’s expected requirements of the Product (Strength 2) during the launch period and shall incorporate in the then current Forecast (in accordance with
Paragraph 18.01) the requirements of Strength 2 for the [***] starting from the Second Launching Date. 

  
 25 

	17.04	 No later [***] prior to the expected New Launching Date, Recordati shall submit to ARS a PO for a
quantity of Product (Strength 3) which Recordati deems appropriate to fulfill Recordati’s expected requirements of the Product (Strength 3) during launch period and shall incorporate in the then current Forecast (in accordance with Paragraph
18.01) the requirements of Strength 3 for the first [***] starting from the New Launching Date. 

  

	17.05	 For avoidance of doubt, the above Pre-Launching Period POs shall
be on a country-by country basis, and shall be binding. 

  

	18.	 FORECAST AND ORDERS 

 

	18.01	 With the submission by Recordati of the PO set out under Paragraph 17.02, 17.03 and 17.04 above, and
every month thereafter, Recordati shall provide ARS with a written rolling forecast of Recordati’s expected requirements of Product on a country-by-country basis
during the following [***] (each, a Forecast). For clarity, the initial rolling forecast that Recordati shall provide to ARS shall cover the [***] after expected First Launching Date. 

 

	18.02	 Except for the first PO for each Strength as described under Clause 17 above, Recordati shall submit to
ARS a written binding and irrevocable proposal to purchase the Product at [***] prior to the date of delivery set out in such order (each a PO). It is agreed that any PO shall, inter alia, include: 

 

	 	(i)	 name of the Product including Presentation (per each Strength); 

 

	 	(ii)	 the quantities of the Presentation (per each Strength) required on a country by country basis;

  

	 	(iii)	 the date by which the Presentation must be delivered and any delivery instructions; 

 

	 	(iv)	 the delivery address; 

 

	 	(v)	 the indication of the relevant Recordati Livery to be used to label and package the Presentation (per each
Strength); and 

  

	 	(vi)	 the Aggregate Supply Price. 

 

	18.03	 The Parties acknowledge and agree that notwithstanding anything to the contrary: 

 

	 	(i)	 the Forecast shall not be binding upon Recordati or ARS and shall be used for planning purposes only; however,
the first [***] of Product forecasted in each Forecast delivered to ARS following the First Launching Date shall be binding upon ARS and Recordati unless otherwise agreed in writing by both Parties. In addition, starting from the first anniversary
of the First Launching Date, if the PO related to the [***] of Product forecasted in each Forecast is lower by more [***] from the [***] of Product forecasted in the previous Forecast, Recordati shall be responsible for cost of the excess Product if
ARS cannot sell such excess Product outside the Territory; 

  

	 	(ii)	 each PO shall automatically be deemed binding if not rejected in writing by ARS within [***] following the
issuance thereof and ARS shall not have the right to reject POs which comply with the provisions set out in this Agreement; and 

  

	 	(iii)	 the Parties shall use their Commercially Reasonable Efforts in order to supply Product and to quickly react to
the market demand of Products (or change thereof). However, ARS shall not be obligated to Manufacture or supply Recordati with Product in excess of [***] of the most recent [***] estimate of such Product provided to ARS in a Forecast.

  
 26 

	19.	 PRODUCT PURCHASE AGREEMENT 

 

	19.01	 Recordati and ARS, shall be deemed to have entered into a Product Purchase Agreement upon the acceptance
(or deemed acceptance) by ARS of the relevant PO. 

  

	19.02	 Each Product Purchase Agreement shall be governed by: 

 

	 	(i)	 the terms and conditions of the relevant accepted (or deemed accepted) PO; 

 

	 	(ii)	 the terms and conditions of this Agreement; 

 

	 	(iii)	 the terms and conditions of the Technical and Quality Agreement; 

 

	 	(iv)	 Applicable Laws; and 

 

	 	(v)	 the governing laws of specified in Section XVII. 

 

	19.03	 In case of conflict or ambiguity between the provisions of the Product Purchase Agreement(s) and/or the
provisions of this Agreement and/or the provisions of the Technical and Quality Agreement: 

  

	 	(i)	 this Agreement shall prevail – unless it is expressly set out that a deviation from this Agreement has
been agreed upon in the relevant PO – on all matters other than those matters strictly concerning the quality of the Product; and 

  

	 	(ii)	 the Technical and Quality Agreement shall prevail on all matters strictly concerning the quality of the
Product. 

  

	20.	 DELIVERY 

 

	20.01	 Unless otherwise agreed upon in the relevant Product Purchase Agreement, the delivery of the Product
provided under each Product Purchase Agreement will be [***] contract manufacturer facility. 

  

	20.02	 ARS shall be responsible, at its own costs and expenses, to apply for any prescribed permissions and to
obtain documentation for the exportation and importation of the Product, if any. 

  

	20.03	 ARS shall have the option to ship Product to Recordati up to [***] prior to date of delivery set out in
each PO if [***] (or other contract manufacturer engaged by ARS in accordance to this Agreement) Manufactures and delivers Product up to [***] earlier. 

  

	20.04	 For avoidance of doubt, ARS shall not accept any returns from Recordati except: 

 

	 	(i)	 as pursuant to receipt of the Non-Fit for Use Notice per Clause 21
below; or 

  

	 	(ii)	 for Products which have a minimum shelf life lower of [***] of the Product shelf life pursuant to the
Specifications. 

  

	21.	 QUALITY INSPECTION OF THE PRODUCT
AND CLAIMS 

  

	21.01	 ARS acknowledges that Recordati may, at its own expenses, inspect and test each and any shipment of
Product delivered by ARS pursuant to this Agreement in order to determine whether such Product is compliant with the Specifications (the Inspection). 

  
 27 

	21.02	 Any claim of Recordati on defects of the Product shall be made in writing and shall report the results
of the relevant Inspection (the Non-Fit for Use Notice). 

  

	21.03	 The Non-Fit for Use Notice will be sent to ARS within:

  

	 	(i)	 in case of patent defects (e.g. damages to the packaging of the Presentation), [***] from the discovery of such
defects; 

  

	 	(ii)	 in case of non-compliance of the Product with the Specifications, the
earlier of: (a) [***] from the discovery of such defects; or (b) the elapsing of the relevant expiry date of such Product; or 

  

	 	(iii)	 in case of latent defects which are not detectable by means of the Inspection, the earlier of: (a) [***] from
the discovery of such defects; or (b) the elapsing of the relevant expiry date of such Product. 

  

	21.04	 Within [***] from receipt of the Non-Fit for Use Notice, ARS
shall carry out the necessary investigation to assess whether to accept the findings of the relevant Inspection (the Counter Inspection). 

  

	21.05	 In the event the results of the Counter Inspection: 

 

	 	(i)	 confirm the results of the relevant Inspection ARS shall, [***]: 

 

	 	(a)	 replace the defective Product with shipping expenses at ARS’ charge; or 

 

	 	(b)	 reimburse the Aggregate Supply Price to Recordati; 

 

	 	(ii)	 do not confirm the results of the relevant Inspection and the Parties do not reach – within a reasonable
period of time following receipt of the Non-Fit for Use Notice – an agreement on the conformity of the Product to the Specifications, then the Parties, shall submit, together with representative samples
of the relevant batch of the Product, to the judgment of an independent neutral external Third Party laboratory to be mutually agreed between the Parties, acting reasonably. The outcome of the test shall be binding to the Parties and the Party who
has been decided against will pay all expenses charged by the aforementioned independent neutral external Third Party laboratory. In case the aforementioned outcome of the test shall confirm the results of the Inspection, Paragraph 21.05(i) shall
apply mutatis mutandis. 

  

	21.06	 It is however understood that in any event of alleged defectiveness of the Product either accepted or
not by ARS, the Parties shall use their Commercially Reasonable Efforts to co-operate in such a way to avoid the risk of out of stock for Recordati and to put ARS in the effective position to replace the
disputed Product. 

  

	21.07	 For the avoidance of doubt, it is agreed that the provision of Paragraph 21.02 above, shall apply also
in case of supervening defects, in so far they are not attributable to the Recordati’s behavior or misuse of the Product. 

  

	22.	 INABILITY TO SUPPLY 

 

	22.01	 In the event that ARS cannot, or becomes aware that it will be unable to fulfil its Manufacturing and
supply obligations set out in this Agreement for any reason – ARS undertakes to [***] notify Recordati in writing of such inability to Manufacture and supply the Product, stating the reasons thereof. 

  
 28 

	22.02	 Following receipt of the notice set out in Paragraph 22.01 above and during the persisting of ARS’
inability to Manufacture and supply the Product to Recordati ARS shall allocate the available Product and existing stock of Product available to ARS (or its Affiliates) proportionally among ARS, Recordati and ARS’ licensees outside the
Territory based upon the last [***] respective Commercialization in Presentation before the aforementioned inability to Manufacture and supply occurred. 

  

	22.03	 Without prejudice to the provisions set out in Paragraph 22.02, if so requested by Recordati, ARS
undertakes to use its Commercially Reasonable Efforts to fulfil its obligations set out in Clause 13 above. 

 SECTION
VI – CONDITION PRECEDENT 
  

	23.	 CONDITION PRECEDENT 

 

	23.01	 Recordati’s undertaking set out under Section III, Section VII, Section IX, Clause 17 and Clause 18
of this Agreement, shall be conditional on the execution between ARS and [***] of a long term Manufacturing and supply agreement for the Product (the Conditions Precedent). 

 

	23.02	 ARS acknowledges that the agreement set out under Paragraph 23.01 above shall not contain provisions
conflicting with ARS undertakings set out in this Agreement. 

  

	23.03	 ARS will promptly notify in writing Recordati upon becoming aware that the Condition Precedent has been
satisfied transmitting complete executed copy of the relevant agreement set out under Paragraph 23.01 above. 

 SECTION
VII – PAYMENTS 
  

	24.	 UPFRONT PAYMENT 

 

	24.01	 Recordati – as partial consideration for the License – undertakes to pay to ARS a one-time, non-refundable upfront payment equal to Euro 10,000,000 (ten million) upon execution of this Agreement, with payment terms at [***] from the date of receipt of the
relevant invoice by ARS. 

  

	25.	 REGULATORY MILESTONES 

 

	25.01	 Following ARS written notice indicating that each of the below regulatory milestones has been achieved,
Recordati – as partial consideration for the License – undertakes pay to ARS the following amounts: 

  

	 	(i)	 [***] once the [***]; 

 

	 	(ii)	 [***]; 

  

	 	(iii)	 [***]. 

  

	25.02	 In accordance with the provision set out in Paragraph 25.01 above, ARS shall issue the invoice for the
payment of each relevant regulatory milestone once due with payment terms at [***] from the date of receipt of the relevant invoice. 

  

	26.	 LAUNCH MILESTONE 

 

	26.01	 Recordati – as partial consideration for the License – undertakes to provide written notice
and to pay to ARS the following amounts upon achievement of the below launch milestones: 

  
 29 

	 	(i)	 Euro [***]; 

  

	 	(ii)	 Euro [***]; 

  

	 	(iii)	 Euro [***]; 

  

	 	(iv)	 Euro [***]; 

  

	 	(v)	 Euro [***]. 

  

	26.02	 In accordance with the provision set out in Paragraph 26.01 above, ARS shall issue the invoice for the
payment of each relevant launch milestone once due with payment terms at [***] from the date of receipt of the relevant invoice. 

  

	27.	 SALES MILESTONES 

 

	27.01	 Recordati – as final consideration for the License – undertakes to pay to ARS the following
amounts upon achievement of the below sales milestones: 

  

	 	(i)	 Euro [***] when Annual Net Sales first reach Euro [***]; 

 

	 	(ii)	 Euro [***] when Annual Net Sales first reach Euro [***]; 

 

	 	(iii)	 Euro [***] when Annual Net Sales first reach Euro [***]; 

 

	 	(iv)	 Euro [***] when Annual Net Sales first reach Euro [***]; 

 

	 	(v)	 Euro [***] when Annual Net Sales first reach Euro [***]. 

 

	27.02	 In accordance with the provision set out in Paragraph 27.01 above, ARS shall issue the invoice for the
payment of each relevant sales milestone once due with payment terms at [***] from the date of receipt of the relevant invoice. 

  

	27.03	 For the avoidance of doubt, the Parties acknowledge that each of the sales milestones payment would be
made only once. The sales milestones shall be additive, so that if multiple sales milestone events set out in Paragraph 27.01 above are achieved in the same Calendar Year, then the milestone payments for all such sales milestone events set out in
Paragraph 27.01 above that are achieved shall become payable. 

  

	28.	 SUPPLY PRICE AND ROYALTY

  

	28.01	 ARS shall supply the Product to Recordati at the relevant Supply Price set out in Annex 6.

  

	28.02	 Recordati shall pay to ARS tiered royalties quarterly on the Net Sales as follows:

  

	 	(i)	 [***] on the portion of Net Sales equal or below Euro [***] of Annual Net Sales (the Tier 1
Royalty); 

  

	 	(ii)	 [***] on the portion of Net Sales above Euro [***] up to Euro [***] (the Tier 2 Royalty) of
Annual Net Sales; 

  

	 	(iii)	 [***] on the portion of Net Sales above Euro [***] (the Tier 3 Royalty) of Annual Net Sales.

  

	28.03	 Without prejudice to the provision set out in Paragraph 45.04 below, the Parties agree that – on a
[***] – the total consideration to be paid by Recordati to ARS for all the Presentations cannot be higher than the Annual Cap. 

  
 30 

	28.04	 The Parties acknowledge that on a Calendar Year basis: 

 

	 	(i)	 If the sum of (a) the Tier 1 Royalty (after adjustment pursuant to Paragraph 28.05) plus (b) the
Aggregate Supply Price for the Products sold that generated the Net Sales upon which the Tier 1 Royalty is calculated would exceed [***] of Annual Net Sales equal or below Euro [***] (the First Cap), then the Tier 1 Royalty for such
Calendar Year shall be reduced as necessary so that such sum equals the First Cap; 

  

	 	(ii)	 If the sum of (a) the Tier 2 Royalty (after adjustment pursuant to Paragraph 28.05) plus (b) the
Aggregate Supply Price for the Products sold that generated the Net Sales upon which the Tier 2 Royalty is calculated would exceed [***] of Annual Net Sales above Euro [***] up to Euro [***] (the Second Cap), then the Tier 2 Royalty
for such Calendar Year shall be reduced as necessary so that such sum equals the Second Cap; 

  

	 	(iii)	 If the sum of (a) the Tier 3 Royalty (after adjustment pursuant to Paragraph 28.05) plus (b) the
Aggregate Supply Price for the Products sold that generated the Net Sales upon which the Tier 3 Royalty is calculated would exceed [***] of Annual Net Sales above Euro [***] (the Third Cap), then the Tier 3 Royalty for such Calendar
Year shall be reduced as necessary so that such sum equals the Third Cap. 

  

	28.05	 The Parties acknowledge that, on a
country-by-country basis, the Tier 1 Royalty, Tier 2 Royalty and Tier 3 Royalty shall be reduced by [***], should (and as long as) Competing Products collectively
account for [***] or more of the in-market sales for the same indication for which the Products are marketed in such country on a [***] basis according to [***] data, either in unit or in volume, in a given
country in the Territory; it being understood that in the event that the Competing Products no longer collectively accounts for [***] or more of all sales across all indications for which the Products are marketed in such country, then the reduction
set out in this Paragraph 28.05 shall no longer apply. 

  

	28.06	 In the event that the level of competition, patent protection or general commercial environment for the
Product, on a country-by-country basis, materially affects the commercial viability of the Product in a country at the royalty rate applicable under Paragraph 28.05
above as shown in a written analysis provided by Recordati to ARS, the Parties shall negotiate in good faith an appropriate reduction to such royalty rates. 

  

	28.07	 For the avoidance of doubt, ARS acknowledges that ARS will be responsible for any royalty payment due by
ARS to Third Parties for the rights on the Product granted to ARS by such Third Parties (including [***]). 

  

	29.	 REPORT 

 

	29.01	 Within [***] after the end of each [***] following the First Launching Date, Recordati shall furnish to
ARS its estimates of gross sales in the Key-Countries [***]. 

  

	29.02	 Within [***] after the end of each [***] following the First Launching Date, Recordati shall furnish to
ARS a written report (the Royalty Report) showing in reasonably specifics detail, on a country-by-country and Presentation-by-Presentation basis, (example of which is attached hereto as Annex 7): 

 

	 	(i)	 the gross sales of the Product during such [***] and the calculation of the Net Sales from such gross sales
during such [***]; 

  

	 	(ii)	 based upon such Net Sales and pursuant to the provisions set out in Paragraphs 28.02, 28.03, 28.04, 28.05 and
28.06 above and on the data included in the ARS Report, the calculation of the royalty applicable during the relevant [***] (for any foreign currency conversion to Euro required for the calculation of the relevant royalty, such conversion shall be
made at the average of such [***] rates normally recorded and used by Recordati); 

  
 31 

	 	(iii)	 the withholding taxes, if any, required by the Applicable Laws to be deducted with respect to such Net Sales;

  

	 	(iv)	 the exchange rates, if any, used to determining the amount of local currency transformed in Euro; and

  

	 	(v)	 any further adjustment to the calculation of royalties in compliance with this Agreement as required to correct
any mistake from previous calculations (including final calculation of the aggregate royalties due in each [***] under this Agreement which shall be adjusted using the average [***] foreign currency conversion to Euro rates normally recorded and
used by Recordati for consolidation purposes). 

  

	30.	 PAYMENT METHOD 

 

	30.01	 ARS shall issue: 

 

	 	(i)	 the invoice for the payment of the Aggregate Supply Price due to ARS under the relevant Product Purchase
Agreement, upon shipment; and 

  

	 	(ii)	 the invoice for the payment of the royalty set out in the Royalty Report, upon receipt of the Royalty Report.

  

	30.02	 Recordati shall pay: 

 

	 	(i)	 the Aggregate Supply Price, within [***] from the date of receipt of the relevant invoice by ARS; and

  

	 	(ii)	 the royalty set out in the Royalty Report, within [***] from the date on which the relevant invoice has been
received by Recordati. 

  

	30.03	 All payments owed under this Agreement shall be paid in Euro in immediately available funds and shall be
made by wire transfer to a United States of America or EU bank account held in the name of ARS (details of which will be set out in the relevant invoice).Recordati shall, upon ARS’ request, provide all reasonable details of currency conversion
applied for calculation of the royalties due pursuant to Paragraph 29.02(ii) and 29.02(v) above. 

  

	31.	 ACCOUNTING AUDIT 

 

	31.01	 Upon the written request of a Party and no more than once in each [***], the other Party shall permit
and independent certified public accounting firm of nationally recognized standing, selected by the requesting Party and reasonably acceptable to other Party, at the requesting Party’s expenses, to have access during normal business hours to
such of the records of the other Party as may be reasonably necessary to verify the accuracy of the Royalty Reports for any year ending not more than [***] prior to the date of such request. The accounting firm shall be required to sign a
confidentiality agreement for the benefit of, and in a form reasonably acceptable to, the other Party, and shall disclose to ARS and Recordati only whether the Royalty Reports are correct or not and the specific details concerning any discrepancies.
No other information shall be shared. 

  
 32 

	31.02	 If such accounting firm concludes that: 

 

	 	(i)	 additional payments were owed during the audited period by Recordati to ARS, Recordati shall pay such
additional amounts within [***] after the date ARS delivers to Recordati (a) such accounting firm’s written report so concluding; and (b) the relevant invoice; 

 

	 	(ii)	 Recordati has made overpayments during the audited period, ARS shall refund to Recordati the amount overpaid
within [***] after the date Recordati delivers to ARS (a) such accounting firm’s written report so concluding, and (b) the relevant invoice. 

  

	31.03	 The fees charged by the accounting firm shall be paid by requesting Party, except in the case of an
audit by ARS of Recordati’s records, such audit discloses an underpayment by Recordati of more than [***] of the amount of payments due to ARS under this Agreement for any applicable [***], in which case, Recordati shall bear the cost of such
audit. 

  

	31.04	 The Parties shall treat all financial information subject to review pursuant to this Clause 31, as
confidential information pursuant to the provision of Clause 47 below and shall cause the accounting firm to retain all such information in confidence. 

  

	32.	 TAXES AND DUTIES 

 

	32.01	 The Parties acknowledge and agree that it is their mutual objective and intent to minimize, to the
extent feasible and in compliance with Applicable Laws, taxes payable with respect to their arrangement under this Agreement and that they shall use Commercially Reasonable Efforts to cooperate and coordinate with each other to achieve such
objective and intent. As such, if (i) Recordati is required to make a payment to ARS that is subject to a deduction or withholding of tax, and (ii) such withholding or deduction obligation arises as a result of an assignment of this
Agreement by Recordati pursuant to Clause 54 below, then the sum payable by Recordati (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that ARS receives a sum equal to
the sum that it would have received had no such assignment occurred. Notwithstanding the foregoing or anything herein to the contrary in this Agreement, if Recordati does not assign this Agreement pursuant to Clause 54 below, Recordati shall not
have to increase any sum payable to ARS in respect to any deduction or withholding of tax which Recordati may become required to make on payments due to ARS under this Agreement following the Effective Date. The Parties shall cooperate to help ARS
obtain benefits under any applicable tax treaty or domestic provisions, including the reduction or exemption from any withholding tax and the procurement of any available tax refunds. 

 

	32.02	 If Recordati is required to withhold any tax from any payment made to ARS under this Agreement pursuant
to the Applicable Laws, before making any such tax deduction or withholding, Recordati shall use Commercially Reasonable Efforts to provide ARS with 5 (five) days advance written notice of the intention to make such deduction or withholding, and
shall use Commercially Reasonable Efforts to cooperate with any reasonable request from ARS to obtain reduction of or relief from such deduction or withholding. In case the Tax Withholding Documents are not available to Recordati at the due date of
such payments to ARS or the Tax Withholding Documents provided by ARS to Recordati do not call for a complete exemption on withholding taxes, Recordati will (i) deduct applicable withholding taxes from the payment made to ARS, (ii) timely
pay such taxes to the proper taxing authority, (iii) send proof of such withholding tax payment to ARS and certify its receipt by the taxing authority within [***] following such payment and (iv) to the extent that amounts are so deducted
or withheld, and duly paid to the appropriate governmental authority in accordance with Applicable Law, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to ARS. Recordati shall use Commercially Reasonable
Efforts to assist ARS in filing for the refund, if any, of any withholding taxes paid within [***] following the receipt of the Tax Withholding Documents from ARS. Any such refund filing shall request that the amount of the refund be wired
directly to an ARS authorized bank account. 

  
 33 

 SECTION VIII – FURTHER OBLIGATION OF THE PARTIES 

 

	33.	 GOVERNANCE AND REPORTING 

 

	33.01	 Pursuant to this Agreement, a Joint Steering Committee meeting to be held either by conference call or
by physical meeting – at date, time, and location (if applicable) agreed by the Parties – shall be convened by either Party at least [***] for the first [***] after the First Launching Date and at least [***] thereafter (the JSC
Meeting). 

  

	33.02	 The JSC shall be comprised of at least [***]. A Party may change any one or more of its JSC
representatives at any time upon written notice to the other Party. The representatives of the JSC will mutually agree on the schedule for JSC Meetings. 

  

	33.03	 Each Party shall use reasonable efforts to cause its representatives to attend the meetings of the JSC.
If a Party’s representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting in place of the absent representative. 

 

	33.04	 The JSC will: 

 

	 	(i)	 coordinate the activities of the Parties under this Agreement, and provide a forum for and facilitate
communications between the Parties under this Agreement; 

  

	 	(ii)	 discuss and determine a strategy for the development of the Product in the Territory, including, without
limitation, discussion of the status of the Paediatric Development and/or any other clinical or non-clinical studies relating to the Product in the Territory; 

 

	 	(iii)	 discuss Manufacturing and product supply relating to the Product in the Territory; 

 

	 	(iv)	 monitor the progress of the regulatory procedures relating to the Product in the Territory including, without
limitation, reviewing and coordinating strategy for regulatory filings for the Product in the Territory, and facilitate exchange of regulatory data for the Product; 

 

	 	(v)	 inform the Parties on the Commercialization of the Product; 

 

	 	(vi)	 discuss scientific publication and congresses strategies and plans related to the Product;

  

	 	(vii)	 evaluate in good faith each Parties comments to the other Parties’ regulatory strategy with a view to
avoiding possible negative impacts on the regulatory strategy outside and inside of the Territory; and 

  

	 	(viii)	 discuss any other matters that that both Parties mutually intend to discuss. 

 

	33.05	 Records of all significant decisions of the JSC will be reflected in written minutes of the JSC Meetings
that shall be prepared by ARS and circulated to all JSC representatives (who took part to the relevant meeting) for review and comment before being signed by all of the JSC Meeting representatives and filed as final records of the JSC Meeting.

  
 34 

	33.06	 All decisions of the JSC shall be made by [***], with each Party’s representatives collectively
having one vote. If after reasonable discussion and good faith consideration of each Party’s view on a particular matter before the JSC, the representatives of the Parties cannot reach an agreement as to such matter within [***] after such
matter was referred to the JSC, such disagreement shall be referred to the Chief Executive Officer of ARS and the Chief Executive Officer of Recordati (or the Senior Executive of Recordati appointed for the purpose) for resolution as follows:

  

	 	(i)	 if such matter relates [***], the Chief Executive Officer of [***] shall be entitled to make the final decision
regarding such matter; provided that such decision shall be consistent with the terms and conditions of this Agreement; 

  

	 	(ii)	 if such matter relates to the [***], the Chief Executive Officer of [***] shall be entitled to make the final
decision regarding such matter; provided that such decision shall be consistent with the terms and conditions of this Agreement; and 

  

	 	(iii)	 the JSC shall have only such powers as are expressly assigned to it in this Agreement, such powers shall be
subject to the terms and conditions of this Agreement, and the JSC shall not have the power to amend or modify this Agreement. 

  

	34.	 PHARMACOVIGILANCE AND RECALL 

 

	34.01	 Following the Effective Date, the Parties shall enter into good faith negotiation for the implementation
of a SDEA. The Parties’ respective rights, obligations and responsibilities relating to pharmacovigilance, safety data exchange and reporting shall be handled in accordance with the provisions of such SDEA to be entered into between the Parties
within [***] from the Effective Date, being understood that from the Effective Date, ARS shall forward to Recordati any received or known safety information along with the relevant English translation within [***]. Once executed and effective
between both Parties, the SDEA, shall be deemed to be an ancillary agreement to this Agreement, shall be governed exclusively by its own terms and conditions and shall be deemed to be several and independent from this Agreement. In the event of a
conflict between any of the provisions of the SDEA and this Agreement, the latter shall prevail and apply, except if the conflict is with a provision having as object pharmacovigilance or safety data exchange or reporting matters to which the
provision of the SDEA shall always prevail and apply. 

  

	34.02	 In any event of request of Recall of the Product, the Parties shall comply with the Recall procedure set
out in the Technical and Quality Agreement. 

  

	34.03	 If the Recall is found to be the fault of: 

 

	 	(i)	 ARS (in case of disagreement between the Parties, the matter shall be referred to the external laboratory
pursuant to the terms set out in Paragraph 21.05(ii) above), ARS shall bear any costs and expenses reasonably incurred by either Party in connection with the Recall, without prejudice to other Recordati’s rights under this Agreement and under
the Applicable Laws; or 

  

	 	(ii)	 Recordati (in case of disagreement between the Parties, the matter shall be referred to the external laboratory
pursuant to the terms set out in Paragraph 21.05(ii) above), Recordati shall bear all costs and expenses reasonably incurred by either Party in connection with the Recall, without prejudice to other ARS’ rights under this agreement and under
the Applicable Laws. 

  
 35 

 SECTION IX – FURTHER OBLIGATIONS OF RECORDATI 

 

	35.	 SELLING PRICE REIMBURSEMENT 

 

	35.01	 Recordati shall use Commercially Reasonable Efforts to obtain price and reimbursement approval for the
Product in the Territory. 

  

	35.02	 In case any further studies are required for pricing and reimbursement purposes in the Territory,
Recordati shall bear all costs of such studies. 

  

	35.03	 The price and reimbursement approval proposed by the Regulatory Authorities shall be considered finally
obtained by Recordati only once such price and reimbursement approval is considered adequate according to Recordati’s sole judgement. 

  

	36.	 MARKETING OF THE PRODUCT

  

	36.01	 ARS acknowledges that Recordati shall be free to Commercialize the Product under either the ARS
Trademarks or the Recordati Trademarks. 

  

	36.02	 Recordati shall use Commercially Reasonable Efforts to: 

 

	 	(i)	 act with a view to maximizing the sales of the Product within the Territory; 

 

	 	(ii)	 keep ARS informed of any material changes in the Applicable Laws relating to the marketing activity of the
Product to End-Users; and 

  

	 	(iii)	 refrain to market and/or sell the Product within territories other than the Territory. 

 

	 	(iv)	 No later than the date of approval of the Marketing Authorization, to prepare a preliminary non-binding Commercialization plan for the marketing, promotion and pricing of Products during the first [***] after expected First Launching Date in the Territory, which plan shall be reasonable in scope and
detail. Such plan will be updated on a yearly basis, and Recordati shall provide updates to ARS regarding Commercialization activities. 

  

	36.03	 Subject to Applicable Laws, (i) neither Recordati nor its Affiliates or Sublicensees will engage in
any advertising or promotional activities relating to the Product directed primarily to customers or other buyers or users of the Product located outside of the Territory or accept orders for the Product from or sell the Product into any country or
jurisdiction outside the Territory for its own account, and, if Recordati receives any order for the Product for any country or jurisdiction outside the Territory, it shall refer such orders to ARS, and (ii) neither ARS or its Affiliates or
licensees outside the Territory will engage in any advertising or promotional activities relating to the Product directed primarily to customers or other buyers or users of the Product located in the Territory or accept orders for the Product from
or sell the Product into the Territory for its own account, and, if ARS receives any order for the Product for the Territory, it shall refer such orders to Recordati. Each Party will use reasonable efforts to monitor and prevent exports of the
Product from its own territory (the Territory as to Recordati, or outside the Territory as to ARS) for Commercialization in the other Party’s territory using methods permitted under Applicable Laws that are commonly used in the industry for
such purpose (if any). 

  

	37.	 PRODUCT STORAGE 

 

	37.01	 Following delivering of the Product pursuant to Clause 20 above, Recordati undertakes to store (or have
stored) the Product in a suitable and duly authorized warehouse located in the Territory, properly rotated and under proper storage and security conditions complying with the Specifications and in accordance with the terms and conditions set out in
the Technical and Quality Agreement and with the Applicable Laws. 

  
 36 

	37.02	 Recordati shall maintain adequate stocks of the Product, consistent with the Forecast using [***] method
of usage. 

 SECTION X – FURTHER OBLIGATIONS OF ARS 

 

	38.	 UNDERTAKINGS OF ARS 

 

	38.01	 On the terms and conditions set out in this Agreement, ARS undertakes to: 

 

	 	(i)	 provide Recordati with any necessary and available information and documents relating to the Product in
ARS’ possession and Control to allow Recordati to perform its activities in accordance with this Agreement; 

  

	 	(ii)	 update Recordati with all of the relevant scientific, development, Manufacturing, quality and regulatory
information on the Product which may become available to ARS; 

  

	 	(iii)	 furnish to Recordati the documentation listed in the Technical and Quality Agreement to be provided by ARS;

  

	 	(iv)	 retain a sample of each batch of sold and delivered Product (the Sample), in accordance with
Applicable Laws, the whole as per the Technical and Quality Agreement; 

  

	 	(v)	 make, upon written request of Recordati, the Sample available to Recordati for inspection; it being understood
that the retained sample shall be sufficient in size to allow the independent laboratory set out in Paragraph 21.05(ii) below to perform the complete sets of analysis (as described in the Technical and Quality Agreement) to determine whether the
Product meets the Specifications; 

  

	 	(vi)	 keep on file for the time period set out in the Technical and Quality Agreement the manufacturing records and
analytical results pertaining to the Manufacture of each batch of the Product as are required under the Dossier; it being understood that ARS shall make such records available to Recordati (or the Third Party designated by Recordati) for review upon
at least [***], and during normal business hours, not more than [***] 

  

	 	(vii)	 [***] 

SECTION XI – REPRESENTATION AND WARRANTIES 
  

	39.	 REPRESENTATION AND WARRANTIES 

 

	39.01	 Each Party gives the following representations and warranties to the other Party: 

 

	 	(i)	 It is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and
it has the requisite power and authority to enter into and perform this Agreement; 

  

	 	(ii)	 it has obtained all corporate authorizations required to empower it to enter into and perform its obligations
under this Agreement, and all governmental statutory, regulatory or other consents, licenses, authorizations, waivers or exemptions required to empower it to enter into this Agreement have been obtained; 

  
 37 

	 	(iii)	 the entry into and performance of this Agreement does not constitute (a) a breach of any provision of its
constitutional documents under the laws or regulations in its jurisdiction of incorporation; (b) a breach of any of the Applicable Laws; or (c) a breach of an agreement binding upon it or upon any of its assets; 

 

	 	(iv)	 it is not insolvent or bankrupt under the laws of its jurisdiction of incorporation; 

 

	 	(v)	 there are no proceedings in relation to any winding up, bankruptcy or insolvency proceedings concerning it; and

  

	 	(vi)	 this Agreement will, when executed, constitute valid and binding obligations of it, enforceable in accordance
with its terms. 

  

	39.02	 Recordati gives the following representations and warranties to ARS: 

 

	 	(i)	 it (directly or through its Affiliates or through the Sublicensees) possesses the necessary governmental
licenses, facilities and services to import, market, distribute and sell the Product in the Territory and otherwise perform its obligations under this Agreement, as is appropriate and lawful in the Territory, and neither it nor any of its Affiliates
or, to its knowledge, Sublicensees are, or have been, debarred or disqualified by any Regulatory Authority; 

  

	 	(ii)	 to the best of its knowledge, the sales of the Product within the Territory do not constitute a breach of the
Applicable Laws; 

  

	 	(iii)	 it (directly or through its Affiliate or through the Sublicensees) has the requisite expertise, ability,
capacity, skills and know-how, including all the qualified and experienced workforce to perform its obligations under this Agreement; 

 

	 	(iv)	 there are no legal claims, judgments or settlements against or owed by Recordati or its Affiliates, or pending
or, to Recordati’s or its Affiliates’ knowledge, threatened, legal claims or litigation, in each case, relating to antitrust, anti-competition, anti-bribery or corruption violations; 

 

	 	(v)	 it will comply with all Applicable Laws and the terms of this Agreement in its performance of its obligations
hereunder; 

  

	 	(vi)	 the Product will be handled in compliance with all Applicable Laws, including but not limited to, cGMP
standards and/or guidelines and cGDP; 

  

	 	(vii)	 the Product will be stored and shipped in compliance with the provision set out Clause 37, all Applicable Laws,
including but not limited to, cGMP standards and/or guidelines and cGDP; and 

  

	 	(viii)	 in making its decision to enter into this Agreement and to consummate the transactions contemplated hereby,
relied on its own independent investigation, analysis and evaluation and on the representation and warranties of ARS. 

  

	39.03	 ARS gives the following representations and warranties to Recordati: 

 

	 	(i)	 ARS has made available to Recordati all material information related to ARS Intellectual Property Rights and
Products in ARS’ possession or Control, and such information, and all such information provided as of the Effective Date are true, correct and complete in all material respects; 

 

	 	(ii)	 as of the Effective Date, it has completed the studies of Strength 1 required by EMA to grant the EU Marketing
Authorization for the Strength 1; 

  
 38 

	 	(iii)	 based upon feedback (the Feedback) ARS has received from the Rapporteur and the Co-Rapporteur in the context of the EU Marketing Authorization application pre-submission meeting held on 10 September 2020 (as reflected in the draft minutes
prepared by ARS and sent to Rapporteur and Recordati on Monday 14 September 2020 (the Minutes)), the submission of the application for the EU Marketing Authorization for the Strength 1 to the EMA can be performed on the
legal basis of article 8(3) of the EU Directive 2001/83/EC since the results from the pharmacodynamic studies conducted by ARS and to be included in the Dossier will be considered by EMA as a surrogate for efficacy; 

 

	 	(iv)	 it has the right to provide Recordati with the
ARS-Know-How set out in this Agreement; 

  

	 	(v)	 it has Control to and of the Patents and ARS Intellectual Property Rights free and clear from any encumbrances;

  

	 	(vi)	 it has the right to grant the Licenses to Recordati as set forth in and pursuant to this Agreement;

  

	 	(vii)	 no claim or action has been brought against ARS, or threatened in writing to ARS, by any Third Party alleging
that the Patents or ARS Intellectual Property Rights are invalid or unenforceable (and thus are valid, effective and enforceable) and, to ARS’s knowledge, no interference, opposition, cancellation or other protest proceeding has been filed
against a Patent owned by ARS, and ARS has obtained from all inventors of the Patents owned by ARS effective assignments of all ownership rights of inventors in, to and under such Patents to ARS, all application, registration, maintenance and
renewal fees in respect of the Patents have been paid and to ARS’s knowledge, all necessary documents and certificates have been filed with the relevant agencies for the purpose of maintaining such Patents; 

 

	 	(viii)	 ARS has not receive any written notice and does not otherwise have knowledge prior to Effective Date that its
activities with the Product (or the Manufacture, export, Commercialization thereof) has infringed any patents or other Intellectual Property Rights Controlled by a Third Party; 

 

	 	(ix)	 to ARS’ knowledge, there are no activities by Third Parties that would constitute infringement or
misappropriation of the ARS Intellectual Property Rights; 

  

	 	(x)	 it (directly or through its Affiliates or Third Party contractors) has the requisite expertise, ability,
capacity, skills and know-how, including all the qualified and experienced workforce and possesses all necessary governmental licenses, facilities and services to perform its obligations under this Agreement,
and neither it nor any of its Affiliates or, to its knowledge, its Third Party contractors, are, or have been, debarred or disqualified by any relevant authority; 

 

	 	(xi)	 [***]; 

  

	 	(xii)	 [***]; 

  

	 	(xiii)	 [***]; 

  

	 	(xiv)	 [***]; 

  

	 	(xv)	 [***]; 

  
 39 

	 	(xvi)	 there are no actual, or to ARS’ knowledge, threatened enforcement actions by any world-wide local or
national authority (including Regulatory Authority) which has jurisdiction over ARS’s, ARS’ Affiliates’ or [***]’ operations relating to the Product; and 

 

	 	(xvii)	 [***]; 

  

	 	(xviii)	 in making its decision to enter into this Agreement and to consummate the transactions contemplated hereby,
relied on its own independent investigation, analysis and evaluation and on the representation and warranties of Recordati. 

  

	39.04	 Each Party hereby covenants to the other Party that: 

 

	 	(i)	 it shall not, in the performance of this Agreement, perform any actions that are prohibited by local and other
anti-corruption laws (collectively Anti-Corruption Laws) that may be applicable to either or both Parties; 

  

	 	(ii)	 it shall not, in the performance of this Agreement, directly or indirectly, make any payment, or offer or
transfer anything of value, or agree or promise to make any payment or offer or transfer anything of value, to a government official or government employee, to any political party or any candidate for political office or to any other Third Party
with the purpose of influencing decisions related to either Party or its business in a manner that would violate Anti-Corruption Laws; 

  

	 	(iii)	 it shall, on request by the other Party, verify in writing that to the best of such Party’s knowledge,
there have been no violations of Anti-Corruption Laws by such Party or persons employed by or subcontractors used by such Party in the performance of the Agreement, or shall provide details of any exception to the foregoing; and

  

	 	(iv)	 it shall maintain records (financial and otherwise) and supporting documentation related to the subject matter
of the Agreement in order to document or verify compliance with the provisions of this Paragraph, and upon request of the other Party, upon reasonable advance notice, shall provide a Third Party auditor mutually acceptable to the Parties with access
to such records for purposes of verifying compliance with the provisions of this Paragraph, it being agreed that the costs related to the Third Party auditor to be fully paid by the Party requesting the audit, any auditing activities may not unduly
interfere with the normal business operations of the Party subject to such auditing activities, and the audited Party may require the Third Party auditor to enter into a reasonable confidentiality agreement in connection with such an audit.

  

	39.05	 The Parties acknowledge that, the representation and warranties set out in this Clause 39 are the only
representation and warranties provided by the Parties under this Agreement and thus no representation and warranties beyond those set out in this Clause 39. 

SECTION XII – INDEMNIFICATION – NOTICE OF CLAIM 
  

	40.	 LIMITED LIABILITY 

 

	40.01	 Neither Party shall be liable to the other Party for any incidental, indirect or special or
consequential damages however caused and irrespective of the legal basis thereof, arising out of this Agreement even if it has been advised, knew or should have known of the possibility of such loss or damage or if such loss or damage could have
been reasonably foreseen. 

  
 40 

	40.02	 The limitation of Paragraph 40.01 above with respect to a Party’s liability shall not apply in
cases of (i) such Party’s wilful misconduct or gross negligence, (ii) breach of obligations under Clause 47, and (iii) statutory mandatory liability (including, for the avoidance of doubt, personal injury and death). Nothing in
Paragraph 40.01 above shall be construed to limit either Party’s indemnification obligations with respect to Third Party Claims under Clause 41. 

  

	41.	 INDEMNIFICATION 

 

	41.01	 ARS undertakes to defend, indemnify and hold Recordati, Recordati’s Affiliates, and their
respective officers, directors and employees (the Recordati Representatives) harmless from, against and in respect of any and all damages, losses, expenses, claims, demands, suits, penalties, judgments or administrative and judicial
orders and liabilities (including reasonably counsel fees and expenses) (the Losses) incurred by any of them resulting from any claims, actions and proceedings made or instituted by any Third Party (the Third Party
Claims) to the extent such Losses arise out of: (i) ARS’s, its Affiliates’ and/or ARS Representatives’ gross negligence or wilful misconduct, (ii) ARS’s material breach of any representation,
warranty or any other obligation under this Agreement or (iii) the handling, storage, Manufacture, export, Commercialization of the Product by ARS or its Affiliates or any other Third Party licensee outside the Territory (excluding any
activities by or on behalf of Recordati or its Affiliates or Sublicensees); the whole except to the extent that any such Losses result from Recordati’s, its Affiliates and/or Recordati Representatives’ gross negligence or wilful misconduct
or the material breach by Recordati of any representation, warranty or any other obligation under this Agreement. 

  

	41.02	 Recordati undertakes to defend, indemnify and hold ARS and ARS’s Affiliates, and their respective
officers, directors and employees (the ARS Representatives) harmless from, against and in respect of any and all Losses incurred by any of them resulting from any Third Party Claims to the extent such Losses arise out of:
(i) Recordati’s, its Affiliates’ and/or Recordati Representatives’ gross negligence or wilful misconduct, (ii) Recordati’s material breach of any representation, warranty or any other obligation under this Agreement, or
(iii) the Recordati’s Development Activities, use, handling, storage, Manufacturing, or Commercialization of the Product by Recordati or its Affiliates, Sublicensees; the whole except to the extent that any such Losses result from
ARS’s, its Affiliates’ and/or ARS Representatives’ gross negligence or wilful misconduct or the material breach by ARS of any representation, warranty or any other obligation under this Agreement. 

 

	42.	 NOTICE OF CLAIM 

 

	42.01	 Any Party seeking to be indemnified by virtue of the provisions set out in Clause 41 of this Agreement
(Indemnified Party) shall notify the Party from which indemnification is sought (Indemnifying Party) promptly in writing – and in any event not later than [***] from the date on which the Indemnified Party became
aware of the event which could reasonably give rise to the Indemnifying Party’s liability under Clause 41 – of any and all respective Third Party Claims; made or instituted against it (including a copy of any related complaint, summons,
notice or other instrument); provided that failure to promptly provide such notice within the time period set out above shall not relieve the Indemnifying Party of any of its obligations hereunder except to the extent the Indemnifying Party defences
vis-à-vis the Third Party Claim are prejudiced by such failure. 

 

	42.02	 With respect to any Third Party Claim: 

 

	 	(i)	 the Indemnified Party shall cause that any such Third Party Claim is diligently and properly defended;

  
 41 

	 	(ii)	 the Indemnifying Party shall have the right to participate and, to the maximum extent permitted by the
Applicable Laws, join at its cost, through counsel of its choosing, in the defense of the Third Party Claim; 

  

	 	(iii)	 the Parties shall, and shall cause their respectively appointed counsel and experts to, actively cooperate with
each other in the proper and diligent defense of the Third Party Claim and shall keep each other timely informed of all facts, circumstances and documents relating to the Third Party Claim (it being understood, however, that the Indemnified Party
shall have the right to control the litigation strategy); and 

  

	 	(iv)	 the Indemnified Party shall not make or accept any settlement of the Third Party Claim without the prior
written consent of the Indemnifying Party, not to be unreasonably withheld or delayed, it being understood that: 

  

	 	(a)	 if the Indemnified Party enters into any settlement of the Third Party Claim without the prior written consent
of the Indemnifying Party (acting reasonably), the Indemnifying Party shall not be per se liable vis-à-vis the Indemnified Party for the matter giving rise
to the Third Party Claim; and 

  

	 	(b)	 if a firm offer is made to the Indemnified Party to settle any matter giving rise to the Third Party Claim
which the Indemnifying Party, but not the Indemnified Party, is willing to accept, the Indemnified Party shall be free not to enter into such settlement and to commence or continue litigation, at the Indemnified Party’s own expense, but the
Indemnifying Party’s liability shall be limited to the amount of the proposed settlement. 

 SECTION XIII –
SPECIAL PROVISIONS 
  

	43.	 IP OWNERSHIP; IP RIGHTS INFRINGEMENT LAWSUIT

  

	43.01	 The Parties acknowledge and agree that, as between the Parties, all right, title and interest in and to
any ARS Intellectual Property Rights shall be owned solely by ARS. All right, title, and interest in and to any inventions made, developed, conceived or reduced to practice by or on behalf of Recordati or any of its Affiliates or Sublicensees in the
course of performance of this Agreement based upon the ARS Intellectual Property Rights (or otherwise generated with use of or reference to a Compound or Product, or Confidential Information of ARS), and all Intellectual Property Rights therein
(collectively, New IP) shall be owned solely by ARS. In connection with the foregoing: (i) Recordati shall promptly disclose in writing to ARS all New IP, (ii) Recordati hereby does, and shall cause its Affiliates and
Sublicensees and its and their employees and representatives to, assign and transfer to ARS all right, title, and interest in and to such New IP and agrees to take all further acts reasonably required to evidence such assignment and transfer to ARS;
(iii) such New IP shall constitute ARS Intellectual Property Rights for purposes of this Agreement; and (iv) Recordati shall have the royalty-free, fully paid-up right (with the right to sublicense)
to use the New IP for the Territory during the Term. 

  

	43.02	 ARS shall have the sole right, as between ARS and Recordati, in its discretion, to control the
preparation, filing, prosecution (including any interferences, reissue proceedings and re-examinations) and maintenance of all Patents, at its sole cost and expense and by counsel of its own choice. Upon
request of ARS, Recordati shall provide ARS with reasonable assistance and cooperation in connection therewith. ARS shall keep Recordati reasonably informed of progress with regard to the preparation, filing, prosecution and maintenance of Patents,
including content, timing and jurisdiction of the filing of such Patents. 

  
 42 

	43.03	 The Parties shall notify each other in writing of any potential or actual infringement or
misappropriation (of which it has or obtains knowledge) in the Territory by any Third Party of the ARS Intellectual Property Rights (or part thereof) and shall provide each other with any available evidence of such infringement or misappropriation
in its possession or under its control. 

  

	43.04	 In the event a notice under Paragraph 43.03 above is submitted by either Party, the Parties shall then
discuss in good faith the best possible strategy and course of action (and payment of all related costs and expenses), it being understood and agreed that should the Parties not agree with the aforementioned strategy and course of action:

  

	 	(i)	 ARS, shall have the first right (but not the obligation, as between ARS and Recordati) for taking all
reasonable steps necessary to enjoin and prevent such infringement or misappropriation of the ARS Intellectual Property Rights, including, without limitation, the institution and maintenance of legal or equitable proceedings, and Recordati shall
cooperate with respect thereof, including by way of executing such documents and performing such other acts as may be reasonably required [***]; 

  

	 	(ii)	 in the event that ARS chooses not to take any action with respect to such infringement or misappropriation of
the ARS Intellectual Property Rights, Recordati shall have the right (but not the obligation) to take any such reasonable steps necessary to enjoin and prevent such infringement or misappropriation, including, without limitation, the institution and
maintenance of legal or equitable proceedings, and ARS shall cooperate with respect thereof, including by way of executing such documents and performing such other acts as may be reasonably required [***]; and 

 

	 	(iii)	 in any case, (a) each Party shall have the right to participate in the litigation controlled by the other
Party, the whole at its cost and expense, (b) neither Party shall enter into any settlement that would in any manner alter, diminish, or be in derogation of the other Party’s rights under this Agreement shall be made without the prior
approval of the other Party, acting reasonably (it being understood and agreed that (1) no Party shall have the right to bind the other Party, (2) no Party shall have the obligation to make any admission, (3) no Party shall have the
obligation to pay any amount of money, and (4) [***] shall not be obliged to agree to any reduction of the length of any Patent relating to the Product in the Territory); and 

 

	 	(iv)	 except as otherwise agreed by the Parties in writing as part of a cost-sharing arrangement, any recovery or
damages realized as a result of such action or proceeding with respect to ARS Intellectual Property Rights shall be used first [***]. 

  

	43.05	 Each Party shall promptly notify the other in writing of any allegation by a Third Party that the
development, Manufacture or Commercialization of the Product infringes or may infringe any Intellectual Property Right of a Third Party. If a Third Party asserts that any of its Intellectual Property Rights are infringed by the development,
Manufacture or Commercialization of the Product in the Territory by Recordati or its Affiliates or Sublicensees, Recordati shall have the right but not the obligation to defend against any such assertions. In the event that Recordati elects not to
defend against such Third Party claims within [***] of learning of same, ARS shall have the right, but not the obligation, to defend against such an action. In any event, the other Party shall cooperate fully and shall provide full access to
documents, information and witnesses as reasonably requested by the Party defending such action. The Party defending the action will reimburse all Third Party costs incurred in connection with such requested cooperation. 

  
 43 

	43.06	 For clarity, ARS reserves all rights to prepare, file, prosecute (including any interferences, reissue
proceedings and re-examinations), maintain, defend and enforce all Intellectual Property Rights owned or controlled by ARS related to the Product outside the Territory. 

SECTION XIV –TERM AND TERMINATION OF THIS AGREEMENT 
  

	44.	 TERM 

 

	44.01	 This Agreement shall become effective as of the Effective Date and shall remain in full force and
effect, unless terminated by one of the Parties pursuant to the provisions of Clause 45 below, so long as Recordati, or Recordati’s Affiliates or Sublicensees are Commercializing any Product in the Territory (the Term).

  

	45.	 TERMINATION OF THIS AGREEMENT

  

	45.01	 Each Party (the Terminating Party) shall, without limiting any right under the Applicable
Laws, have the right to terminate this Agreement at any time forthwith upon written notice to the other Party (the Terminated Party), in any of the following events, in so far as permitted under Applicable Laws: 

 

	 	(i)	 if the Terminated Party commits a material breach of this Agreement which is not fully and effectively remedied
by the Terminated Party within [***] (or [***] in the event of any payment obligation) from the receipt of the written notice given to such effect by the Terminating Party (the Cure Period). If there is a dispute with respect to the
existence of a Material Breach or as to whether a Material Breach is capable of being cured (a Breach Process Dispute), the Terminated Party may contest the allegation by referring such matter for resolution in accordance with Clause
61 below and the time for the Cure Period will be extended until such time as such dispute is resolved. It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect
and the Parties shall continue to perform all of their respective obligations hereunder and, if it is finally determined that the Terminated Party committed such Material Breach, then the Terminating Party may terminate the Agreement; or

  

	 	(ii)	 if the Terminated Party is dissolved, wound up or liquidated, whether voluntarily or involuntarily, or it files
a voluntary petition in bankruptcy or is declared bankrupt or becomes subject to reorganization or similar procedures, it settles or compounds with its creditors or has a receiver, liquidator or trustee of its assets appointed or it otherwise sells
or disposes of all or substantially all of its assets in such insolvency event. 

  

	45.02	 Recordati may also terminate this Agreement on a country-by-country basis (except if the EU Marketing Authorization is finally rejected by the European Commission as described below in 45.02(i), in which case, Recordati may terminate the agreement in all
countries in the EU Territory) at any time forthwith upon written notice given to ARS: 

  

	 	(i)	 with respect to the EU Territory, if the EU Marketing Authorization application is finally rejected by the
European Commission, and if there is no reasonable basis for approval on resubmission of an application that addresses the deficiencies; or 

  

	 	(ii)	 with respect to the UK, if the UK Marketing Authorization application is rejected by the MHRA, and if there is
no reasonable basis for approval on resubmission of an application that addresses the deficiencies; or 

  
 44 

	 	(iii)	 on a country-by-country basis
with respect to the Ex-EU Territory if the Marketing Authorization application is rejected by the Regulatory Authority of the relevant country of the Ex-EU Territory,
and if there is no reasonable basis for approval on resubmission of an application that addresses the deficiencies. 

  

	45.03	 ARS shall have the right to terminate this Agreement in its entirety upon written notice to Recordati if
Recordati or any of its Affiliates directly, or indirectly through any Third Party, (i) commences any interference or opposition proceeding with respect to, or opposes any extension of or the grant of a supplementary protection certificate with
respect to, any Patent, or (ii) institutes, actively participates as an adverse party in, or otherwise provides material support to, any action, suit or other proceeding to invalidate any Patent or to obtain a ruling that any claim within any
Patent is unenforceable or not patentable. 

  

	45.04	 ARS shall have the right to terminate this Agreement in its entirety upon written notice to Recordati
if: 

  

	 	(i)	 a Sublicensee directly, or indirectly through any Third Party, (a) commences any interference or
opposition proceeding with respect to, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any Patent, or (b) institutes, actively participates as an adverse party in, or otherwise provides
material support to, any action, suit or other proceeding to invalidate any Patent or to obtain a ruling that any claim within any Patent is unenforceable or not patentable; and 

 

	 	(ii)	 Recordati does not terminate the agreement with the Sublicensee described in Paragraph 45.04(i) above.

  

	46.	 EFFECTS OF TERMINATION 

 

	46.01	 Upon this Agreement expiring or being terminated pursuant to one or more of the provision set out in
Clause 45 above, ARS, at its own discretion, shall elect to either: 

  

	 	(i)	 purchase from Recordati all of the Product that at that time Recordati will have at stock for a price equal to
Supply Price actually paid by Recordati to the ARS under the relevant Product Purchase Agreement(s); or 

  

	 	(ii)	 allow Recordati – on the same terms and conditions set out in this Agreement – to sell the Product
that at that time Recordati will have at stock. 

  

	46.02	 Should ARS exercise the right set out under Paragraph 46.01(i) above, Recordati undertakes to assign and
procure the assignment of each and any purchase order and/or tender, and/or agreement for those Products then currently placed from an End-User to Recordati, so as to substitute ARS (or any Third Party
indicated by ARS) in such purchase orders and/or tenders and/or agreements, or, as the case may be, perform any action or give the necessary notices to any End-User relating to the termination or expiration of
this Agreement. 

  

	46.03	 Upon any termination of this Agreement: 

 

	 	(i)	 all rights and obligations of the Parties under this Agreement will terminate except as provided in this
Paragraph 46.03 or Paragraph 46.04, and all sublicenses under the ARS Intellectual Property Rights granted by Recordati will automatically terminate, in each case on the effective date of termination; 

  
 45 

	 	(ii)	 ARS shall notify Recordati within [***] after the effective date of termination whether it wishes to obtain the
assignments set forth in Paragraph 46.03(ii), which assignments will be at ARS costs; as promptly as practicable (and in any event within [***]) after such notice, Recordati shall: (I) to the extent not previously provided to ARS, deliver to
ARS true, correct and complete copies of all regulatory filings (including Marketing Authorizations and Regulatory Approvals) for the Product in the Territory; (II) effective upon such termination, transfer and assign, or cause to be
transferred or assigned, to ARS or its designee (or to the extent not so assignable, take all reasonable actions to make available to ARS or its designee all of the benefits of) all such regulatory filings (including Marketing Authorizations and
Regulatory Approvals) for the Product in the Territory, whether held in the name of Recordati or its Affiliate or Sublicensee; and (III) take such other actions and execute such other instruments, assignments and documents as may be necessary
to effect, evidence, register and record the transfer, assignment or other conveyance of rights under this Paragraph 46.03(ii) to ARS; 

  

	 	(iii)	 Recordati shall, as directed by ARS, either wind-down any ongoing Recordati Development Activities in an
orderly fashion or promptly transfer such Recordati Development Activities to ARS or its designee, in compliance with all Applicable Laws; and 

  

	 	(iv)	 except to the extent that a receiving Party obtains or retains the right to use the disclosing Party’s
Confidential Information, each receiving Party shall promptly destroy, all relevant records and materials in such receiving Party’s possession or control containing Confidential Information of the disclosing Party; provided that such receiving
Party may keep one copy of such materials solely for the purposes of verifying compliance with this Agreement and/or maintaining regulatory compliance subject to continuing confidentiality obligations. 

 

	46.04	 The use by either Party hereto of a termination right provided for under this Agreement shall [***].
Expiration or termination of this Agreement shall not relieve the Parties of any obligation or right accruing prior to such expiration or termination and shall not affect continuing rights and/or obligations set forth in Paragraphs 38.01(iv),
38.01(v), 38.01(vi) and Clauses 39, 40, 41, 47, 49, 53, 60 and 61. 

 SECTION XV – GENERAL PROVISIONS 

 

	47.	 CONFIDENTIALITY 

 

	47.01	 Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the
Parties, the receiving Party shall keep confidential, shall not disclose to third persons and shall not use for purposes other than those of this Agreement any Confidential information of the other (disclosing Party) without the prior written
consent of the disclosing Party. The receiving Party shall reveal Confidential Information of the disclosing Party to its Affiliates and to its and its Affiliates employees, contractors and other representatives on a strict need to know basis only
to persons directly engaged with its activity under this Agreement and shall impose the obligation of secrecy on these persons as well. For clarity, all New IP will be deemed ARS’s Confidential Information and ARS shall be considered the
disclosing Party and Recordati shall be considered the receiving Party with respect thereto. 

  

	47.02	 The foregoing obligations shall not apply, however, to any part of such information received, which the
receiving Party can show by written documentation: 

  

	 	(i)	 to have been known to recipient prior to the disclosure by the other Party (provided that this exception shall
not apply to Recordati’s knowledge of any New IP); or 

  

	 	(ii)	 was known to the public or generally available to the public prior to the date of the disclosure to the
recipient by the other Party by the receiving Party; or 

  
 46 

	 	(iii)	 comes into public domain by publication or otherwise through no breach of this Agreement; or

  

	 	(iv)	 to have been made known to a recipient without any secrecy obligation from a Third Party having the bona
fide right to disclose or make available such information; 

  

	47.03	 The receiving Party may disclose Confidential Information of the disclosing Party as expressly permitted
by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances: 

  

	 	(i)	 regulatory filings for the Product (for Recordati, only in the Territory) that such Party has a license or
right to develop hereunder in a given country or jurisdiction; 

  

	 	(ii)	 [***]; 

  

	 	(iii)	 prosecuting or defending litigation arising under this Agreement; and 

 

	 	(iv)	 disclosure that is required by law, provided that a written notification of such disclosure is given and that
the recipient, upon request of the disclosing Party (and at the disclosing Party’s cost), will reasonably cooperate with the disclosing Party in taking all lawful action against or in complying with such compelled disclosure, provided always
that any disclosure shall be only to the extent so required. 

  

	47.04	 As of the Effective Date, the terms of this Clause 47 shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) relating to the subject of this Agreement. Any information disclosed pursuant to any such prior agreement shall be
deemed Confidential Information for purposes of this Agreement. 

  

	47.05	 Given the nature of the Confidential Information and the competitive damage that a Party would suffer
upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages would not be a sufficient remedy for any breach of this Clause 47. In addition to all other remedies, a Party
shall be entitled to specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Clause 47. 

  

	47.06	 The obligations under this Clause 47 shall continue to remain valid and in force after the expiration or
termination of this Agreement for so long as the information remain confidential and not in the public domain, and in any case for a period not to exceed 5 (five) years. 

 

	48.	 FORCE MAJEURE 

Any failure by either Party to comply with its obligations under this Agreement (other than any obligation to make payment when due) shall be excused if and
for so long as compliance by such Party is hindered, prevented, or delayed by a Force Majeure event. The Parties shall notify each other immediately, report the expected duration and the extent of such events or circumstances, and shall discuss how
to proceed further. The Party affected by the Force Majeure event shall be obligated to make Commercially Reasonable Effort, to limit the disruption caused by the Force Majeure. 

  
 47 

	49.	 INSURANCE 

 

	49.01	 For the entire duration of this Agreement and for [***] thereafter, ARS and Recordati undertake to
maintain appropriate insurance coverage, including commercial general liability insurance, which adequately covers each Parties’ obligations under this Agreement, as well as adequate products liability and property insurance, which insurances
shall afford limits of not less than Euro [***] per occurrence and per Calendar Year in the aggregate. For general liability, and not less than Euro [***] per occurrence and per Calendar Year in the aggregate for product liability.

  

	49.02	 Each Party if requested by the other Party will provide such other Party with a certificate of insurance
evidencing the above and showing the name of the issuing company, the policy number, the effective date, the expiration date and the limits of liability. 

SECTION XVI – MISCELLANEOUS 
  

	50.	 ENTIRE AGREEMENT 

 

	50.01	 This Agreement constitutes the entire agreement between the Parties with respect to the subject matter
thereof, and supersedes all prior representations, negotiations and understandings between the Parties, whether in writing or otherwise. Neither Party shall have the authority to make any statements, representations, or commitments of any kind, or
to take any action, that will be binding (or purport to be binding) on the other. 

  

	50.02	 Without prejudice to Paragraph 50.01 above, all Product Purchase Agreements are entered in reliance of
the fact that this Agreement and all Product Purchase Agreements form a single agreement between the Parties in respect of the subject matter thereof, and that the Parties would not otherwise have entered into a Product Purchase Agreement.

  

	51.	 AMENDMENTS 

This Agreement may only be amended or modified with the written consent of the Parties. Any Party may, as to itself, waive in writing the performance of any
provision of this Agreement intended for its benefit. 
  

	52.	 PARTIAL INVALIDITY 

In the event that any provision of this Agreement or the application of any provision hereof is declared to be illegal, invalid or otherwise unenforceable by a
court of competent jurisdiction, such provision shall be reformed, if possible, or otherwise deleted, and the remainder of this Agreement shall not be affected except to the extent necessary to reform such illegal, invalid or unenforceable provision
unless reforming or deleting the provision held invalid shall substantially impair the benefits of the remaining portion of this Agreement. 
  

	53.	 NOTICES 

Any communication pursuant to this Agreement shall be carried out in writing and shall be considered effectively and validly executed provided that it is
addressed by international courier (return receipt requested) as follows: 
  

			
	 -   to ARS:
	  	 3525 Del Mar Heights Rd.
 San Diego, CA 92130,
USA
  
 Attn. of Chief Executive Officer;

		
	 -   to Recordati:
	  	 Raheens East, Ringaskiddy,
 Co Cork, P43 KD30,
Ireland
  
 Attn. of Managing Director;

  
 48 

 or to a different address that each of the Parties may communicate to the other in writing after the date
hereof, it being understood that the above mentioned addresses or any addresses communicated in writing in the future are to be considered as the legal addresses of the Parties for any purpose concerning this Agreement, including legal
notifications, settlement procedures and/or arbitration. 
  

	54.	 NO ASSIGNMENT 

Without prejudice to the provision set out in Paragraph 3.03, neither this Agreement nor any of the rights, interests or obligations hereunder shall be
assigned or delegated by a Party to any Person without the previous written consent of the other Party, such consent not to be unreasonably withheld or delayed; except that (i) [***]. This Agreement shall inure to the benefit of and be binding on
the Parties’ successors and permitted assignees. Any assignment or transfer in violation of this Clause 54 shall be null and void and wholly invalid, the assignee or transferee in any such assignment or transfer shall acquire no rights
whatsoever, and the non-assigning non-transferring Party shall not recognize, nor shall it be required to recognize, such assignment or transfer. 

 

	55.	 WAIVER 

The tolerance of either Party of any breach of the provisions set out in this Agreement by the other Party shall not be construed as a waiver or variation of
the relevant breached provisions, or to the right to require the full performance of all the obligations of the other Party on the term and conditions hereunder. 
  

	56.	 INDEPENDENT CONTRACTORS 

The Parties are independent contractors, and this Agreement will not establish any relationship of partnership, joint venture, employment, franchise, or agency
between the Parties. 
  

	57.	 COSTS AND EXPENSES 

All costs and expenses, including, without limitation, fees and disbursements of legal counsel, financial, accounting and other advisors incurred in connection
with this Agreement and the transactions contemplated by this Agreement shall be paid by the Party incurring such costs and expenses. 
  

	58.	 COUNTERPARTS 

This Agreement may be executed in several counterparts, all of which together shall constitute one agreement binding on all Parties hereto, notwithstanding
that all the Parties have not signed the same counterpart. The Parties agree that this Agreement may be exchanged by facsimile, pdf or other electronic means, which upon request of a Party shall be followed up with originals. 

 

	59.	 ANNOUNCEMENT 

The Parties agree that in case they will estimate their joint best interest to make a public announcement concerning their relationship under this Agreement,
they will agree to issue a joint or separate press releases in a form and substance reasonably acceptable to both, provided however, that such press release shall not include financial or other patently confidential aspects concerning the subject
matter hereof. The Parties will agree on the text of such press releases. Notwithstanding the forgoing, the Parties agree that on the Effective Date each Party may separately release the announcements attached hereto under Annex
8. 

  
 49 

 SECTION XVII – GOVERNING LAW AND JURISDICTION 

 

	60.	 GOVERNING LAW 

This Agreement and any non-contractual obligations arising out of or in connection with this Agreement shall be
governed by, and interpreted in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles. The application of the U.N. Convention on Contracts for the International Sale of Goods
(1980) is excluded. 
  

	61.	 DISPUTE RESOLUTION 

 

	61.01	 The Parties recognize that disputes as to matters (i) arising under, or relating to, this Agreement
or (ii) either Party’s rights and obligations hereunder may arise from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of such disputes in an expedient manner by mutual cooperation and
without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Clause 61 to resolve any such dispute if and when it arises. 

 

	61.02	 Except as otherwise provided in Paragraph 33.06, if an unresolved dispute as to matters arising under or
relating to this Agreement or either Party’s rights and obligations hereunder arises, either Party may refer such dispute to the Chief Executive Officers (or the Senior Executive of Recordati appointed for the purpose) of the respective
Parties, who shall meet in person or by telephone within [***] after such referral to attempt in good faith to resolve such dispute. If such matter cannot be resolved by discussion of such Chief Executive Officers (or the Senior Executive of
Recordati appointed for the purpose) within such [***] period (as may be extended by mutual written agreement), such dispute shall be resolved in accordance with Paragraph 61.03. 

 

	61.03	 Any dispute between the Parties which cannot be amicably resolved between the Parties as provided in
Paragraph 61.02 shall be finally settled by binding arbitration pursuant to this Paragraph 61.03, except for any dispute, controversy or claim that concerns (a) the validity, enforceability or infringement of a patent, trademark or copyright or
(b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. 

  

	 	(i)	 The arbitration shall be conducted under the Arbitration Rules of the International Chamber of Commerce as then
in effect by a panel of [***] arbitrators appointed in accordance with said rules, none of whom shall be a current or former employee or director, or a then-current stockholder, of either Party, their respective Affiliates or any Sublicensee. If
either Party intends to commence binding arbitration of such dispute, such Party will provide written notice to the other Party informing the other Party of such intention and the issues to be resolved. Within [***] after the receipt of such notice,
the other Party may, by written notice to the Party initiating binding arbitration, add additional issues to be resolved. 

  

	 	(ii)	 The seat of the arbitration shall be New York, New York. The arbitrators shall resolve the dispute on the basis
of the substantive law chosen by the Parties under Clause 60 above. The arbitration award rendered in any such arbitration will be final and not appealable and may be executed by any court of competent jurisdiction. All proceedings of the
arbitration, including arguments and briefs, shall be conducted in English. 

  

	 	(iii)	 It is the intention of the Parties that discovery, although permitted as described herein, will be limited
except in exceptional circumstances. The arbitrators will permit such limited discovery necessary for an understanding of any legitimate issue raised in the arbitration, including the production of documents. No later than [***] after selection of
the arbitrators, the Parties and their representatives shall hold a preliminary meeting with the arbitrators, to mutually agree upon and thereafter follow procedures seeking to assure that the arbitration will be concluded within [***] from such
meeting. Failing any such mutual agreement, the arbitrators will design and the Parties shall follow procedures to such effect. 

  
 50 

	 	(iv)	 Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered
or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party
pending the arbitration award. The arbitrators shall have no authority to award punitive or any other non- compensatory damages. The award shall be in writing and shall describe the basis for the award and the
arbitrators’ decision(s). The arbitrators shall have the power to order that all or part of the legal or other costs incurred by a Party in connection with the arbitration be paid by the other Party. Each Party shall bear an equal share of the
arbitrators’ and any administrative fees of arbitration. 

  

	 	(v)	 Except to the extent necessary to confirm or enforce an award or as may be required by Applicable Law, neither
a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable
proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations. 

SECTION XVIII – ANNEXES 
  

	62.	 ANNEXES 

The following Annexes are attached to this Agreement: 
  

			
	Annex 1	  	EU Territory;
		
	Annex 2	  	Ex-EU Territory;
		
	Annex 3	  	Patents;
		
	Annex 4	  	Paediatric Development;
		
	Annex 5	  	Remaining Strength 1 Studies;
		
	Annex 6	  	Supply Price;
		
	Annex 7	  	Annual Report Example;
		
	Annex 8	  	Announcements.

 [Remainder of page intentionally left blank] 

  
 51 

 *** 

In witness whereof, each of the Parties has caused this Agreement to be initialled on each page and signed by its duly authorized representative as of the
date and in the place specified herein below. 
  

					
	Cork, 21 September 2020	 	        	  	San Diego, 21 September 2020
			
	 /s/ Cédric Ripert
	 		  	 /s/ Richard Lowenthal

	  
 Recordati Ireland, Ltd

Mr. Cédric Ripert
 Title: Managing Director
	 		  	  
 ARS Pharmaceuticals, Inc.

Mr. Richard Lowenthal
 Title: President & Chief
Executive Officer

  
 52 

 Annex 1 

EU Territory 
  

					
	 Austria
	  	 France**
	  	 Malta

	 Belgium
	  	 Germany
	  	 The Netherlands

	 Bulgaria
	  	 Greece
	  	 Poland

	 Croatia
	  	 Hungary
	  	 Portugal

	 Cyprus
	  	 Ireland
	  	 Romania

	 Czech Republic
	  	 Italy
	  	 Slovakia

	 Denmark*
	  	 Latvia
	  	 Slovenia

	 Estonia
	  	 Lithuania
	  	 Spain

	 Finland
	  	 Luxembourg
	  	 Sweden

  

	*	 including Faroe Islands 

	**	 including DOM-TOM 

  
 53 

 Annex 2 

Ex-EU Territory 
  

									
	 EFTA
	 	 Other Europe
	 	 CIS
	 	 Middle East
	 	 Africa

	Iceland	 	Albania	 	Armenia	 	Afghanistan	 	Algeria
	Lichtenstein	 	Andorra	 	Azerbaijan	 	Bahrain	 	Benin
	Norway	 	Bosnia-Herzegovina	 	Belarus	 	Egypt	 	Burkina Faso
	Switzerland	 	Georgia	 	Kazakhstan	 	Iran	 	Burundi
		 	Monaco	 	Kyrgyzstan	 	Iraq	 	Cameroon
		 	Montenegro	 	Moldova	 	Israel	 	Central African Rep.
		 	North Macedonia	 	Russia	 	Jordan	 	Chad
		 	Ukraine	 	Tajikistan	 	Kuwait	 	Congo
		 	San Marino	 	Uzbekistan	 	Lebanon	 	Dem. Rep. Congo
		 	Serbia	 		 	Oman	 	Djibouti
		 	Vatican City	 		 	Pakistan	 	Equatorial Guinea
		 		 		 	Palestine	 	Ivory Coast
		 		 		 	Qatar	 	Lybia
		 		 		 	Saudi Arabia	 	Madagascar
		 		 		 	Syria	 	Mali
		 		 		 	Turkey	 	Mauritius
		 		 		 	United Arab Emirates	 	Morocco
		 		 		 	Yemen	 	Niger
		 		 		 		 	Rwanda
		 		 		 		 	Senegal
		 		 		 		 	Seychelles
		 		 		 		 	Togo
		 		 		 		 	 Tunisia

 For the sake of clarity, the United Kingdom (UK) is part of the Territory definition. 

  
 54 

 Annex 8 

Announcements 
  

 
 ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional
countries for NeffyTM (ARS-1; epinephrine nasal spray) 

Agreement will give access to millions at risk for severe allergic reaction to new pain-free delivery method for epinephrine and will help
in efforts to gain regulatory approval for ARS-1 (known as NeffyTM in the U.S.) around the world 

SAN DIEGO SEPTEMBER 21, 2020—ARS Pharmaceuticals (ARS) announced that it has entered into an exclusive licensing agreement with
Recordati for marketing rights in the European Union, Iceland, Liechtenstein, Norway, Switzerland, United Kingdom, Russia/CIS, Turkey, Middle East and French-speaking African countries, for ARS-1 (known
as NeffyTM in the United States), an epinephrine nasal spray. This agreement will allow ARS, a pharmaceutical company dedicated to empowering at-risk
patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, to continue the important work of gaining regulatory approval in the United States and globally by providing additional capital
through licensing milestones and future royalties on sales. 
 “We are thrilled that Recordati has recognized the importance of this new delivery
technology for epinephrine that will provide an improved therapy for the millions of people in Europe living with life-threatening allergies. With their strong track-record in specialty medicines, we are excited to work with the team at Recordati,
to help deliver a new, easier to dose, pain-free way to treat severe allergic reactions and prevent progression to anaphylaxis,” said Richard Lowenthal, President and Chief Executive Officer of ARS Pharmaceuticals. “The agreement with
Recordati is critical in our continued journey towards NeffyTM (ARS-1) approval in the United States and Worldwide.” 

Recordati will receive exclusive rights to develop, register and commercialize ARS-1 (known as NeffyTM in the United States) in 93 countries including Europe in return for an upfront and subsequent payments based on successful achievement of regulatory and commercial milestones. ARS Pharmaceuticals
will manufacture and supply ARS-1 (known as NeffyTM in the United States) to Recordati as part of the agreement, and receive tiered royalties based on net
sales. 
 Because of its innovative delivery method, NeffyTM
(ARS-1) has the potential to be a much more effective treatment in preventing severe allergic reactions than currently available. Its needle-free, small and easy-to-use delivery system may help eliminate anxiety and overcome hesitation that is common with injectable epinephrine. The marketing authorization application for the 1 mg dose, for patients 30kg or
greater, is expected to be filed in the EU by the end of 2020. A dosage strength of 0.65 mg is under development for children weighing between 15kg and 30kg and is expected to be filed shortly after the initial approval. 

  
 55 

 In Europe, based on epidemiology data about 4% of the general population have experienced an anaphylactic
episode. Overall annual net sales of epinephrine auto-injectors in Europe are around $120 million USD based on IQVIA prescription data, representing less than 10% of the eligible population. According to the European Anaphylaxis Registry, less
than 15% of anaphylaxis episodes are self-treated with an auto-injector. The introduction of NeffyTM (ARS-1) would be a welcome new tool to safely,
quickly and painlessly administer lifesaving epinephrine. 
 About ARS Pharmaceuticals, Inc. 

ARS Pharmaceuticals is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe
allergic reactions that could lead to anaphylaxis. The Company is developing NeffyTM (ARS-1), an intranasal epinephrine spray with a unique absorption
technology that could be easy-to-use, needle-free, convenient and more reliable for patients and loved ones at-risk of severe
allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis. For more, visit www.ars-pharma.com. 

About Recordati 
 Recordati, established in 1926, is an
international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of
pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient
field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is
a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was
€ 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million. 
 Contact:
Margaret Long 
 margaret.long@porternovelli.com 
 571-445-4428 

  
 56 

			
	

	  	

 RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION 

Milan, 21 September, 2020—Recordati announces the signing of an exclusive license agreement with ARS Pharmaceuticals, a private
U.S. company, for the commercialization in the European Union, Iceland, Liechtenstein, Norway, Switzerland, United Kingdom, Russia/CIS, Turkey, Middle East and French-speaking African countries, of ARS-1, an
epinephrine nasal spray in late-stage development for the emergency treatment of severe allergic reactions that can lead to anaphylaxis. Under the terms of the agreement an upfront payment is due by Recordati upon signature of the contract and
further milestone payments are linked to the regulatory process and commercial performance. 
 Anaphylaxis is a severe, generalized allergic reaction,
characterized by life-threatening breathing or cardiovascular problems and usually associated with skin and mucosal changes. The trigger is exogenous and can be associated with food, insect bites or other allergenic substances. ARS-1 is a liquid formulation of epinephrine associated with Intravail®, an absorption enhancer, contained in a disposable, mono-dose nasal spray device. This
innovative formulation represents a new route of administration compared to existing products, increasing patient compliance and fulfilling an unmet medical need.
Easy-to-use and needle-free, this solution may eliminate the anxiety and hesitation associated with using an injection device. With use at the first signs of allergic
response, it could provide patients and their families the preventive solution to anaphylactic progression. 
 The marketing authorization application for
the 1 mg dose of the product is expected to be filed in the EU by the end of 2020. Furthermore, a dosage strength of 0.65 mg is under development for pediatric patients. 

“We are very pleased that ARS Pharmaceuticals has granted Recordati the exclusive license to market its innovative product for the prevention of severe
allergic reactions in Europe, Russia, the Middle East and other countries”, stated Andrea Recordati CEO. “This effective innovative formulation of a product for the prevention of life-threatening allergic reactions reinforces our Specialty
and Primary care pipeline and provides further diversification to our portfolio in an area where medical needs are not fully satisfied.” 

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI,
Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of
Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative
pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories.
Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net
income was € 368.9 million. 

  
 57 

 For further information: 

Recordati website: www.recordati.com 
  

			
	Investor Relations 	  	Media Relations
	Marianne Tatschke	  	Studio Noris Morano
		
	(39)0248787393	  	(39)0276004736, (39)0276004745
	e-mail: investorelations@recordati.it	  	e-mail: norismorano@studionorismorano.com

 Statements contained in this release, other than historical facts, are “forward-looking statements” (as such term
is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and
assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company’s control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All
mentions and descriptions of Recordati products are intended solely as information on the general nature of the company’s activities and are not intended to indicate the advisability of administering any product in any particular instance.

  
 58

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]